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 for my family 
The most exciting phrase to 
hear in science, the one that 
heralds new discoveries, is 
not “Eureka!” (I've found it!), 
but “That's funny...” 
Isaac Asimov 
 
 
 
 
 
 
 
Statement to my Thesis 
Statement to my Thesis 
 
 My thesis is written in a cumulative format. It consists of a synopsis about 
a topic related to my work (the role of bacterial infection in tumourigenesis), followed 
by chapters presenting a published research article, a submitted manuscript, a 
manuscript in preparation with a short summary and unpublished results obtained 
during my work. Finally, I resume the major findings of my thesis, draw conclusions 
and discuss some aspects and open questions of this work. 
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 Synopsis 
Mechanisms of tumour formation 
The Role of Bacterial Pathogens in Tumour Formation 
 
General introduction 
Francis Peyton Rous’ discovery early in the last century that an infectious 
agent, later identified as a virus, can cause tumours arising from the connective 
tissue in chicken established the link between infection and tumour (Rous, 1911). 
Today, experimental and epidemiological evidence propose a variety of infectious 
agents to be one of the main causes of tumours worldwide – accounting for 
estimated 17.8% (1.9 million cases) of the incidence of tumours in 2002 (Parkin, 
2006). This fact was acknowledge by this years Nobel prize in medicine given to H. 
zur Hausen for his discovery of human papilloma viruses causing cervical cancer 
(Nobelprize.org, 2008). Part of the reason for the interest in investigating the 
infectious origins of tumours lies in the realization that a tumour connected to 
infection is preventable (Kuper et al., 2000). Amongst the major infectious agents 
classified as carcinogenic by the IARC (International Agency for Research on 
Cancer) Helicobacter pylori is so far the only one of bacterial origin, the others being 
viruses and parasites. Nonetheless, a number of bacteria are thought to be 
associated with tumour formation (Vogelmann and Amieva, 2007; Mager, 2006). The 
awareness that the infectious agent may persist silently for many years and actually 
cause tumours in only a few of the chronically infected individuals and that especially 
bacteria often are not sufficient to induce tumour on their own, that chronic 
inflammation might be an important underlying process and independent alterations 
in oncogenic signalling pathways might be needed, illustrates the complexity 
between infection and tumourigenesis and emphasizes the central question of “cause 
and effect”. Understanding pathogen-host interactions is thereby a key component to 
unravel bacteria-associated tumour formation. 
The first part of this synopsis introduces the basic and relevant mechanisms of 
tumour formation. The second part gives examples of bacteria associated with 
tumourigenesis. 
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Definition 
Originally, “tumour” described any abnormal swelling, lump or mass. Today 
however, it is used as a synonym for neoplasm – the medical term for a pathological 
lesion characterized by the progressive or uncontrolled proliferation of cells. A 
neoplasm can be benign or malignant. In contrast to malignant tumours (also called 
cancer), benign tumours usually grow slowly and remain localized – meaning that 
they do not grow in an unlimited, aggressive manner and especially do not invade 
surrounding tissues and do not metastasize (McGraw-Hill, 2004). Yet not all tumours 
classified as benign are harmless to the host. Benign tumours may give rise to 
cancers via additional genetic changes in a subpopulation of the tumour cells or 
secondary difficulties may occur as a result of mechanical pressure. 
 
Steps of tumour formation 
The genetic model of oncogene activation, loss of tumour suppressor genes 
and genomic instability for colorectal tumour development (Vogelstein et al., 1988) 
provided the framework for studies addressing the independent multiple steps 
involved in the transition of a normal cell towards an overt and complex disease via 
tumour initiation, promotion and progression (illustrated in figure 1). 
 
 
Figure 1 Tumour initiation occurs when a cell is freed from growth restraints, usually irreversibly by 
mutation. Promoting agents, mutagenic and non-mutagenic, provide an anti-apoptotic and proliferative 
state enabling the mutated cell to build up a colony. Further progression and growth of tumour needs 
the capacity to induce blood-vessel formation and leads to an increase in malignant features such as 
invasion and metastases (Lax and Thomas, 2002). 
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The so-called hallmarks of cancer include the acquisition of self-sufficient 
signals for growth, the capacity to extend proliferation, resistance to growth-inhibiting 
signals, the ability to evade cell death signals (apoptosis), the potential for tissue 
invasion and metastasis, and the power to induce blood-vessel formation 
(angiogenesis) (Hanahan and Weinberg, 2000). Whereas some of these traits are 
the properties of the tumour cells themselves explained by mutations affecting cell 
cycle, proliferation, programmed cell-death and genome integrity, others depend on 
communication between tumour cells and their environment. Although having 
provided a wealth of information about processes inside cells, the reductionist focus 
on tumour as renegade cell-based disease is heavily discussed. Alternatively tumour 
is viewed as a complex tissue in which tumour cells interact with and subvert normal 
cells – as a developmental process gone awry (Sonnenschein and Soto, 2008; 
Hanahan and Weinberg, 2000) (figure 2). 
 
 
Figure 2 Left side: Cell-centred reductionist concept of tumour formation. Right side: tumour as a 
complex tissue. The interactions between the genetically altered tumour cells and the supporting 
normal cells will prove to be critical to understand tumour pathogenesis (Hanahan and Weinberg, 
2000). 
 
Tumour angiogenesis 
Like normal tissues, tumours require an adequate supply of oxygen, 
metabolites and an effective way to remove waste products (Papetti and Herman, 
2002). This obligates virtually all cells in a tissue to reside within 100 to 200 μm of a 
capillary blood vessel – the diffusion limit for oxygen. Hence, angiogenesis – the 
growth of new capillaries out of existing blood vessels – is central to the growth of 
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tumours to overcome size limitation and is one of the discrete steps of tumour 
progression (see figure 1) (Bergers and Benjamin, 2003). Angiogenesis itself is a 
highly orchestrate and tightly regulated process. A balance of pro- and anti-
angiogenic signals usually keeps the vasculature in a quiescent state (figure 3). An 
up-regulation of pro-angiogenic factors (such as vascular endothelial growth factor, 
VEGF), or a down-regulation of anti-angiogenic factors (such as angiostatin) may 
trigger the “angiogenic switch” – the initiation of angiogenesis. 
 
 
Figure 3 Angiogenesis is orchestrated by a variety of activators and inhibitors — only a few of which 
are listed above. In general, the levels of activators and inhibitors dictate whether an endothelial cell 
will be in a quiescent or an angiogenic state. It is believed that changes in the angiogenic balance 
mediate the angiogenic switch (Bergers and Benjamin, 2003). 
 
Various signals that trigger the angiogenic switch have been discovered. 
These include metabolic stress (low pO2, low pH, low level of sugar), mechanical 
stress (pressure generated by proliferating cells), immune/inflammatory response 
(cells from the immune system that have infiltrated the tissue), and genetic mutations 
(activation of oncogenes or deletion of tumour suppressor genes controlling the 
production of angiogenesis regulators) – demonstrating a complex interplay of 
environmental and genetic mechanisms influencing tumour angiogenesis. Pro- and 
anti-angiogenic stimuli might come from tumour cells themselves, endothelial cells 
(ECs), stromal cells, blood and extracellular matrix (Carmeliet and Jain, 2000). 
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In contrast to normal physiological angiogenesis (such as for example 
angiogenesis in injured tissue) where new vessel rapidly mature and become stable, 
tumours are described as “wounds that never heal” having lost the proper balance 
between positive and negative control (Dvorak, 1986). Tumour blood vessels are 
different in their architecture than their normal counterparts – they are less organized, 
irregularly shaped, dilated, have altered interactions with pericytes, and are often 
leaky. Whereas in normal tissue vessel density is dynamically controlled by the 
metabolic needs of nutrients and oxygen, tumour vasculature fails to become 
quiescent and enables constant growth of new tumour blood vessels (Bergers and 
Benjamin, 2003). 
 
Chronic inflammation and tumourigenesis 
Links between tumour and inflammation were first made on the basis of 
observations that tumours often arose at sites of chronic inflammation and that 
inflammatory cells are present in tumour environment (Balkwill and Mantovani, 2001). 
Several other lines of evidences summarized in table 1 are consistent with the view 
that inflammation plays an important role in malignant progression. 
 
Table 1 The links between cancer and inflammation (Balkwill et al., 2005). 
 
 
Acute inflammation is a rapid and self-limiting process: chemical mediators are 
induced in a tightly regulated sequence, and immune cells move in and out of the 
affected area, destroying infectious agents, repairing damaged tissue, and initiating a 
specific and long-term response to the pathogen. However, acute inflammation does 
not always resolve. In chronic conditions initiating factors persist or mechanisms 
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required for resolving the inflammatory response fail. This can lead to abnormalities 
and ultimately pathogenesis (Balkwill et al., 2005). As mentioned before tumours can 
bee viewed as “wounds that never heal” (Dvorak, 1986). 
Chronic inflammation is thought to be implicated in all stages of 
tumourigenesis, i.e. initiation, promotion and progression. The interplay of both the 
extrinsic pathway (driven by inflammatory conditions within the microenvironment 
surrounding a pre-tumourous cell) and the intrinsic pathway (driven by genetic 
alterations in the pre-tumourous cell that cause inflammation) is required for 
inflammation-associated tumourigenesis (Balkwill and Mantovani, 2001). Persistent 
inflammation leads to tissue damage – nitric oxide and reactive oxygen species from 
inflammatory cells may induce DNA damage, which increase the risk for malignant 
transformation of a cell. In addition various factors such as cytokine, chemokines and 
growth factors from inflammatory cells (table 2) as well as produced by tumour cells 
themselves alter crucial biological processes responsible to maintain normal cellular 
homeostasis and genomic stability, increasing the risk of tumour development (figure 
4) (Kundu and Surh, 2008; Yoshimura, 2006). 
 
Table 2 Macrophage products with potential to influence tumourigenesis (Yoshimura, 2006). 
 
 
A-6 
Mechanisms of tumour formation 
 
Figure 4 Inflammation is implicated in multi-step tumourigenesis. ROS/RNS or other reactive species 
derived from inflammatory stress can attack DNA and cause mutations in oncogenes/tumour 
suppressor genes or other genetic alterations. This will lead to initiation of tumour formation. 
Inflammation also contributes to tumour promotion and progression by stimulating the proliferation of 
initiated or premalignant cells, enhancing angiogenesis and metastasis, and inhibiting cell apoptosis 
(Kundu and Surh, 2008). 
 
A-7 
Role of bacterial infection in tumourigenesis 
The role of bacterial infection in tumourigenesis 
 
Bacterial infection and tumour 
A number of epidemiological evidences link bacterial infections to tumour, but 
causality and the underlying molecular mechanism are far from clear. Studies in 
animal models support a causative role for several bacterial pathogens in tumour 
formation, but the relevance of experimental animal results needs to be transmitted 
to humans. Many bacteria and their products show properties that could modulate 
tumourigenesis, but there is no known link to human tumour. A general perception in 
all those studies aiming to unravel the role of bacterial infection in tumourigenesis is 
the awareness that bacteria often are not sufficient to induce tumour on their own, 
that the process might be accompanied by chronic inflammation and modulation of 
host immune response, depend on susceptibility factors on the host side, and need 
independent alterations in oncogenic signalling pathways (Vogelmann and Amieva, 
2007; Mager, 2006). Bacteria would thus promote tumour formation by disrupting 
interactions between cells involved in maintaining tissue organization, repair, and 
local homeostasis – altering microenvironments and relaxing restraints controlled by 
tissue organization. Hence, the knowledge about bacteria-host interactions is crucial 
to the understanding of the role of bacterial infection in tumour development. 
 
The paradigm of increased host inflammatory response 
The Gram-negative bacterium Helicobacter pylori (Hp) colonises the 
stomachs of more than half of the world's population from childhood – making it one 
of the most successful bacterial pathogens (Suerbaum and Michetti, 2002). The 
majority of those infected will carry and transmit Hp without any symptoms of disease 
(Blaser, 1997). However, Hp infections are also responsible for a heavy toll of 
morbidity and mortality as a consequence of ulcer disease, lymphoma of the 
mucosa-associated lymphoid tissue (MALT) and, the most dangerous complication of 
Hp infection, gastric adenocarcinoma (Peek and Blaser, 2002; Sepulveda and 
Graham, 2002). The IARC classification of H. pylori infection as class I carcinogen 
itself was entirely based on epidemiological evidence (IARC, 1994). Meanwhile 
pathogenesis of Hp has been addressed by infection studies using animal models, 
analysis of cellular signalling mechanism perturbed by Hp infection, and the 
elucidation of possible roles of Hp gene products (Kusters et al., 2006). Hp isolates 
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are surprisingly diverse in their genome sequence and their virulence. Increased 
pathogenicity has been linked, although not exclusively, to the presence of the cag 
pathogenicity island (PAI), encoding a type IV secretion system (T4SS), and the 
thereby translocated CagA protein. CagA can activate a number of signal 
transduction pathways that resemble signalling by growth factor receptors. CagA is 
also involved in binding and perturbing the function of epithelial junctions, resulting in 
aberrations in tight junction function, cell polarity and cellular differentiation (Fig. 5) 
(Amieva and El-Omar, 2008; Backert and Selbach, 2008). 
 
 
Figure 5 Model for the role of Hp T4SS effectors CagL, peptidoglycan and CagA in host cell 
interaction and signal transduction. T4SS effectors alter different cellular processes in gastric epithelial 
cells as illustrated. Bacterial effector molecules are shown in red, host signalling molecules in yellow 
and actin filaments in green. CagA is injected into the membrane of infected gastric epithelial cells and 
modulates various signalling cascades associated with cell proliferation, motility, actin cytoskeletal 
rearrangements, disruption of tight junctions, pro-inflammatory responses and suppression of 
apoptosis, as shown. Receptor tyrosine kinases, ERK and small Rho GTPases Rac1 and Cdc42 can 
also be activated by a yet unknown T4SS protein. In addition, translocated peptidoglycan appears to 
activate the intracellular receptor Nod1 which activates NF-κB in a T4SS-dependent manner (Backert 
and Selbach, 2008). 
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Another amongst the numerous Hp virulence factors is the vacuolating toxin 
VacA, demonstrating multiple actions contributing to Hp colonization of the stomach 
(Cover and Blanke, 2005). Hp virulence factors elicit both pro-inflammatory and 
immunosuppressive effects in the gastric mucosa resulting in a robust but specific 
form of chronic inflammation, ineffective in clearing the infection (Amieva and El-
Omar, 2008). The resulting continuous production of reactive oxygen species can 
give rise to DNA damage, thus inducing the multiple mutations thought to be required 
for initiation of tumourigenesis (Kundu and Surh, 2008). In summary, Hp expresses 
several proteins that might independently influence tumour development and cancer 
risk would be the summation of the polymorphic nature Hp virulence factors, 
environmental exposures, as well as host genetic factors affecting differentially host 
inflammatory responses and epithelial-cell physiology (Amieva and El-Omar, 2008; 
Peek and Blaser, 2002). 
Streptococcus bovis (Sb), a member of the gastrointestinal tract flora of 
humans, is considered as a lower grade pathogen frequently involved in bacteraemia 
and endocarditis. Yet, Sb infection is often associated to colorectal tumours (Klein et 
al., 1979). Moreover, it was reported that faecal carriage of Sb was increased in 
patients with colon carcinoma (Klein et al., 1977). Taken together these data suggest 
a correlation between Sb infection and the development of colorectal cancer. 
Indications for an active role of Sb in tumourigenesis are given by studies done with 
rats pre-treated with a chemical carcinogen (azoxymethane, AOM). Injections of Sb 
or bacterial wall extracted antigens (WEA) promoted the progression of early AOM-
induced preneoplastic lesions in the colonic mucosa, enhanced expression of 
proliferation markers and increased production of the chemokine interleukin (IL)-8 
(Ellmerich et al., 2000). Similarly as for Hp, the synthesis of pro-inflammatory proteins 
(e.g. IL-8, prostaglandin E2, cyclooxygenase-2) in human colon carcinoma cells 
(Caco-2) and in the rat colonic mucosa point to a role of oxygen radicals in colon 
tumourigenesis induced by chronic infection with Sb (Biarc et al., 2004). Thus, Sb 
could contribute to tumour development in a chronic infection / inflammation-
dependent manner where bacterial components in addition interfere with cell 
function. Presently though, the available data do not prove a causal relationship and 
it remains to be answered whether the increased presence of Sb in colonic cancers 
results from the preferential bacterial colonization of these cancers and their 
precursors or whether Sb as such initiates tumourigenesis (zur Hausen, 2006). 
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The gram-negative obligate intracellular Chlamydia (Chlamydophila) 
pneumoniae (Cp) are a common cause of acute respiratory infections, several 
chronic lung diseases, and proposed to be associated to an elevated risk of lung 
cancer (Laurila et al., 1997). Similar as proposed for Hp, Cp could increase the risk 
through mediators of inflammation. Furthermore studies showed that Cp can inhibit 
host cell apoptosis (Airenne et al., 2002) and triggers the type of activation required 
for the induction of secreted macrophage-derived mediators of angiogenesis, such as 
VEGF (Carratelli et al., 2007). It is also proposed that Cp acts synergistically with 
smoking to increase the risk of cancer. Smoking impairs lung immunity which may 
allow Cp to more easily colonize the lungs and then initiate a chronic inflammatory 
response (Littman et al., 2005). The current evidences linking Cp and lung cancer 
are based on serology and direct antigen detection and are somewhat controversial 
and at the end – although maybe truly suggesting an association – it remains 
uncertain whether Cp infection increases the risk of lung cancer, or whether lung 
cancer favours a Cp infection. Indeed, a recent publication negates that Cp infection 
is an important cause of lung cancer, in particular among non-smokers (Smith et al., 
2008). Likewise, studies done to address the role of Chlamydia trachomatis in 
cervical cancer are discussed (Al-Daraji and Smith, 2008). 
 
Proliferative infections 
Inflammation is not always a feature of bacterial infections associated with 
proliferative lesions. The obligate intracellular bacterium Lawsonia intracellularis 
(Li) was identified as the agent triggering proliferative intestinal lesions termed 
proliferative enteropathy (PE) in pigs and other animals (Smith and Lawson, 2001). Li 
infects the undifferentiated crypt cells of the epithelium of the intestinal tract and 
promotes their proliferation without affecting the normal uninfected epithelium 
(McOrist et al., 1996). Cells infected with Li continue to divide and migrate to 
populate the epithelium and thus colonise the epithelium with bacteria. In addition, 
dividing cells better promote the growth of bacteria than non-dividing cells (Lawson et 
al., 1993). Remarkably, the stimulatory effect of bacteria does no persist once the 
lesion becomes fully developed (McOrist et al., 1996). Furthermore, despite showing 
a fully developed proliferative lesion the inflammatory response is very limited 
(Rowland and Rowntree, 1972). Hence, persistent infection, facilitated by the 
absence of cellular inflammation and limited immune response, enables the bacteria 
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to promote a cellular niche for its replication and spread. The bacterial factors 
involved in induction of cell proliferation and modulation of the immune response 
remain to be discovered (Smith and Lawson, 2001). 
Similar lesions are observed in mice infected with the non-invasive enteric 
pathogen Citrobacter rodentium (Cr), which causes a disease called transmissible 
murine colonic hyperplasia (TMCH) characterised by epithelial proliferation and 
variable limited inflammation (Barthold et al., 1978). Cr-infection increases the 
susceptibility to the carcinogenic effect of a chemical (DMH). Hyperplasia induced by 
Cr reduces the latency period for early neoplastic lesions (Barthold and Jonas, 1977). 
Cr uses the same molecular mechanisms of type III secretion system (T3SS) as 
enteropathogenic (EPEC) or enterohemorrhagic E. coli (EHEC) to colonise the 
epithelial cells of the gut. A pathogenicity island termed locus of enterocyte 
effacement (LEE) encodes the gene needed to induce attaching and effacing (A/E) 
lesions where the brush-border microvilli are destroyed and bacteria intimately attach 
to the host epithelial cells (Garmendia et al., 2005). The ubiquitous transcription 
factor NF-κB, controlling the expression of genes involved in immune responses, 
apoptosis, and cell cycle, is activated in TMCH. Nevertheless, blocking NF-κB activity 
does not alter Cr-induced hyperproliferation (Wang et al., 2006), implying other 
mechanisms to explain the mitogenic stimulus. The mitochondrial associated protein 
(Map) is amongst the LEE-encoded effector proteins. Not essential for A/E lesion 
formation in vitro, Map has been reported to be targeted to host mitochondria, where 
it interferes with membrane potential. Disruption of mitochondrial structure and 
function by Cr is proposed to drive the infected cells into impaired cellular 
metabolism. Reduction in host cell energy might be beneficial for Cr by limiting the 
ability of the cells to combat the infection (Ma et al., 2006). Furthermore, ∆map 
mutants induced a low level of hyperplasia while efficiently colonizing the colon at 
late stage of the infection suggesting that Map thus could modulate host cell 
responses influencing proliferation (Mundy et al., 2004). 
 
Bacterial effectors with tumourigenic potential 
Bacteria express a range of proteins that interact with host cell in a precise 
manner. Bacterial products could directly damage DNA by enzymatic attack, 
indirectly by provoking an inflammatory cell response producing free radicals, or even 
by affecting DNA repair mechanisms. Interference with signal pathway resulting in 
A-12 
Role of bacterial infection in tumourigenesis 
the disruption of the normal balance of growth, cell division and apoptosis might 
encourage tumour promotion. Metastatic potential and tumour progression could be 
facilitated by uncoupling of the anchorage-dependent growth (table 3). An underlying 
characteristic that is likely to be important for most aspects of tumour causation is 
chronic exposure to a stimulus (Lax, 2005). 
 
Table 3 Potential tumourigenic properties of bacterial toxins (Lax, 2005). 
 
 
The so far best characterized example of a bacterial protein with tumourigenic 
potential is the mitogenic toxin PMT produced by some strains of Pasteurella 
multocida. PMT has been shown to modulate the activity of the Gq/11 family of 
heterotrimeric G proteins as well as the small GTPase Rho resulting in the 
stimulation of a number of signalling proteins involved in tumourigenesis, such as 
RhoA, Src, focal adhesion kinase (FAK), epidermal growth factor receptor (EGFR), 
and extracellular signal-regulated kinase ERK1/2 (Oswald et al., 2005). Similarly, the 
Rho family of small GTPase is activated by cytotoxic necrotizing factor (CNF), 
expressed by many human Escherichia coli isolates (Landraud et al., 2004). 
Although inducing quiescent cells to enter the cell cycle and undergo DNA synthesis, 
CNF interferes via activation of Rho GTPase with normal cytokinesis – thus cell cycle 
is perturbed and multinucleated cells are generated (Horiguchi et al., 1993). There 
are also evidences that CNF inhibits apoptosis by increasing the expression of the 
Bcl-2 family proteins (Fiorentini et al., 1998). Cycle inhibiting factor (Cif) translocated 
by the LEE type III secretion system of EHEC and EPEC E. coli strains is another 
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bacterial factor inhibiting cell cycle transition, yet independent of Rho activation but 
linked to inactivation of the cyclin-dependent kinase Cdc2 (Marches et al., 2003). 
Another pathway to disturb cell cycle is used by the Bacterioides fragilis toxin 
(BFT). BFT is a metalloproteinase cleaving E-cadherin, an important protein for cell-
cell interaction, thus releasing β-catenin which migrates to the nucleus and mediates 
the transcritptional activation of c-myc resulting in cell proliferation (Wu et al., 2003). 
In contrary to the proteins mentioned before, cytolethal distending toxin (CDT) 
directly damages DNA. The CtdB subunit is a DNase harbouring a nuclear 
localization signal and catalyzing double-stranded DNA breaks that induce repair 
mechanisms to cause cell cycle arrest (Hassane et al., 2003). CDT is produced by a 
broad range of bacteria including E. coli, Shigella dysenteriae, Campylobacter 
spp., Salmonella typhi, Haemopilus ducreyi, Hp species, and Actinobacillus 
actinomycetemcomitans (Oswald et al., 2005). 
In summary, it is tempting to speculate that the activity of cyclomodulins such 
as CDT could also act as predisposing factors for the initiation of tumour. Likewise, 
cyclomodulins such as Cif or CNF inducing DNA replication in absence of cell 
division could promote genetic abnormalities. In general, alterations in cell growth – 
the ratio of apoptosis to proliferation and differentiation – are important mechanisms 
driving the clinical manifestation of bacterial infection (Oswald et al., 2005). 
 
Bartonella species and tumour-like vasoproliferative lesions 
Verruga peruana (VP) and Bacillary angiomatosis / peliosis (BA/BP) lesions 
illustrate the remarkable capacity of three among 21 Bartonella species. to trigger 
vasoproliferative processes resembling tumour angiogenesis (Chian et al., 2002). 
Bartonellae are gram-negative α-proteobacterial pathogens infecting in a rather 
specific manner their mammalian hosts (Dehio, 2004). Bacteria are transmitted via 
blood-sucking arthropods or by direct contact. The hallmark of Bartonella-infection is 
a long-lasting intraerythrocytic bacteraemia in their reservoir host(s). Whereas ECs 
seem to be targeted in both reservoir and incidental host (Dehio, 2005). 
The human specific Bartonella bacilliformis (Bb) causes Carrion’s disease – 
a biphasic disease endemic in the highlands of Peru, where the ecological conditions 
meet the needs of its transmission vector the sandfly Lutzomia verrucarum (Spach 
and Koehler, 1998). The initial acute phase, Oroya fever, is characterized by sever – 
even fatal if not treated – haemolytic anaemia (Caceres-Rios et al., 1995). Thus, in 
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contrary to the other Bartonella-infections were infected erythrocytes keep circulating 
in the bloodstream for their remaining lifespan (Schulein et al., 2001), Bb induces 
lysis of red blood cells. The subsequent chronic phase, VP, presents as vascular 
tumour-like lesions showing varying degrees of inflammation, compact proliferation of 
ECs and the formation of Rocha-Lima's inclusions, EC colonization with Bb (Arias-
Stella et al., 1986). The mechanism by which an angiogenic response is 
accomplished remains elusive. The bacteria could synthesize some diffusible product 
that, in analogy with known angiogenic factors, could stimulate ECs to participate in 
angiogenesis (Garcia et al., 1990). The bacterial chaperon GroEL has been 
proposed to be involved in the observed Bb mitogenic activity (Minnick et al., 2003). 
Alternatively or in addition, host angiogenic factors could be produced as a 
consequence of either the infection of ECs or an immune response against the 
bacteria, or the infected cells themselves may have angiogenic potential. VP has 
been proposed to be the result of Bb-induced autocrine production of angiopoietin-2 
(Ang-2), with paracrine contribution of VEGF secreted outside of the infected 
endothelium (Cerimele et al., 2003). 
Bartonella quintana (Bq) is another human specific pathogen. Bq is 
transmitted by human body lice and causes a spectrum of clinical diseases such as 
cycling fever (trench fever), endocarditis, chronic lymphadenopathy, and the already 
mentioned BA lesions (Maurin and Raoult, 1996). BA lesions are histologically very 
similar to VP associated with infection by Bb. Little is known about the mechanisms 
of Bq pathogenicity related to vasoproliferation. Bq replicates within ECs in 
Bartonella-containing vacuoles (BCVs) (Brouqui and Raoult, 1996). While early 
during infection apoptosis is induced by the activation of Apaf-1 and caspase-8, at 
later times the apoptotic process is inhibited by an overexpression of the anti-
apoptotic bcl-2. Bcl-2 activation could partially explain survival and proliferation of 
ECs (Liberto et al., 2003). The triggered peak of apoptosis was further associated 
with induction of p38 MAPK and SAPK/JNK, followed by next to Bcl-2 induction also 
a mitotic activation via the cyclin-dependent kinase Cdc2 (Liberto et al., 2004). 
Variably expressed outer membrane proteins (Vomps) belong to a class of trimeric 
autotransporter adhesins (TAA) (Linke et al., 2006; Zhang et al., 2004). Vomp 
expression has been shown to correlate with the ability of Bq to induce paracrine 
production of VEGF in infected THP-1 macrophages and HeLa cells (Schulte et al., 
2006). 
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The zoonotic pathogen Bartonella henselae (Bh), the object of research in 
this work, causes asymptomatic long-lasting intraerythrocytic bacteraemia in its 
natural feline reservoir host and is responsible for a number of clinical outcomes 
during infection of the human incidental host. Disease manifestations range from self-
limiting but long-lasting swelling of lymph nodes (cat-scratch-disease, CSD) in 
immunocompetent patients to the aforementioned tumour-like vasoproliferative 
lesions on the skin or inner organs known as BA/BP especially in patients with a 
compromised immune system, such as AIDS patients (Fig. 6) (Florin et al., 2008). 
 
 
Figure 6 Bh causes a sub-clinical intraerythrocytic bacteraemia in its reservoir host, the cat. Through 
the bite of an infected cat flea or through direct contact (cat scratch), the pathogen is transmitted from 
cat to cat or from cat to human, respectively. Depending on the immune status of the human host, Bh 
can lead to different clinical manifestations, including CSD (swelling of lymph nodes with fever) in 
immunocompetent individuals, or BA/BP in immunocompromised patients (Dehio, 2005). 
 
The fact that antibiotic treatment leads to regression of those lesions (Koehler 
and Tappero, 1993) indicate a causative and active role of Bh triggering these 
vascular proliferations. In addition, the close association of Bh with proliferating ECs 
in BA/BP (Chian et al., 2002) prompted to speculate that Bh could subvert EC 
functions. Indeed, striking changes have been described for human umbilical vein 
endothelial cells (HUVECs) upon infection with Bh in vitro – namely (i) uptake of 
individual bacteria in so-called BCVs (Kyme et al., 2005), (ii) massive cytoskeletal 
actin rearrangements leading to a unique structure termed invasome (Dehio et al., 
1997), (iii) a NF-κB-dependent pro-inflammatory response (Fuhrmann et al., 2001), 
(iv) the inhibition of apoptosis (Kirby and Nekorchuk, 2002), and a direct mitogenic 
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stimulation of ECs (Conley et al., 1994). With the exception of BCVs, in part the NF-
κB-dependent pro-inflammatory response, and the direct mitogenic stimulus these 
activities dependent on the VirB/VirD4 T4SS of Bh and its translocated Bartonella 
effector proteins (BepA-BepG) (Fig. 7) (Schulein et al., 2005; Schmid et al., 2004). 
Intriguingly, the VirB/VirD4 T4SS even counterbalances the potent mitogenic 
stimulus (Schmid et al., 2004). T4SSs are membrane-associated transporter 
complexes ancestrally related to conjugation systems used by a number of bacteria 
to deliver proteins or protein-DNA complexes into a wide range of target cells 
(Christie et al., 2005). Common to all Beps is a modular structure harbouring a 
bipartite translocation signal at the C-terminus composed of a BID (Bep intracellular 
delivery) domain of about 140 amino acids and an unconserved positively charged 
tail. In their N-terminus the Beps contain next to additional BID domains (BepE-
BepG) other domains such as FIC (filamentation induced by cAMP, BepA-BepC) or 
tandem-repeated peptide motifs resembling eukaryotic tyrosine-phosphorylation sites 
(BepD-F) (Backert and Selbach, 2005; Schulein et al., 2005). 
 
 
Figure 7 a) The genetic structure of the virB/virD4/bep pathogenicity island. b) Model of the VirB/VirD4 
T4SS machinery and modulary domain structure of BepA-G. Green boxes represent tyrosine-
containing sequence repeats resembling tyrosine-phosphorylation motifs (indicated by Y) or FIC 
(filamentation induced by cAMP) domain and blue the BID (Bep intracellular delivery) domain (Dehio, 
2005; Schroder and Dehio, 2005). 
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Experimental infection of rats with B. tribocorum (Bt), a close relative of Bh, 
further emphasizes the importance of the VirB/VirD4 T4SS – non-polar inframe 
deletions of structural component such as virB4 or virD4 result in the complete loss of 
the ability of the bacteria to cause bacteraemia (Schulein and Dehio, 2002). 
Additional data indicating a relevance for Bh-EC interaction are the expression of the 
Bh virB-operon induced upon EC contact (Schmiederer et al., 2001) and the 
transcriptional profiling of HUVECs upon infection with Bh revealing the regulation of 
a number of genes controlling innate immune responses, cell cycle, and vascular 
remodelling (Dehio et al., 2005). 
The molecular and cellular mechanisms targeted by the Beps are subject of 
current research. BepA has been shown to be targeted to the host cell plasma 
membrane and to inhibit apoptosis in HUVECs via a rise in the cytosolic 
concentration of the second messenger cAMP (see chapter 1) (Schmid et al., 2006). 
BepD is tyrosine-phosphorylated upon translocation in ECs (Schulein et al., 2005). 
The c-Src tyrosine kinase (Csk) binds to a tyrosine-phosphorylation motif, which is 
very similar to the Csk-binding site in VE-cadherin, in the N-terminus of BepD. Also 
the protein tyrosine phosphatase SHP2 binds to BepD in a tyrosine-phosphorylation 
dependent manner (Guye, 2006). Thus BepD is hypothesised to provide docking 
sites for cell signalling proteins once translocated into the host cell (Pulliainen and 
Dehio, 2008). BepG is able to promote actin rearrangements required for invasome-
mediated invasion. This process seems independent of the small GTPase RhoA but 
relying on Rac1 and Cdc42 involving the recruitment of the Arp2/3 complex 
(Rhomberg et al., 2008). Despite those striking VirB/Bep-dependent changes in ECs, 
the causal role and importance of the Bh VirB/VirD4/Bep system in BA/BP remains 
elusive, in part due to the lack of a suitable animal model or a sophisticated in vitro 
model (addressed in chapter 2). 
The vasoproliferative lesions are typically infiltrated by polymorphonuclear 
neutrophils (PMN) and monocytes indicating an inflammation (Chian et al., 2002). 
Activation of a pro-inflammatory response might favour the recruitment of monocytes, 
which upon infection with Bh are activated to release pro-angiogenic factors such as 
VEGF, which could promote EC proliferation in a paracrine manner (Resto-Ruiz et 
al., 2002; Kempf et al., 2001). Thereby another Bh virulence factor, the nonfimbrial 
adhesin BadA (Bartonella adhesin A) a homologue of the Bq Vomps (Linke et al., 
2006), is thought to be an essential factor eliciting the secretion of VEGF by 
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activating the transcription factor hypoxia-inducible factor (HIF)-1 (Riess et al., 2004). 
NF-κB, a major factor controlling inflammation, has been shown to be activated both 
dependent on the VirB/VirD4 T4SS (Schmid et al., 2004) and generally upon Bh-
infection (Fuhrmann et al., 2001). The role of the VirB/VirD4/Bep system in triggering 
VEGF production upon infection has not been addressed so far (see chapter 4), 
neither was the effect of exogenous VEGF, and thus the contribution of the paracrine 
loop to BA/BP, on Bh-infected ECs assessed (see chapter 3). In summary, the 
current model for Bh-triggered vascular tumour formation proposes a direct activation 
of ECs and stimulation of proliferation, inhibition of apoptosis, and the activation of a 
paracrine loop of pro-angiogenic factors such as VEGF released from infected 
monocytic cells (Fig. 8). 
 
 
Figure 8 Infection of ECs with Bh results in the direct stimulation of EC proliferation and inhibition of 
apoptosis. Bacteria also trigger a nuclear factor NF-κB-dependent pro-inflammatory response leading 
to the recruitment of monocytes. Bacterial colonization of macrophages results in hypoxic conditions 
that lead to activation of HIF-1 and the subsequent upregulation of VEGF expression. The release of 
VEGF by macrophages results in paracrine stimulation of EC proliferation (Dehio, 2005). 
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As mentioned in the “Mechanisms of tumour formation” part, the development 
of a tumour is a multistep process that can take years before clinical manifestations 
can be observed. Especially infectious agents might be cleared long before the 
obvious onset of disease. Benign proliferative tumour lesions triggered by pathogenic 
bacteria like Bartonella spp., L. intracellularis or C. rodentium occur much faster and 
thus are experimentally more assessable. Besides providing insights into the 
pathogenesis of Bh, the study of bacteria-host cell interactions might be useful to 
explore general mechanisms involved in processes such a pathological angiogenesis 
– a hallmark of tumour growth and of cardiovascular and inflammatory diseases. In 
addition the VirB/VirD4/Bep system itself provides an elegant though complex tool to 
elucidate cellular functions. 
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Aim of the Thesis 
Aim of the Thesis 
 
Started in November 2004, the primary aim of this thesis was to elucidate the 
molecular and cellular mechanisms involved in Bartonella henselae (Bh)-triggered 
vasoproliferation – to asses the angiogenic properties of Bh with a focus on the role 
of the VirB/VirD4/Bep system. Following a participation in the characterization of the 
VirB/VirD4-translocated effector BepA protecting endothelial cells (ECs) from 
apoptosis, I adapted and used a three-dimensional in vitro sprouting angiogenesis 
assay of collagen-embedded EC spheroids to elucidate pro- and anti-angiogenic 
effects of Bh. In addition to directly assessing the impact of the VirB/VirD4/Bep 
system on a paracrine loop model of Bh-triggered vascular endothelial growth factor 
(VEGF), I also investigated the effect of exogenous VEGF on Bh-infected ECs. 
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The capacity of Bartonella henselae (Bh) to inhibit apoptosis during endothelial 
cell (EC) infection is dependent on a functional VirB/VirD4 type IV secretion system 
(T4SS) and at least one of the T4SS-translocated Bartonella effector proteins (Beps). 
In this study, BepA was identified to mediate the inhibition of apoptosis in human 
umbilical vein endothelial cells (HUVECs). 
A nonpolar deletion of bepA resulted in complete loss of the anti-apoptotic 
effect, which could be restored by complementation in trans. Furthermore, the 
expression of BepA in the effector-less ∆bepA-G mutant restored the anti-apoptotic 
activity to wild-type level. Using caspase-3/-7 assays we tested the ability of BepA 
homologues of different Bartonella species to inhibit apoptosis. Only BepA 
homologues from Bartonella species known to induce angioproliferative tumour 
formation were able to protect ECs from apoptosis. The calmodulin-dependent 
adenylate cyclase (cya)-reporter assay was used to demonstrate translocation of the 
two putative effector proteins BepA from Bh and B. quintana (Bq) into HUVECs. 
Translocation of BepA into the host cell was confined to the C-terminus and 
dependent on a functional VirB/VirD4 T4SS. 
We constructed different GFP-BepA fusion proteins to delineate the functional 
domain of BepA required to inhibit apoptosis. These fusion proteins were ectopically 
expressed in HUVECs and the apoptotic cell population was determined. A 140 aa 
domain of BepA was sufficient to inhibit apoptosis in HUVECs. This domain 
corresponds to the conserved BID domain of BepA, which is part of the bipartite 
translocation signal. To investigate the subcellular localization of BepA in the host 
cell different GFP-BepA fusion constructs were expressed in HUVECs and samples 
were analyzed by immunocytochemistry as well as by subcellular fractionation 
experiments. BepA was localized to the cytoplasmic membrane of the host cell. 
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Interestingly, we observed that only anti-apoptotic GFP-BepA fusion constructs 
associated to the membrane. 
To elucidate the mechanism of inhibition of apoptosis by BepA, microarray 
data obtained for the transcriptome of HUVECs infected with wild-type versus the 
ΔvirB4 mutant were studied. These revealed a VirB-dependent upregulation of NF-κB 
and the cAMP/CREM/CREB regulon in infected endothelial cells. The NF-κB pathway 
did not show any specific activation by anti-apoptotic homologues of BepA. However, 
upregulation of cAMP-regulated gene expression and increased intracellular cAMP 
level correlated with the ability of BepA to inhibit apoptosis. Artificially elevated cAMP 
levels protected ECs from apoptosis, thus BepA might mediate anti-apoptosis of ECs 
by increasing cAMP levels by a plasma membrane-associated mechanism. 
Furthermore, expression of BepA in endothelial cells resulted in a significantly 
increased resistance to cytotoxic T-lymphocytes (CTL) mediated cell death. 
These results indicate that BepA, a novel T4SS effector protein, could 
contribute indirectly to vasoproliferative growth by enhancing cell survival. 
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in the cell (Fig. 3D, p. C-8), the caspase-3/-7 assays testing the effect of artificially 
elevated intracellular cAMP on HUVECs (Fig. 6, p. C-11) as well as further developed 
the FACS assay used to analyze the capacity of BepA to inhibit CTL mediated cell 
death (Fig. 7, p. C-12). Microarray data and the experimental setup for real time PCR 
were provided by Dr. M. Dehio. The other data showed in the manuscript were 
provided by Dr. M. Schmid. 
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The modulation of host cell apoptosis by bacterial pathogens is of critical importance for the outcome of the infection
process. The capacity of Bartonella henselae and B. quintana to cause vascular tumor formation in immunocompro-
mised patients is linked to the inhibition of vascular endothelial cell (EC) apoptosis. Here, we show that translocation of
BepA, a type IV secretion (T4S) substrate, is necessary and sufficient to inhibit EC apoptosis. Ectopic expression in ECs
allowed mapping of the anti-apoptotic activity of BepA to the Bep intracellular delivery domain, which, as part of the
signal for T4S, is conserved in other T4S substrates. The anti-apoptotic activity appeared to be limited to BepA
orthologs of B. henselae and B. quintana and correlated with (i) protein localization to the host cell plasma membrane,
(ii) elevated levels of intracellular cyclic adenosine monophosphate (cAMP), and (iii) increased expression of cAMP-
responsive genes. The pharmacological elevation of cAMP levels protected ECs from apoptosis, indicating that BepA
mediates anti-apoptosis by heightening cAMP levels by a plasma membrane–associated mechanism. Finally, we
demonstrate that BepA mediates protection of ECs against apoptosis triggered by cytotoxic T lymphocytes, suggesting
a physiological context in which the anti-apoptotic activity of BepA contributes to tumor formation in the chronically
infected vascular endothelium.
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Introduction
Bacterial pathogens have developed various strategies to
subvert host cell functions to their benefit. In particular,
intracellular bacteria have adapted mechanisms to modulate
the apoptotic pathway of their host cells [1]. The resulting
induction or inhibition of apoptosis is often crucial for a
successful infection of the host. Pathogen-induced apoptosis
can serve to eliminate key immune cells or to evade other
host defenses [1]. Several bacteria elicit an inflammatory
process by inducing a specific form of apoptotic cell death,
which at the place of infection leads to the disruption of
tissue barriers and thus may secure efficient microbial spread
in the host [2,3]. In contrast, inhibition of apoptosis may be
essential for intracellular pathogens to establish chronic
infection. Pathogen-triggered anti-apoptosis of infected host
cells facilitates a slow microbial replication process and
enables persistence in the infected host. For example, the
obligate intracellular pathogen Chlamydia pneumoniae de-
grades—by an unknown effector mechanism—pro-apoptotic
BH-3 host cell proteins [4]. Rickettsia rickettsii protects invaded
host cells from apoptosis by activating a nuclear factor kappa
B (NFjB)–dependent survival pathway [5]. For many human
pathogens, the activation and inhibition of the apoptotic
machinery of the infected host cell thus has a central role
during the infection process [1].
The bacterial effectors known to modulate apoptosis are
mostly pro-apoptotic. The only described anti-apoptotic
effector is the outer membrane protein PorB of Neisseria
meningitidis [6]. PorB has been shown to interact with
mitochondria, where it is thought to block apoptosis by
preventing mitochondrial depolarization and cytochrome C
release. Interestingly, opposite effects were reported for the
PorB ortholog of N. gonorrhoea, which provokes a pro-
apoptotic effect upon interaction with mitochondria [7,8].
Bartonellae are facultative intracellular pathogens associ-
ated with the formation of vasoproliferative tumors in
humans (e.g., bacillary angiomatosis, bacillary peliosis, and
verruga peruana) [9]. These vascular lesions consist of an
increased number of endothelial cells (ECs), which are
colonized by extracellular and intracellular bacteria.
Although at least nine Bartonella species are known to infect
humans, vascular proliferation is mainly caused by the species
Bartonella henselae (Bh), B. quintana (Bq), and B. bacilliformis [9].
Upon EC infection in vitro, Bh and Bq are able to stimulate
proliferation and inhibition of apoptosis [9–11]. The anti-
apoptotic activity of bartonellae is considered to contribute
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synergistically to an unrelated mitogenic activity and results
in the formation of vascular tumors [10,11].
In Bh, inhibition of apoptosis is dependent on a functional
VirB/VirD4 system [12,13]. This type IV secretion (T4S)
system is a major virulence determinant for Bartonella–EC
interaction [12–14]. T4S systems are versatile transporters
ancestrally related to bacterial conjugation machines. Differ-
ent human pathogens have recruited such conjugation
machineries to inject macromolecular effectors across the
bacterial and host cell membranes directly into the host cell
cytosol, where they alter various cellular processes [15]. Bh
carries a pathogenicity island that encodes next to the virB/
virD4 locus seven putative T4S substrates, the Bartonella-
translocated effector proteins Bh BepA–G [13]. Deletion of
the pathogenicity island regions encoding bepA–G abolishes
the anti-apoptotic activity and all other VirB/VirD4-depend-
ent EC phenotypes [13]. However, the contribution of
individual Bh Beps to anti-apoptosis and the other cellular
phenotypes is unknown. All seven Bh Beps carry in their C-
terminus at least one conserved region, called the Bep
intracellular delivery (BID) domain [13]. The positively
charged C-terminal tail sequence together with the proximal
BID domain constitute a bipartite signal for T4S. Based on a
Cre-recombinase assay for translocation (CRAfT), this T4S
signal was shown to be functional for VirB/VirD4-dependent
transfer of four different Bh Beps (Bh BepB, Bh BepC, Bh
BepD, and Bh BepF) [13]. Evidence for translocation of Bh
BepA, Bh BepE, and Bh BepG is still missing.
Bh BepA, Bh BepB, and Bh BepC are paralogous proteins. A
Bh BepA ortholog is found in the animal pathogen B.
tribocorum (Bt) [16]. Remarkably, all BepA homologs encode
in their N-terminal part a conserved FIC (filamentation
induced by cyclic adenosine monophosphate [cAMP]) do-
main, which was proposed to be involved in bacterial cell
division [17], while the putative effector function within
human cells is unknown.
In this paper, we identify BepA as anti-apoptotic effector
of the vasoproliferative bartonellae Bh and Bq. We show that
this effector is translocated by the VirB/VirD4 system into
ECs. Further, we show that the anti-apoptotic activity is
confined to the BID domain of Bh BepA, which also mediates
localization to the EC plasma membrane. We demonstrate
that Bh BepA provokes an elevation of intracellular cAMP
and the upregulation of cAMP-responsive genes, suggesting
that plasma membrane–associated Bh BepA triggers cAMP
production and signaling, resulting in the abrogation of
apoptotic processes. Accordingly, we were able to mimic the
anti-apoptotic effect of BepA by artificially increasing the
intracellular cAMP level in ECs. Finally, we demonstrate that
BepA can inhibit cytotoxic T lymphocyte (CTL)–mediated
apoptosis of ECs.
Results
Bh BepA Mediates Anti-Apoptosis in ECs
The anti-apoptotic activity of Bh on human umbilical vein
endothelial cells (HUVECs) requires a functional VirB/VirD4
system and at least one of the putatively secreted effectors Bh
BepA–G [12,13]. To identify the effector(s) required for
inhibition of apoptosis, we expressed them individually in the
substrate-free bepA–G mutant and assayed for anti-apoptotic
activity. To this end, HUVECs were infected with the
different Bh strains and apoptosis was induced by exposure
to actinomycin D. Morphological examination (Figure 1A),
measuring of caspase-3/-7 activity (Figure 1B), and flow
cytometric analysis of Annexin V– and propidium iodide
(PI)–stained cells (Figure 1C) were used to monitor apoptosis.
DbepA–G did not display anti-apoptotic activity as reported
previously [13]. Strikingly, the expression of Bh BepA (by
plasmid pBh BepA) restored the anti-apoptotic activity to
wild-type level (Figure 1), whereas no other Bh Bep interfered
with actinomycin D–triggered apoptosis (unpublished data).
Consistently, strain DbepA carrying an in-frame deletion of
bepA did not protect HUVECs from apoptosis, whereas
complementation of this mutant with pBh BepA restored
the anti-apoptotic activity (Figure 1). To test for functionality
of the VirB/VirD4 system in the DbepA mutant, we monitored
the T4S-dependent process of invasome formation [12,18],
and furthermore quantified the translocation efficiency of a
reporter substrate (encoded by pRS51) using CRAfT [13].
Both assays confirmed that the VirB/VirD4 T4S system is
functional in the DbepA strain (unpublished data).
Taken together, these results provide evidence that Bh
requires the putative T4S substrate Bh BepA to protect
HUVECs from apoptosis.
Bh BepA Is a VirB/VirD4 Substrate Translocated into ECs
CRAfT was used to demonstrate functionality of most of
the C-terminal bipartite T4S signals of Bh Beps [13], while this
assay was negative for the putative T4S substrate Bh BepA
(unpublished data). Here, we adapted the calmodulin-
dependent adenylate cyclase (Cya) reporter assay [19,20] as
an alternative to test for translocation of Bh BepA into
HUVECs. Translocation of a Cya reporter fusion is demon-
strated by the increase in the intracellular cAMP level. An N-
terminal FLAG-tag epitope was fused to Cya to determine the
stability of fusion proteins by immunoblot analysis (Figure 2A
and 2C). As positive control, the T4S signal of Bh BepD (Bh
BepD352–534) [13] was fused to the FLAG-Cya reporter
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The capacity of infected host cells to die by apoptosis (programmed
cell death) is critical for controlling pathogen replication and
survival. Bacterial pathogens have thus developed strategies to
inhibit host cell apoptosis, allowing them to preserve their cellular
habitat during chronic infection. For instance, the capacity of the
facultative intracellular pathogen Bartonella henselae to trigger
tumor formation as a consequence of chronic infection of the
human vasculature is linked to the inhibition of endothelial cell
apoptosis. This study describes the identification and functional
characterization of the anti-apoptotic bacterial effector protein BepA
of B. henselae, which is shown to be sufficient to inhibit endothelial
cell apoptosis, i.e., as triggered by activated cytotoxic T lympho-
cytes. Upon translocation into endothelial cells via a bacterial type IV
secretion system, BepA localizes to the plasma membrane, where it
triggers the production of second messenger cyclic adenosine
monophosphate in quantities effective for blocking apoptosis.
Strikingly, the capacity of BepA to mediate membrane localization,
cyclic adenosine monophosphate production, and the resulting
inhibition of apoptosis is confined to a conserved domain that
originally evolved in bacteria as a signal for type IV secretion. This
study thus highlights the convergent evolution of an anti-apoptotic
effector protein of purely bacterial origin.
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Figure 1. Bh BepA Meditates Inhibition of Apoptosis in ECs
(A and B) HUVECs were infected for 24 h with the indicated Bh strains (MOI¼ 300) or left uninfected for this period (control). If not indicated differently,
apoptosis was then triggered by the addition of actinomycin D. Then, 12 h later, (A) morphological changes were visualized by recording phase contrast
images (bar¼ 40 lm), and (B) caspase-3/-7 activities were determined with a specific fluorogenic peptide substrate. Arrowheads (A) indicate apoptotic
cells displaying membrane blebbing.
(C) Twenty-four hours after induction of apoptosis, the loss of membrane asymmetry was quantified by flow cytometric analysis of AlexaFluor488
Annexin V– and PI-stained cells, allowing us to quantify the rate of apoptotic cells (Annexin V–positive and PI-negative). Mean and standard deviation
(SD) are shown for one representative out of three independent replica experiments. All strains were tested a minimum of three times in triplicate
samples.
doi:10.1371/journal.ppat.0020115.g001
PLoS Pathogens | www.plospathogens.org November 2006 | Volume 2 | Issue 11 | e1151085
A Bacterial Protein Mediating Anti-ApoptosisChapter 1
C-5
(pFLAG-Cya–Bh BepD352–534). To test for translocation of Bh
BepA, either full-length protein (Bh BepA1–544) or the C-
terminal domain harboring the putative T4S signal (Bh
BepA305–544) was fused to FLAG-Cya. These reporter con-
structs were expressed either in Bh wild-type or in the DvirB4
mutant lacking a functional VirB/VirD4 system. HUVECs
infected with wild-type-expressing FLAG-Cya did not display
any significant increase of the cAMP level compared with
wild-type without the pFLAG-Cya plasmid. In contrast,
FLAG-Cya fused to either Bh BepD352–534, Bh BepA1–544, or
Bh BepA305–544 resulted in an approximately 10-fold increase
of intracellular cAMP levels in HUVECs (Figure 2B). This
effect was dependent on a functional VirB/VirD4 system. In
summary, we show that BepA is a VirB/VirD4 substrate that
harbors a functional C-terminal T4S signal.
The BID Domain of Bh BepA Is Sufficient to Inhibit
Apoptosis
Next, we determined whether ectopic expression of Bh
BepA in HUVECs is sufficient to mediate anti-apoptosis. N-
terminal green fluorescent protein (GFP) fusions to full-
length Bh BepA or fragments thereof were constructed in an
appropriate eukaryotic expression vector. As control we
included the expression vector pGFP encoding just GFP
(Figure 3A). Then, 24 h after transfection of HUVECs with the
different GFP fusion constructs, cells were either exposed to
actinomycin D (apoptosis induction) or left untreated (non-
induced control) for another 12 h. Then, cells were stained
with Annexin V and PI, and the proportion of apoptotic cells
among the GFP-positive cell population was quantified by
flow cytometry.
HUVECs transfected with pGFP and treated with actino-
mycin D displayed an apoptotic rate of 13% (Figure 3B).
Fusion of full-length Bh BepA to the C-terminus of GFP
(pGFP–Bh BepA1–544) reduced the apoptotic population
almost 4-fold to a level similar to that of the non-induced
control. The same anti-apoptotic activity was observed when
only the C-terminal bipartite T4S signal of Bh BepA was
fused, thus missing the first 304 N-terminal amino acids
encoding the FIC domain (pGFP–Bh BepA305–544). In contrast,
fusion of the FIC domain (pGFP–Bh BepA1–304) did not result
in inhibition of apoptosis. Further analysis showed that
fusion of the BID domain (142 amino acids [aa]) to GFP
(pGFP–Bh BepA305–446) was sufficient to inhibit apoptosis,
whereas fusion of the positively charged C-terminal tail plus
only part of the BID domain (pGFP–Bh BepA403–544) did not
result in anti-apoptosis (Figure 3B). Rather, expression of the
latter construct had a pro-apoptotic effect, as indicated by
Figure 2. Bh BepA Is a Genuine VirB/VirD4 T4S Substrate That Is
Translocated into ECs
(A) The bars indicate the parts of Bh BepA or Bh BepD that were fused to
Cya. These reporter fusions were used to monitor translocation via the
VirB/VirD4 system. All constructs contain an N-terminal FLAG epitope for
immunological detection of the encoded fusion protein.
(B) Quantification of the amount of intracellular cAMP in HUVECs
infected for 20 h with the indicated bacterial strains (MOI¼300). Isogenic
strains with a functional (wild-type) or non-functional (DvirB4) VirB/VirD4
T4S system were used to express the different Cya reporter constructs.
Mean and SD are shown for one representative out of three independent
replica experiments.
(C) Steady-state FLAG-Cya fusion protein levels of the indicated Bh strains
grown on IPTG-containing medium.
doi:10.1371/journal.ppat.0020115.g002
PLoS Pathogens | www.plospathogens.org November 2006 | Volume 2 | Issue 11 | e1151086
A Bacterial Protein Mediating Anti-ApoptosisChapter 1
C-6
the increased apoptotic cell population in the untreated
sample. Taken together, these data demonstrate that ectopic
expression of the BID domain as part of the bipartite T4S
signal of Bh BepA in ECs is sufficient to mediate protection
against apoptosis.
Anti-Apoptotic Bh BepA Constructs Associate with the
Plasma Membrane
To test for the subcellular localization of Bh BepA in host
cells, the generated GFP fusions (Figure 3A) were ectopically
expressed in HEK293T cells for 24 h, followed by immuno-
cytochemical staining for the cell surface with Texas Red–
conjugated wheat germ agglutinin (WGA). Samples were
analyzed by confocal microscopy by taking images in the xy-
plane. To better distinguish between cytoplasmic and
membrane-associated localization, we also captured images
in an xz-plane (indicated in Figure 3C by dashed lines).
Ectopically expressed GFP localized to the cytoplasm of
HEK293T cells, whereas the GFP–Bh BepA1–544 fusion
localized to the plasma membrane (Figure 3C). Interestingly,
all fusion proteins with anti-apoptotic activity localized to the
plasma membrane, while those that did not confer protection
localized primarily to the cytoplasm.
Fractionation of post-nuclear extracts of the transfected
HEK293T cells by ultracentrifugation was used as an
independent biochemical assay for analyzing the membrane
or cytosolic localization of ectopically expressed GFP-BepA
fusions. The obtained data (Figure 3D) were in good agree-
ment with the microscopic analysis presented in Figure 3C,
except that construct pGFP–Bh BepA403–544 displayed both
cytosolic and membrane localization.
Taken together, these data suggest that association with the
plasma membrane is critical for the anti-apoptotic activity of
Bh BepA.
Only BepA Orthologs from Vasoproliferative Bartonella
Species Display Anti-Apoptotic Activity
To assess whether anti-apoptosis is a general feature of
BepA homologs, we tested the orthologs encoded by other
Bartonella species for this activity. Bq was previously shown to
cause vascular tumor formation, whereas Bt was never
associated with vascular lesions [9]. Consistent with these
observations, only Bh and Bq, but not Bt wild-type, were able
to block actinomycin D–triggered caspase-3/-7 activation in a
T4S-dependent manner (Figure 4A). In the genome sequence
of Bq, the bepA gene is annotated as a pseudogene [21]. Closer
inspection of the sequence revealed that because of an
internal stop codon and a downstream-located start codon in
frame, this bepA locus is split into two open reading frames (Bq
bepA1 and Bq bepA2). Bq bepA1 encodes a FIC domain, and Bq
bepA2 encodes a BID domain and the positively charged C-
terminal tail, the latter representing a putative T4S signal.
Comparison of the amino acid sequences of Bq BepA1 and Bq
BepA2 with Bh BepA revealed high similarity (59% and 63%,
respectively). We cloned Bt bepA and Bq bepA2 into expression
plasmids, which were introduced into DbepA–G (Figure 4B). As
controls we included the paralogs Bh bepB and Bh bepC, which
in the initial screening of Bh Beps were found to lack anti-
apoptotic activity (Figure 4B and unpublished data). HUVECs
were infected for 24 h with the different isogenic strains, and
subsequently apoptosis was induced by actinomycin D. Of the
tested BepA homologs, only Bh BepA and Bq BepA2 inhibited
actinomycin D–triggered caspase-3/-7 activation (Figure 4C).
These findings revealed that Bq bepA2 encodes an anti-
apoptotic effector. To assign Bq BepA2 as a novel T4S
substrate, we translocated a FLAG-Cya-BepA2 fusion from Bh
into HUVECs by the Cya reporter assay (unpublished data).
These results show that the anti-apoptotic activity of BepA is
conserved among two human pathogens with vasoprolifer-
ative capacity (Bh and Bq), but not in Bt, which has not been
associated with vasoproliferation. Moreover, these data
confirm the localization of the anti-apoptotic activity to the
C-terminal region of BepA that composes a functional T4S
signal [13].
Inhibition of Apoptosis Correlates with an Increased
Intracellular cAMP Level
To identify potential survival pathways mediated by anti-
apoptotic BepA, we analyzed Affymetrix GeneChip data
obtained for the transcriptome of HUVECs infected with Bh
wild-type versus the DvirB4 mutant impaired in T4S (M.
Dehio, M. Schmid, M. Quebatte, and C. Dehio, unpublished
data). These data revealed a T4S-dependent upregulation of
the NFjB- and cAMP-dependent CREM/CREB regulons in
HUVECs. Both signaling pathways have been described to
mediate, among other functions, protection against apoptosis
[22–24].
We tested whether these pathways were activated by anti-
apoptotic BepA homologs. We monitored activation of the
NFjB pathway in infected HUVECs by measuring the release
of interleukin 8 (IL-8). Bh wild-type triggered an increased IL-
8 release compared with DbepA–G or the uninfected control.
In contrast, none of the BepA homologs expressed in DbepA–
G induced increased IL-8 secretion (Figure 5A). This finding
indicates that the survival mechanism triggered by anti-
apoptotic BepA homologs is independent from the activation
of the NFjB pathway triggered by wild-type bacteria.
Activation of the cAMP-dependent CREM/CREB pathway
was assayed by quantitative real-time PCR of two cAMP-
inducible genes, namely pde4B and crem [25,26]. Only strains
translocating anti-apoptotic BepA homologs were found to
induce the expression of these genes in a statistically
significant manner (Figure 5B). By quantifying intracellular
cAMP upon infection of HUVECs by the various isogenic Bh
strains, we further demonstrated that anti-apoptotic BepA
homologs significantly increase the intracellular cAMP level
(Figure 5C).
A Rise in Intracellular cAMP Results in Protection of ECs
against Apoptosis
Since translocation of anti-apoptotic BepA homologs
resulted in a rise of the intracellular cAMP level, we further
studied the role of cAMP in anti-apoptosis. The intracellular
cAMP level is regulated by adenylate cyclases (ACs) generat-
ing cAMP, and phosphodiesterases degrading cAMP [27,28].
To trigger a physiological rise of the cAMP level in ECs, we
activated ACs with forskolin and in parallel inhibited cAMP
degradation by adding the phosphodiesterase-inhibiting drug
3-isobityl-1-methylxanthine (IBMX) [29,30]. HUVECs were
infected with the substrate-free DbepA–G strain and with the
BepA-expressing strain DbepA–G/pBh BepA in the absence
and presence of forskolin/IBMX. Apoptosis was induced by
exposure to actinomycin D and monitored by measuring
caspase-3/-7 activity. By adding forskolin/IBMX we were able
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to reduce caspase-3/-7 activity in uninfected HUVECs and
cells infected with the DbepA–G strain to a level similar to that
found in cells infected with DbepA–G/pBh BepA. Interestingly,
the addition of forskolin/IBMX did not have an additive
protection effect in DbepA–G/pBh BepA–infected HUVECs
(Figure 6A). The same results were obtained by adding the
cell-permeable cAMP analog dibutyryl cAMP to the culture
medium (Figure 6B). From these data we conclude that a
moderately increased intracellular cAMP level, as triggered
by Bh BepA, is sufficient to protect ECs against apoptosis.
The Role of Bh BepA in Evading CTL-Mediated Apoptosis
During colonization of the human endothelium, intra-
cellular Bh are hidden from antibody- and complement-
mediated immune responses [9]. However, the infected ECs
may be killed by CTLs [31]. To study a putative role of Bh
BepA in protecting ECs from CTL-mediated apoptosis, we
used a major histocompatibility complex (MHC) class I–
restricted CTL clone that kills HLA-A2-positive HUVECs
upon extracellular loading with a Y-chromosome-encoded,
male-specific minor histocompatibility Ag peptide with the
sequence FIDSYICQV (SMCY peptide) [32]. To specifically
measure the rate of EC apoptosis without interference by
apoptotic CTLs, we pre-labeled the EC population with the
fluorogenic dye CSFE. Pre-labeled HUVECs were left unin-
fected (control), or infected with wild-type, DbepA–G, or
DbepA–G/pBh BepA. Then, 24 h after infection, HUVECs were
either pre-loaded for 30 min with the CTL-stimulating SMCY
peptide (105 M) or not pre-loaded. After washing, CTLs were
added in an effector-to-target cell ratio of 5:1. At different
time points (0 h, 2.5 h, and 6 h), Annexin V and PI staining
was performed to quantify the amount of apoptotic HUVECs
(CSFE-positive, Annexin V–positive, and PI-negative) (Figure
7A and 7B). SMCY-treated HUVECs, which were either
uninfected or pre-infected with the BepA-deficient DbepA–G
mutant strain, displayed a time-dependent increase in the
apoptotic population in comparison with respective control
cells without pre-loading of the CTL-activating SMCY
peptide. In sharp contrast, SMCY-treated HUVECs pre-
infected with wild-type or the BepA-expressing strain
DbepA–G/pBh BepA did not display any significant increase
of apoptosis over control cells without pre-loading with the
SMCY peptide. These data indicate that BepA is capable of
protecting ECs against the MHC class I–restricted apoptotic
activity of CTLs. Consistently, we noticed that BepA-express-
ing bacteria, as well as the ectopic expression of a GFP–Bh
BepA fusion protein alone, protected ECs against cell death
triggered by a different CTL clone, which was activated by
phytohemagglutinin in an MHC class I–independent manner
(unpublished data). Together, these data indicate that trans-
located Bh BepA can effectively protect the chronically
infected vascular endothelium against CTL-mediated cell
death.
Discussion
The modulation of host cell apoptosis is a recurrent theme
in bacterial pathogenesis [1]. Research in this area focused
initially on the pro-apoptotic mechanisms triggered by
pathogens that typically cause acute infections (e.g., Shigella,
Salmonella, and Yersinia species). Some pro-apoptotic effectors
and their targeted cellular pathways have been studied in
molecular detail [33,34]. More recently, pathogen-triggered
anti-apoptosis was recognized as an important virulence trait
of bacteria that predominately cause chronic infection (e.g.,
Bartonella, Brucella, Chlamydia, Helicobacter, Mycobacterium, and
Rickettsia species) and thus need to protect their cellular
habitats by suppressing host-triggered apoptosis [35]. How-
ever, the bacterial effectors, and to a large extent also the
cellular pathways involved in mediating pathogen-induced
anti-apoptosis, remain poorly defined. In the case of Bh and
Bq, the formation of vascular tumors in immunocompro-
mised patients was shown to be linked to the inhibition of
apoptosis of infected ECs [10]. In this report, we identified the
anti-apoptotic factor of these vasoproliferative bartonellae.
Deletion of the Bh bepA gene resulted in the complete loss of
the anti-apoptotic activity of Bh, whereas expression of Bh
bepA in trans restored the activity to wild-type level. Bh BepA
was previously described as a putative substrate of the T4S
system VirB/VirD4 [13]; we used the Cya reporter assay to
demonstrate that Bh BepA is indeed translocated into ECs in
a T4S-dependent manner. Bh BepA is thus a genuine T4S
effector that inhibits apoptosis upon translocation into
HUVECs. It is worth noting that we have been unable to
show translocation of Bh BepA by CRAfT, an assay that we
previously used to demonstrate translocation of several other
Bh Beps [13]. Nuclear import of the Cre reporter protein
fusion is a prerequisite for a positive readout by CRAfT [13],
suggesting that the negative readout obtained for Bh BepA
fusions could result from protein recruitment to an intra-
cellular localization that interferes with nuclear import.
Indeed, ectopic expression of full-length Bh BepA fused to
GFP revealed a prominent localization of the fusion protein
to the plasma membrane, in contrast to the cytosolic
localization of GFP alone. Unlike ectopically expressed GFP,
the GFP–Bh BepA fusion also conferred protection against
EC apoptosis. These data demonstrate that Bh BepA is not
only required but also sufficient for inhibiting EC apoptosis,
Figure 3. Delineation and Subcellular Localization of the Region of Bh BepA Required for Inhibition of Apoptosis
(A) Schematic presentation of N-terminal GFP fusions to parts of Bh BepA.
(B) Determination of apoptosis following ectopic expression of the constructs illustrated in (A). GFP-BepA fusion proteins were ectopically expressed in
HUVECs for 24 h, followed by 12 h incubation in the presence or absence of actinomycin D as indicated. The loss of membrane asymmetry in
transfected cells (GFP-positive) was then quantified by flow cytometric analysis of APC-Annexin V– and PI-stained cells, allowing us to quantify the rate
of apoptotic cells (Annexin V–positive and PI-negative). The means and SD of three independent replica experiments are shown. The p-values were
determined by using an unpaired Student’s t-test.
(C) The GFP–Bh BepA fusion proteins illustrated in (A) were ectopically expressed for 24 h in HEK293T cells. Cells were immunochemically stained to
label the cell surface with Texas Red–conjugated WGA. Confocal pictures were taken for GFP (green channel) and WGA (red channel) in the xy-plane
(upper image, overlay both channels, bar ¼ 10 lm), and also in the xz-plane at the dashed stroke line (lower images, single channels and overlay
channels).
(D) Fractionation of GFP–Bh BepA fusion proteins into membrane and cytosolic fractions by ultracentrifugation of post-nuclear extracts harvested from
transfected HEK293T cells.
doi:10.1371/journal.ppat.0020115.g003
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Figure 4. Comparison of the Anti-Apoptotic Activities of BepA Homologs
(A) Anti-apoptotic activities of wild-type and isogenic DvirB4 mutant
strains of Bh in comparison with Bq and Bt.
(B) Domain structure of Bh BepA, its paralogs Bh BepB and Bh BepC, and
the orthologs Bt BepA and Bq BepA1/Bq BepA2. These homologs contain
conserved FIC and BID domains in their N-terminal and C-terminal
regions, respectively, except for Bq, where the orthologous locus is split
between these domains into two separate open reading frames by an
internal stop codon.
(C) Anti-apoptotic activity of BepA homologs. HUVECs were infected with
the indicated Bh strains for 24 h, followed by apoptotic induction with
actinomycin D for 12 h. Caspase-3/-7 activities were then determined
with a specific fluorogenic peptide substrate. Mean and SD are illustrated
for one representative out of three independent experiments.
doi:10.1371/journal.ppat.0020115.g004
Figure 5. Anti-Apoptotic BepA Homologs Mediate an Increase in
Intracellular cAMP and an Upregulation of cAMP Response Genes
HUVECs were infected with the indicated Bh strains. The means and SD
of one out of three independent replica experiments performed in
triplicate samples are presented.
(A) IL-8 was determined in culture supernatants after infection for 54 h
with MOI¼ 300.
(B) Expression of the cAMP-responsive genes pde4B and crem was
determined by quantitative real-time PCR after infection for 54 h with
MOI¼ 300.
(C) Intracellular cAMP levels were determined after infection for 30 h with
MOI¼ 150.
In (B) and (C), samples marked with an asterisk (p , 0.05) differ
statistically significantly from DbepA–G using an unpaired Student’s t-
test.
doi:10.1371/journal.ppat.0020115.g005
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and that this anti-apoptotic effector localizes to the plasma
membrane. Moreover, ectopic expression of various parts of
Bh BepA fused to GFP revealed a strict correlation of the
capacity to mediate anti-apoptosis with localization to the
plasma membrane (as opposed to the primarily cytoplasmic
localization of fusions that did not cause anti-apoptosis). This
finding indicates that plasma membrane targeting may be
important for the anti-apoptotic activity of Bh BepA.
In search of the cellular pathway by which Bh BepA
mediates anti-apoptosis in ECs, we first tested whether an
NFjB-dependent survival pathway is involved. The anti-
apoptotic activity of R. rickettsii in ECs was reported to
depend on NFjB activation [5], and we have previously shown
that Bh activates NFjB in a VirB/VirD4- and Bep-dependent
manner [13]. Here, we demonstrated that Bh BepA alone does
not trigger the NFjB-dependent secretion of IL-8; even so, it
fully protects against apoptosis. Thus, NFjB does not seem
critical for Bh BepA–mediated anti-apoptosis. Affymetrix
GeneChip experiments indicated that Bh also triggers a cAMP
signaling pathway in a T4S-dependent manner (M. Dehio, M.
Schmid, M. Quebatte, and C. Dehio, unpublished data). Here,
we have shown that the anti-apoptotic activity of Bh BepA in
HUVECs correlates with elevation of the intracellular cAMP
level and results in the upregulation of cAMP-stimulated gene
expression. Recently, it emerged that the regulation of
apoptosis is an important facet of cAMP signal transduction
[30,36–38]. Moderately elevated cAMP levels were reported to
protect several cell types against apoptosis, while the survival
mechanisms differed from cell type to cell type and were
considered to require the activation of protein kinase A,
extracellular signal regulated, mitogen-activated protein
kinase, or guanine nucleotide exchange factor signaling
pathways, which subsequently resulted in the expression of
anti-apoptotic genes [23,36,37,39–44]. In our system, the
specific downstream signaling pathway mediating cAMP-
dependent anti-apoptotis remains elusive: efforts to block
putatively involved signaling molecules (i.e., protein kinase A)
failed because of apparent cytotoxic effects of effective
inhibitor concentrations during the extended time frame of
the apoptosis assay.
Importantly, a physiological rise in the intracellular cAMP
level has been reported to fully protect ECs against apoptosis
[45]. Consistent with this, we observed that increased cAMP
levels caused by the combined action of the AC-activating
drug forskolin and the phosphodiesterase-inhibiting drug
IBMX resulted in a complete suppression of actinomycin D–
induced apoptosis in HUVECs. Forskolin/IBMX-treated cells
displayed an increase in the expression of cAMP-regulated
genes similar to that observed upon infection with anti-
apoptotic Bh strains. cAMP is produced in eukaryotic cells by
the family of membrane-anchored ACs. ACs are activated by
heterotrimeric G proteins that are regulated by G protein–
coupled receptors [46]. Since the anti-apoptotic activity of Bh
BepA in HUVECs is strictly associated with the plasma
membrane localization of this effector, concomitant with an
increase in the cAMP level, we propose that Bh BepA may
trigger anti-apoptosis by interacting either with ACs directly,
or with plasma membrane–associated heterotrimeric G
proteins or G protein–coupled receptors that regulate AC
activity.
Ectopic expression of GFP fusions with different parts of
Bh BepA confined the anti-apoptotic activity to a region of
142 aa, which corresponds to the BID domain. This conserved
domain was previously shown to be present in a least one
copy in all Beps of Bh and Bq [13,14,21]. The BID domain plus
the C-terminal positively charged tail sequence of the Beps
was shown to constitute a bipartite translocation signal for
T4S [13]. Interestingly, in contrast to the BID domain of Bh
BepA, the conserved BID domains of the paralogs Bh BepB
and Bh BepC have not been associated with anti-apoptosis.
This indicates that subsequent to the expansion of this
paralogous protein family by gene duplication, the Bh BepA
BID domain acquired, in addition to its crucial function as a
signal for T4S, the capacity to mediate anti-apoptosis. How
this rather short domain may mediate these unrelated
activities is presently unknown. It may be speculated that
the BID domain represents a basic fold that mediates a
protein–protein interaction with the T4S machinery that is
crucial for protein translocation, and that in Bh BepA this
basic fold is adapted to also mediate specific interaction with
the plasma membrane–associated, cAMP-generating signaling
cascade of ECs.
Each of the paralogs Bh BepA, Bh BepB, and Bh BepC
carries in the N-terminal region one copy of the FIC domain.
While this conserved domain of unknown function might be
Figure 6. A Pharmacologically Increased cAMP Level in ECs Mimics the
Anti-Apoptotic Effect of Bh BepA
HUVECs were infected for 24 h with the indicated Bh strains or left
uninfected (control) in the absence or presence of either (A) forskolin (1
lM) and IBMX (10 lM) or (B) dibutyryl cAMP (1 mM). If indicated,
apoptosis was then induced with actinomycin D. Caspase-3/-7 activities
were determined 9 h later. All strains were tested in triplicates a
minimum of three times.
doi:10.1371/journal.ppat.0020115.g006
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important for the effector function of Bh BepB and Bh BepC,
our results demonstrate that the FIC domain is dispensable
for the anti-apoptotic activity of Bh BepA. Interestingly, an
internal stop codon and downstream-located start codon
within the bepA ortholog of Bq split this locus into two
separate open reading frames (Bq bepA1 and Bq bepA2). Bq
BepA1 has the FIC domain but lacks a T4S signal, and thus
cannot be translocated into ECs. In contrast, Bq BepA2
consists only of the T4S signal, which we have shown mediates
both T4S-dependent translocation and anti-apoptosis in ECs.
It thus appears plausible that the functional diversification of
BepA into an anti-apoptotic effector occurred in the
common ancestor of the closely related species Bh and Bq
[21], and that following speciation the acquisition of addi-
tional mutations resulted in the elimination of the dispen-
sable N-terminal FIC domain in Bq.
Interestingly, unlike Bh BepA and Bq BepA2, the BepA
ortholog of Bt does not mediate any anti-apoptotic activity,
nor any measurable activation of the cAMP pathway. This
observation is in agreement with the previously reported
finding that, among the bartonellae, the anti-apoptotic
activity is limited to the vasoproliferative species Bh and Bq
[10].
To asses if the here identified anti-apoptotic activity of Bh
BepA might be able to protect the cellular habitat of Bh
during the infection process, we used a co-culture system of
HUVECs with human CTLs. CTLs execute cell-mediated
immunity, an immune mechanism probably involved in the
elimination of Bh infection [9,12,47]. Cell-mediated immunity
particularly serves as a defense mechanism against microbes
that survive and replicate inside infected host cells. Upon
recognition of MHC class I–displaying microbial peptides,
CTLs are activated to kill their target cells by the release of
perforin and granzymes [31,48]. Perforin forms pores in the
target cell membrane and assists the delivery of pan-caspase-
activating granzymes into the cytoplasm of the target cell
[44,49,50]. In our study, we used a CTL clone that is activated
in an MHC class I–restricted manner by extracellular loading
of HLA-A2-positive HUVECs with an HLA-A2-specific pep-
tide (SMCY). Such activated CTLs kill their target cells in a
perforin-dependent manner [32], primarily by triggering
granzyme-dependent apoptosis [50,51]. Bh BepA–expressing
strains indeed inhibited CTL-triggered EC apoptosis, indicat-
ing that the biological function of Bh BepA expression in vivo
might be to protect the integrity of its colonized cellular
niche. The Bh BepA–mediated resistance of ECs to CTL-
dependent cell death points towards an important role of
BepA in escaping cell-mediated immunity and thus in
protecting the integrity of the chronically infected vascula-
ture, which is a prerequisite for vascular proliferation. The
establishment of an animal model for Bartonella-triggered
vasoproliferation now appears an urgent need for studying
the precise contribution of BepA-mediated anti-apoptosis in
the process of vascular tumor formation.
In summary, the anti-apoptotic T4S effectors Bh BepA and
Bq BepA2 characterized in this study represent striking
examples of the evolution of new pathogenic traits in
bacteria. The delineation of their anti-apoptotic activity to
the conserved BID domain, and their proposed role in
maintaining the cellular habitat by mediating anti-apoptosis
via specific interaction with the plasma membrane–associ-
ated, cAMP-generating signaling cascade of ECs, should pave
the way for future studies to elucidate the molecular and
structural basis of Bartonella-mediated anti-apoptosis in the
vascular endothelium and the role of this pathological
process in vasoproliferative tumor growth.
Materials and Methods
Bacterial strains and growth conditions. The bacterial strains used
in this study are listed in Table 1. Bartonella spp. were grown on
Columbia agar plates containing 5% defibrinated sheep blood (CBA
plates) at 35 8C and 5% CO2 for 2–4 d. Strain RSE247, a spontaneous
streptomycin-resistant strain of Bh ATCC 49882T [12], served as wild-
type in this study. When indicated, media were supplemented with 30
lg/ml kanamycin, 100 lg/ml streptomycin, 12.5 lg/ml gentamicin,
and/or 500 lM isopropyl b-D-thiogalactosidase (IPTG). Escherichia coli
strains were cultivated in Luria-Bertani liquid medium, or after
addition of agar on plates, at 37 8C overnight. When indicated, media
were supplemented with 50 lg/ml kanamycin, 200 lg/ml ampicillin, 25
lg/ml gentamicin, 500 lM IPTG, and/or 1 mM diaminopimelic acid.
DNA manipulation. Plasmids used in this study are listed in Table
1. Primers are listed in Table 2.
Plasmids for in-frame deletions and complementation of deletion
mutants were constructed as follows: pMS5 used for creating the
DbepA mutant was already described before [13]. The use of pMS5 for
gene replacement in RSE247 resulted in the DbepA mutant MSE154.
Plasmid pRS63, used for generating a DvirB4 in-frame deletion
mutant in Bq, was constructed as follows. The BamHI insert of pRS14
[16] was replaced by a 1,318-bp BamHI fragment of the Bq virB locus
containing a 2,112-bp in-frame deletion in virB4. This fragment was
constructed by megaprime PCR from two PCR products. Product 1
(0.75 kb) was amplified with primers prRS226 and prRS227 and
contained the first 115 bp of the virB4 gene and upstream sequences.
Product 2 (0.55 kb) was amplified with primers prRS228 and prRS229
and contained the last 120 bp of the virB4 gene and downstream
sequences. Megapriming and PCR amplification with primers
prRS226 and prRS229 were performed as described [16].
Plasmids for complementation of DbepA mutant and DbepA–G
mutant were constructed as follows: For constructing vectors
expressing N-terminal FLAG-tagged Bep proteins, the plasmid
pPG100 was used. The fragments were generated by PCR amplifica-
tion from chromosomal DNA of RSE247 and Bt, using oligonucleo-
tide primers prPG92/93, prPG95/129, prPG97/130, or pMS27/28, and
were inserted by the flanking NdeI site into the corresponding site of
pPG100, resulting in pPG101 (encoding Bh BepA), pMS006 (encoding
Bh BepB), pMS007 (encoding Bh BepC), and pMS011 (encoding Bt
BepA). To construct plasmid pMS100, carrying a multiple cloning
site, prGS01 and prGS02 were annealed together and the resulting
45-bp fragment was inserted into pPG100 using the NdeI site. Using
oligonucleotide primers pMS102 and prMS103, a fragment of 0.85 kb
was amplified using chromosomal DNA of Bq as template. Then, using
SalI/XmaI sites, this fragment was inserted into the corresponding site
of pMS100, giving rise to pMS106. Plasmid pMS105 was constructed
as follows: using flanking SalI/XmaI sites, the 1.65-kb PCR fragment
Figure 7. Bh BepA Protects ECs against CTL-Mediated Cell Death
Confluent HUVEC monolayers fluorescently labeled with the cell-tracking dye CFSE were infected with the indicated bacterial strains for 24 h or left
uninfected (control). Then cells were incubated in the presence (þ SMCY) or absence ( SMCY) of SMCY peptides, followed by washing. CTLs were
added in an effector-to-target cell ratio of 5:1 for the indicated period, and after washing and Annexin V– and PI-staining, the apoptotic cell population
of HUVECs was determined by flow cytometry analysis (CFSE-positive, Annexin V–positive, and PI-negative).
(A) Dot plots are shown for representative samples.
(B) Summary graph representing HUVEC apoptosis during CTL co-culture. The mean and SD of one of two independent experiments performed in
duplicates is shown.
doi:10.1371/journal.ppat.0020115.g007
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Table 1. Bacterial Strains and Plasmids Used in This Study
Strain or Plasmid Name Genotype or Relevant Characteristics Reference or Source
Bh strains ATCC 49882T Houston-1, isolated from a bacteremic HIV patient [57]
MSE150 DbepA–G mutant of RSE247 [13]
MSE154 DbepA mutant of RSE247 This work
MSE156 MSE150 containing pPG101 This work
MSE159 MSE150 containing pMS007 This work
MSE162 MSE150 containing pRS51 [13]
MSE164 MSE154 containing pRS51 This work
MSE166 MSE154 containing pPG101 This work
MSE167 MSE150 containing pMS006 This work
MSE175 MSE150 containing pMS011 This work
MSE218 MSE150 containing pMS100-A This work
MSE220 MSE150 containing pMS100-D This work
MSE226 MSE150 containing pMS100-B This work
MSE228 MSE150 containing pMS100-C This work
MSE240 MSE150 containing pMS102 This work
MSE242 MSE150 containing pMS104 This work
MSE249 RSE247 containing pMS400 This work
MSE251 RSE247 containing pMS401 This work
MSE253 RSE247 containing pMS404 This work
MSE255 RSE242 containing pMS400 This work
MSE257 RSE242 containing pMS401 This work
MSE259 RSE242 containing pMS404 This work
MSE269 MSE150 containing pMS106 This work
MSE273 RSE247 containing pMS406 This work
MSE275 RSE242 containing pMS406 This work
MSE277 RSE247 containing pMS405 This work
MSE279 RSE242 containing pMS405 This work
RSE232 RSE242 containing pRS51 [13]
RSE242 DvirB4 mutant of RSE247 [12]
RSE247 Spontaneous Smr strain of ATCC 49882T, serving as wild-type [12]
RSE308 RSE247 containing pRS51 [13]
Bq strains JK-31 Isolated from a bacteremic patient with bacillary angiomatosis [58]
RSE356 Spontaneous Smr strain of JK-31, serving as wild-type This work
RSE569 DvirB4 mutant of RSE356 This work
VR 358 [58]
Bt strains IBS 506T Isolated from a brown rat (Rattus norvegicus) (CIP 105476T) [16]
RSE149 Spontaneous Smr strain of IBS 506T, serving as wild-type [16]
RSE173 DvirB4 mutant of RSE149 [16]
E. coli strains b2150 F’ lacZDM15 lacIq traD36 proAþBþ thrB1004 pro thi strA hsdS lacZDM15
DdapA::erm (ErmR) pir
[16]
NovaBlue endA1 hsdR17(r K12–m K12þ) supE44 thi-1 recA1 gyrA96 relA1 lac[F9 proAþBþ la-
cIqZDM15::Tn10 (TcR)]
Novagen, Madison
Plasmids pPG100 E. coli– Bartonella spp. shuttle vector, encoding a short FLAG epitope [13]
pPG101 Derivative of pPG100, encoding FLAG::Bh BepA This work
pRS40 Cre vector encoding NLS::Cre [13]
pRS48 Cre vector containing NLS::Cre::Bh BepA (aa 305–544) This work
pRS49 Cre vector encoding NLS::Cre::Bh BepB (aa 303–542) [13]
pRS50 Cre vector encoding NLS::Cre::Bh BepC (aa 292–532) [13]
pRS51 Cre vector encoding NLS::Cre::Bh BepD (aa 352–534) [13]
pRS55 Cre vector encoding NLS::Cre::Bt BepA (aa 326–568) This work
pMS005 Mutagenesis vector for generating a DbepA in-frame deletion in Bh [13]
pMS006 Derivative of pPG100, encoding FLAG::Bh BepB This work
pMS007 Derivative of pPG100, encoding FLAG::Bh BepC This work
pMS013 Cre vector containing NLS::Cre::Bh BepA (aa 1–544) This work
pMS011 Derivate of pPG100, encoding FLAG::Bt BepA This work
pMS100 Insertion of a multiple cloning site into pPG100 This work
pMS106 Derivate of pMS100, encoding FLAG::Bq BepA2 This work
pMS100-A Derivate of pMS100, encoding FLAG::Bh BepA (aa 305–542) This work
pMS100-B Derivate of pMS100, encoding FLAG::Bh BepB (aa 303–542) This work
pMS100-C Derivate of pMS100, encoding FLAG::Bh BepC (aa 292–542) This work
pMS100-D Derivate of pMS100, encoding FLAG::Bh BepD (aa 352–534) This work
pMS105 Insertion of Bh BepA into pMS100 This work
pMS111 Containing the hybrid yopE-cyaA gene [19]
pMS400 pMS100 containing a 1.23-kb PCR fragment carrying the cya of Bordetella pertus-
sis (amplified from pMS111-Cornelis)
This work
pMS401 Cya vector encoding Bh BepA (aa 305–542) This work
pMS404 Cya vector encoding Bh BepD (aa 252–534) This work
pMS405 Cya vector encoding Bh BepA This work
pMS406 Cya vector encoding Bq BepA2 This work
doi:10.1371/journal.ppat.0020115.t001
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generated by prMS37/38 (chromosomal DNA of RSE247 serves as a
template) was inserted into the corresponding sites in pRS40, yielding
pMS13. Using flanking SalI/XmaI sites, the 1.65-kb fragment was
shuttled into the SalI/XmaI sites of pMS100. Using oligonucleotide
primers prRS167/180 and prRS187/188, fragments of 0.73-kb size
were amplified using chromosomal DNA of RSE247 and of Bt,
respectively, as template. Using flanking SalI/XmaI sites, the frag-
ments were inserted into the corresponding site of pRS40, giving rise
to pRS48 and RS55, respectively. C-terminal sequences of the
different Bep proteins were shuttled into pMS100 using the flanking
SalI/XmaI sites. The plasmids resulting from this step are given below,
as well as the range of amino acids of a given Bep protein fused to the
N-terminal FLAG: pMS100-A (shuttled from pRS48, aa 305–544 of Bh
BepA), pMS100-B (shuttled from pRS49, aa 303–542 of Bh BepB),
pMS100-C (shuttled from pRS50, aa 292–532), and pMS100-D
(shuttled from pRS51, aa 352–534 of Bh BepD).
Plasmids for expression of Cya-Bep fusion proteins were con-
structed as follows: To construct pMS400, the cya of pMS111 was PCR-
amplified with oligonucleotide primers prMS78/90 introducing a start
and a stop codon to the resulting cya fragment. Using flanking NdeI/
XmaI sites, the 1.23-kb fragment was inserted in the corresponding
sites of pMS100. Plasmid pMS401 was derived by insertion of a 1.2-kb
NdeI/StuI fragment of pMS400, which includes the cya gene without
stop codon, into the corresponding sites of pMS100-A. The NdeI/StuI
fragment of pMS400 was further inserted in the corresponding site of
pMS100-D and pMS105, giving rise to pMS404 and pMS405,
respectively. To construct pMS406, Bq BepA2 was PCR-amplified
from chromosomal DNA of Bq with oligonucleotide primers
prMS103/104. Using flanking PmeI/XmaI sites, the 0.86-kb fragment
was inserted in the StuI/XmaI sites of pMS400.
Plasmids for ectopic expression of GFP-BepA fusion proteins were
constructed as follows: To construct eGFP-Bep fusion proteins (see
Figure 4A), pWAY21 (Molecular Motion Lab, http://momotion.cn-
s.montana.edu), a CMV-driven EGFP for C-terminal fusion, was used
as basic vector. The plasmids resulting from this step and the
oligonucleotide primers used (with incorporated XmaI/XbaI sites
used for cloning to the corresponding sites of pWAY21) are given
below, as well as the range of amino acids of a given Bep protein fused
to eGFP: pMS21 (primers prMS68/69, aa 1–544 of Bh BepA), pMS22
(primer prMS76/77, aa 302–542 of Bh BepB), pMS23 (primers prMS83/
69, aa 305–544 of Bh BepA), pMS24 (primers prMS83/84, aa 305–446
of Bh BepA), pMS25 (primers prMS74/69, aa 403–544 of Bh BepA),
pMS26 (primers prMS68/75, aa 1–304 of Bh BepA), and pMS27
(primers prMS105/106, aa 1–277 of Bq BepA2).
The integrity of all constructs was confirmed by sequence analysis
and Western blotting using anti-FLAG M2 antibodies (Sigma-Aldrich,
http://www.sigmaaldrich.com).
Generation of deletion mutants. pRS63 was used to generate the
DvirB4 mutant RSE569 in the RSE356 background as previously
described for Bt [16]. The spontaneous streptomycin-resistant mutant
RSE356 was obtained by selection of B. quintana JK-31 on 100 mg/l
streptomycin.
Cell lines and cell culture. HUVECs were isolated as described [18].
HUVECs and the human embryonic kidney cell line HEK293T were
cultured as described before [12]. The stable transfected endothelial
cell line Ea.hy296/pRS56-c#B1 was cultured as reported [13].
Infection assay. HUVECs (passage 3–7) were plated as described
before [12]. Unless stated differently, cells were infected with a
multiplicity of infection (MOI) of 300 bacteria per cell [10] in M199/
10% FCS/500 lM IPTG and incubated for the indicated time. If
specified, 100 nM actinomycin D (Sigma-Aldrich) was added to trigger
apoptosis as described before [10,12].
Table 2. Oligonucleotide Primers Used in This Study
Name Sequencea Restriction Site
prCREMfw ATCGCCCGGAAGTTTGC
prCREMrv CAGCTCTCGTTTGCGTGTTG
prGAPDHfw GAAGGTGAAGGTCGGAGTC
prGAPDHrv GAAGATGGT GATGGGATTTC
prGS001 TATGAAGGCCTCGAGTCGACCGCGGCCGCATCGATGACCCGGG
(NdeI/StuI/XhoI/SalI/SacII/NotI/ClaI/XmaI)
prGS002 TACCCGGGTCATCGATGCGGCCGCGGTCGACTCGAGGCCTTCA
(XmaI/ClaI/NotI/SacII/SalI/XhoI/StuI/NdeI)
prMS027 CGGGAATTCCATATGCAAAAGGGAATATTTCACT NdeI
prMS028 CGGGAATTCCATATGTTAGCTGGCTATAGCGAGTA NdeI
prMS037 ACGCGTCGACCTCCAAAGGCAAAAGCAAAAACG SalI
prMS038 TCCCCCCGGGTTAGCTAGCCATGGCAAGC XmaI
prMS068 TCCCCCCGGGATGCCAAAGGCAAAAGCAAAAA XmaI
prMS069 CTAGTCTAGATTAGCTAGCCATGGCAAGC XbaI
prMS074 TCCCCCCGGGAAGCATGTTGCACTCCTCA XmaI
prMS075 CTAGTCTAGATTATTCGGCTTTTGGAGCTGTAA XbaI
prMS076 TCCCCCCGGG GAGCTTGAAAACACGCTCAT XmaI
prMS077 CTAGTCTAGATTAGCTGGCAATAGCAAGCG XbaI
prMS078 GGAATTCCATATGCAGCAATCGCATCAGGCTG NdeI
prMS083 TCCCCCCGGGGAATTAAAAAAAACACTCATCCC XmaI
prMS084 CTAGTCTAGATTAACTTGGCATAGGGACCTCTT XbaI
prMS090 TCCCCCCGGGTTACGAGGCCTGGCGTTCCACTGCGCCCA XmaI/StuI
prMS102 ACGCGTCGACCGATGAGCCATATGAAAAATATCAAA SalI
prMS103 TCCCCCCGGGTTAGCAAACTATTTTAGCTTGC XmaI
prMS104 AGCTTTGTTTAAACGATGAGCCATATGAAAAATATCAAA PmeI
prPG92 GGAATTCCATATGCCAAAGGCAAAAGCAAAAA NdeI
prPG93 GGAATTCCATATGTTAGCTAGCCATGGCAAGC NdeI
prPG095 GGAATTCCATATGTTAGCTGGCAATAGCAAGCG NdeI
prPG097 GGAATTCCATATGTTAGTTGGTAAGAGCCCTTG NdeI
prPG129 GGAATTCCATATGCCAAAAGCAAAAGCAAAAAA NdeI
prPG130 GGAATTCCATATGTTAGAGCATAATTATCTGTA NdeI
prRS167 TCCCCCCGGGTTAGCTAGCCATGGCAAGC XmaI
prRS180 ATGGTGTCGAAAGAATTAAAAAAAACACTCATCC SalI
prRS187 ATGGTGTCGACAAGAGTTAAAAAATATTCTCATTC SalI
prRS188 TCCCCCCGGGTTAGCTGGCTATAGCGAGTA XmaI
aRestriction endonuclease cleavage sites are underlined.
doi:10.1371/journal.ppat.0020115.t002
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HUVEC transfection. HUVECs were transfected using Amaxa
nucleofection technology (Amaxa, http://www.amaxa.com) following
the manufacturer’s guidelines for HUVEC transfection. After trans-
fection, cells were seeded into 24-well plates or six-well plates.
HEK293T cell transfection. Subconfluent (2.5 million cells)
HEK293T cells in 8-cm cell culture dishes were transfected with a
total of 2.5 lg DNA following the protocol ‘‘Calcium phosphate–
mediated transfection of eukaryotic cells with plasmid DNAs’’ [52].
After 12 h, the cell culture medium was replaced and the cells kept in
culture for an additional 24 h before fixation for immunocytochem-
ical staining or harvesting for subcellular localization of the trans-
fected constructs.
Subcellular fractionation. Subcellular fractionation was performed
according to standard protocols [53,54]. Briefly, confluent mono-
layers were washed three times with cold homogenization buffer (10
mM triethanolamine, 10 mM acetic acid, 1 mM EDTA, 250 mM
sucrose [pH 7.4]), and cells were harvested by scraping and
homogenized with a syringe and a 22-gauge 1/4 inch needle. The
post-nuclear supernatant was obtained by centrifugation at 240g (15
min). Membranes were separated from cytosol by ultracentrifugation
of the post-nuclear supernatant at 100,000g (30 min).
Caspase activity assay. The infection of HUVECs and the
determination of caspase-3/-7 activity (MOI ¼ 300) were carried out
as described [12].
cya assay. cAMP was assayed after 20 h contact between bacteria
(MOI ¼ 300) and HUVECs in 24-well plates. HUVECs were washed
one time in pre-warmed PBS and lysed in denaturizing conditions as
described previously [19]. cAMP was assayed by an EIA system
(Biotrak; Amersham, http://www.amershambiosciences.com). Total
cell proteins were assayed by the method of Bradford [55] (Bradford
Reagent, Sigma-Aldrich).
CRAfT. The infection of the stably transfected Ea.hy926/pRS56-
c#B1 cell line and the quantification of GFP-positive cells (percent
positive events) by flow cytometry were carried out as described [13].
Immunoblot analysis. To monitor the steady-state level of Cya
fusion proteins, bacteria were grown on IPTG-containing medium
for 2 d. Cells were harvested and processed as described previously
[13], except that anti-FLAG M2 (Sigma-Aldrich) was used as the
primary antibody.
The stability of the different GFP fusion proteins used for ectopic
expression in HUVECs was monitored after transient transfection of
HEK293T cells. Cells were transfected by FuGENE 6 (Roche, http://
www.roche.com) following the manufacturer’s instructions. After 24 h
expression, cells were washed twice with PBS and harvested in 100 ll
of sample buffer. Samples were then further processed as described
before [13] and probed with anti-GFP (Roche) antibody.
Annexin V assay. Twenty-four hours after infection or transfection
of HUVECs, apoptosis was induced for 12–24 h. Cells were then
collected by mild trypsinization and briefly centrifuged together with
the culture supernatant. The cell pellet was washed, resuspended, and
stained with PI (1 ug/ml) and Annexin V AlexaFluor488 (Molecular
Probes, http://probes.invitrogen.com) or Annexin V APC (Alexis,
http://www.axxora.com). The total apoptotic population was deter-
mined by analyzing Annexin V–positive and PI-negative/positive cells
with a FACSCalibur flow cytometer (BD Biosciences, http://www.
bdbiosciences.com). Prior to determining the apoptotic population,
transfected cells were gated by their positive GFP signal.
Transfection and immunocytochemistry. HEK293T cells were
transfected for 30 h with different GFP-Bep fusion constructs, fixed
with 3.7% paraformaldehyde, and immunocytochemically stained
with Texas Red–labeled WGA (Invitrogen, http://www.invitrogen.
com). Specimens were analyzed by confocal microscopy as described
[12].
Determination of IL-8 secretion. The infection (MOI ¼ 300) of
HUVECs and the determination of IL-8 secretion by IL-8 DuoSet
ELISA kit (R&D Systems, http://www.rndsystems.com) were performed
as described before [12].
Determination of intracellular cAMP level. After infection (MOI¼
150) of HUVECs for 30 h in 24-well plates, cells were washed with pre-
warmed PBS and lysed. Intracellular cAMP level was determined by
the EIA system (Biotrak, Amersham) as described by the manufac-
turer.
Real-time PCR. To quantify the activation of the cAMP pathway,
total cellular RNA was isolated at 54 h after infection as described
above. RNA manipulation and real-time PCR was performed as
previously described [56] using primers listed in Table 2.
Effects of exogenous cAMP and cAMP-elevating agents. HUVECs
were infected in the absence or presence of either forskolin (Sigma-
Aldrich) and IBMX (Sigma-Aldrich) or dibutyryl cAMP (Sigma-
Aldrich) for 24 h with the indicated Bh strains (MOI ¼ 300) or left
uninfected (control). Apoptosis was induced, and caspase-3/-7
activities were monitored as described above.
CTL assay upon infection. Confluent HLA-A2-positive HUVEC (a
gift from B. C. Biedermann, Department of Research, University
Hospital Basel, Basel, Switzerland) monolayers were labeled with 5 lM
carboxyfluorescein diacetate, succinimidyl ester (CFSE, Molecular
Probes), in M199 without FCS according to the manufacturer’s
protocol. Cells were then infected with indicated Bh strains (MOI ¼
300) or left uninfected in M199/10% FCS/500 lM IPTG for 24 h. The
HLA-A2-restricted CTL clones specific to the Y-chromosome-
encoded, male-specific minor histocompatibility peptide antigen
SMCY were generated as described previously [32]. CTLs were washed
by centrifugation and were added in an effector-to-target cell ratio of
5:1 in replacing the infection medium with CTL assay medium (M199,
2% FCS, 500 lM IPTG). Plates were centrifuged to bring the cells in
contact. To quantify the surviving and dead cell rate, we used
Annexin V and PI staining and flow cytometry (described above).
Prior to determining the surviving and dead cell populations, CFSE-
positive cells were gated by their positive GFP signal.
Supporting Information
Accession Numbers
The GenBank (http://www.ncbi.nlm.nih.gov/Genbank) accession num-
bers for orthologous sequences to Bh BepA are Bq (NC 005955) and Bt
(CAD37389).
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Bartonella-triggered vascular proliferations – termed bacillary angiomatosis 
and peliosis in case of B. henselae (Bh)-infection – are reminiscent of tumour 
angiogenesis, the pathological process of formation of new capillaries out of pre-
existing vessels. Those bacteria-induced vasoproliferative lesions are benign and 
depend on the continuous presence of bacteria, which apparently produce factors 
that maintain the angiogenic process. In this study we have addressed the 
angiogenic potential of Bh by employing a three-dimensional in vitro sprouting 
angiogenesis assay of collagen-embedded human umbilical vein endothelial cell 
(HUVEC) spheroids, which allows the quantitative assessment of both pro- as well as 
anti-angiogenic factors. 
Whether non-infected or infected with Bh wild-type respectively different Bh 
mutants, HUVECs formed three-dimensional spheroids of similar size under culture 
condition that allow cellular aggregation. Noteworthy, pre-infection of HUVECs with 
wild-type bacteria resulted in a slightly less regular and compact morphology of 
spheroids. Embedded in collagen gel uninfected spheroids showed a low 
spontaneous sprouting, but capillary-like outgrowths could be readily induced by 
VEGF. Spheroids from HUVECs pre-infected with Bh wild-type showed an increased 
sprouting activity, albeit sprout morphology was distinct from the sprouts induced by 
VEGF. Formation of these sprouts was in part dependent on a functional VirB/VirD4 
T4SS. Importantly, we observed that three out of the seven known translocated 
Bartonella effector proteins (Beps) had distinct and in part opposing activities in this 
assay. 
BepA – inhibiting apoptosis in HUVECs (chapter 1) – showed a marked pro-
angiogenic activity, promoting sprouts similar to those induced by VEGF. Paralleling 
what was previously described for the anti-apoptotic activity, an N-terminally 
truncated version of BepA harbouring only the BID-domain and the C-terminal tail 
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sequence was sufficient to promote sprouting. Likewise, the ectopic expression of a 
GFP-BepA fusion protein alone was sufficient to trigger sprout formation, indicating 
that the same protein domains and effector mechanisms could be involved in anti-
apoptosis and sprout-induction. BepD – phosphorylated on specific tyrosines upon 
translocation into endothelial cells (ECs) – had a moderate stimulating effect. Those 
phosphorylated tyrosines may serve as specific docking sites for host cell signalling 
proteins and the resulting signalling complex could modulate angiogenesis. In 
contrast, BepG – involved in cytoskeletal rearrangement – showed a potent 
interference with sprout formation. BepG might block sprouting angiogenesis by 
altering the actin cytoskeleton and therefore the protrusive force needed for 
outgrowth and EC migration. 
Taken together, we provide in this study a novel in vitro model of Bh-triggered 
sprout formation and an initial characterization of the distinct activities of VirB/VirD4-
translocated Bep effectors modulating sprouting angiogenesis and contributing to the 
regulation of the Bh angiogenic activity in the course of chronic infection of the 
human vasculature. 
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Abstract 
The zoonotic pathogen Bartonella henselae (Bh) can lead to vasoproliferative tumour 
lesions in the skin and inner organs known as bacillary angiomatosis and bacillary 
peliosis. The knowledge on the molecular and cellular mechanisms involved in this 
pathogen-triggered angiogenic process is confined by the lack of a suitable animal 
model and a physiologically relevant cell culture model of angiogenesis. Here we 
employed a three-dimensional in vitro angiogenesis assay of collagen gel-embedded 
endothelial cell (EC) spheroids to study the angiogenic properties of Bh. Spheroids 
generated from Bh-infected ECs displayed a high capacity to form sprouts, which 
represent capillary-like projections into the collagen gel. The VirB/VirD4 type IV 
secretion system (T4SS) and a subset of its translocated Bartonella effector proteins 
(Beps) were found to profoundly modulate this Bh-induced sprouting activity. BepA, 
known to protect ECs from apoptosis, strongly promoted sprout formation. In 
contrast, BepG, triggering cytoskeletal rearrangements, potently inhibited sprouting. 
Hence, the here established in vitro model of Bartonella-induced angiogenesis 
revealed distinct and opposing activities of T4SS effector proteins, which together 
with a VirB/VirD4-independent effect may control the angiogenic activity of Bh during 
chronic infection of the vasculature. 
 
 
Key words: type IV secretion, effector protein, Bartonella henselae, endothelial cell 
spheroid, pathological angiogenesis 
Chapter 2
D-4
Introduction 
Unique within the bacterial kingdom, three members of the gram-negative 
α-proteobacterial genus Bartonella have the capacity to cause vasoproliferative 
tumour lesions in humans. The human-specific pathogen Bartonella bacilliformis (Bb) 
causes vasoproliferative skin lesions known as verruga peruana (VP). Especially in 
immuno-compromised patients, infections with the human-specific pathogen 
Bartonella quintana (Bq) and the feline-specific zoonotic pathogen Bartonella 
henselae (Bh) lead to vasoproliferative lesions in the skin that are termed bacillary 
angiomatosis (BA). Bh also causes similar lesions in inner organs, which are known 
as bacillary peliosis (BP) (Dehio, 2005; Dehio, 2003). BA manifests as reddish-brown 
papules on the skin - an accumulation of immature blood vessels with misshapen 
endothelial cells (ECs), a mixed inflammatory infiltrate, and numerous bacteria 
associated with proliferating ECs (Chian et al., 2002). BP is characterized by vascular 
proliferation in liver and spleen, which results in the formation of blood-filled cysts. 
Similar to BA, bacteria are found in association with proliferating ECs (Tappero et al., 
1993). 
 These bacteria-triggered vascular proliferations are reminiscent of tumour 
angiogenesis, the pathological process of the formation of new capillaries out of pre-
existing vessels. Angiogenesis is a highly orchestrated multistep process involving 
EC activation, the degradation of extracellular matrix (ECM) and basement 
membranes, EC proliferation, EC migration and invasion into the surrounding matrix, 
and finally the formation of tubular structures to build immature vessels later 
stabilized by tight interactions with smooth muscle cells and pericytes (Carmeliet, 
2003). Other than normal vessels, the vessels triggered by tumour angiogenesis are 
not properly matured and will regress upon deprival of the pro-angiogenic signals 
released by the tumour (e.g. overproduction of vascular endothelial growth factor, 
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VEGF). Likewise, Bartonella-triggered vessels do not mature properly, and 
eradication of the bacteria colonizing these newly formed vessels by antibiotic 
treatment leads to vessel regression (Koehler and Tappero, 1993). Thus, the 
Bartonella-induced vascular proliferations are benign and depend on the continuous 
presence of bacteria (Dehio, 2004), which apparently produce angiogenic factors that 
maintain the angiogenic process. 
 Most of the current knowledge on Bartonella-EC interaction is derived from 
two-dimensional cell culture infection assays with Bh. The VirB/VirD4 type IV 
secretion system (T4SS) and the thereby translocated Bartonella effector proteins 
(Beps) of Bh mediate most of the cellular phenotypes associated with infection of 
human umbilical vein endothelial cells (HUVECs), such as (i) cytoskeletal actin 
rearrangements leading to the internalization of a large bacterial aggregate by a 
unique structure called the invasome, (ii) NFκB-dependent pro-inflammatory 
activation, and (iii) inhibition of apoptosis (Schmid et al., 2004). The capacity of Bh to 
prevent EC apoptosis is dependent on the effector BepA and could contribute 
indirectly to vasoproliferative growth by enhancing cell survival (Schmid et al., 2006; 
Kirby and Nekorchuk, 2002). Another prominent phenotype of Bh infection of ECs is 
a direct mitogenic stimulation, which is VirB/VirD4/Bep-independent and is even 
counterbalanced by the VirB/VirD4 system at a high multiplicity of infection (MOI) 
(Schmid et al., 2004). The activation of a pro-inflammatory response in ECs, which 
occurs both in a VirB/VirD4-dependent (Schmid et al., 2004) and -independent 
manner (Fuhrmann et al., 2001), may lead to the recruitment of monocytes, which 
upon activation by Bh-infection release pro-angiogenic factors, such as VEGF, that 
promote EC proliferation in a paracrine manner (Resto-Ruiz et al., 2002; Kempf et al., 
2001). The non-fimbrial adhesin BadA (Bartonella adhesin A) is considered to trigger 
the secretion of VEGF by activating hypoxia-inducible factor (HIF)-1 (Riess et al., 
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2004). In summary, the current model for Bartonella-triggered vascular tumour 
formation proposes for Bh-infected ECs a direct stimulation of proliferation, inhibition 
of apoptosis, and the activation of a paracrine loop of pro-angiogenic factors such as 
VEGF released from infected monocytic cells (Dehio, 2005). 
 A number of rodent animal models of Bartonella-infection have been used to 
study different aspects of the Bartonella infection cycle and the general immune 
response to infection (Resto-Ruiz et al., 2003; Schulein and Dehio, 2002; Arvand et 
al., 2001; Koesling et al., 2001; Schulein et al., 2001). With the exception of one 
report (Velho et al., 2002) no publication indicated the appearance of 
vasoproliferative lesions in Bartonella-infected animals. Due to the absence of a 
suitable animal model, appropriate in vitro models of angiogenesis may represent an 
alternative to study the molecular basis of Bartonella-triggered vasoproliferation. 
Three-dimensional cell culture model offer an option to the complexity of live tissue 
experiments, providing a defined setup where physiological cell-cell and cell-ECM 
interactions are better mimicked than in conventional two-dimensional cultures 
(Pampaloni et al., 2007). Bh was shown to be able to promote survival of EC cords in 
type I collagen matrix as well as matrix invasion, survival and tubular differentiation of 
single embedded cells (Kirby, 2004). The in vitro cord formation assay measures the 
ability of cells to form a web-like network of interconnected cells (cord) and is 
believed to model a late morphogenic step of new vessel formation (Goodwin, 2007), 
whereas formation of capillary networks originating from single gel-embedded cells 
might rather represent a model to study the process of vasculogenesis – the de novo 
formation of a vessel (Davis et al., 2002). Neither of these models does really reflect 
sprouting angiogenesis originating from the confluent endothelium of the pre-existing 
vessel. Systems aiming to mimic a vessel in vitro are based on focal delivery of 
aggregates of EC from which sprouting can occur (Korff and Augustin, 1999). Single 
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non-adherent EC will undergo apoptosis and will not respond to survival factors. In 
contrast, spheroidal aggregation stabilizes the ECs and renders them responsive. 
Within 24 h of spheroid formation, the cells of the spheroidal aggregate 
spontaneously establish a surface monolayer of elongated cells and a core of 
unorganized cells. Embedded in matrices such as type I collagen and stimulated with 
growth factors, e.g. VEGF, those spheroids display radial sprouting. Cross sections 
of collagen gels showed numerous capillary-like structures forming a true lumen. 
Beyond a critical spheroid density, capillary sprouts from neighbouring spheroids will 
even form a complex anatomizing capillary-like network (Korff and Augustin, 1999). 
 Here we adapted this three-dimensional in vitro angiogenesis assay of 
collagen gel-embedded HUVEC spheroids to study the angiogenic properties of Bh 
involved in pathogen-triggered vasoproliferation. Bh wild-type was found to activate 
HUVEC spheroids and to trigger radial outgrowths. Different VirB/VirD4 T4SS 
effectors of Bh individually expressed in trans in the effector-less mutant ∆bepA-G 
had distinct and opposing effects on spheroid sprouting, suggesting that these 
effectors play a modulatory role contributing to the regulation of the Bh angiogenic 
activity in the course of human infection. 
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Results 
The Bartonella henselae VirB/VirD4/Bep system modulates in vitro 
angiogenesis of collagen gel-embedded HUVEC spheroids 
To establish an in vitro assay for studying the angiogenic activity of Bh we 
adapted the in-gel based three-dimensional in vitro angiogenesis model described by 
Korff and Augustin (1998). A defined number of HUVECs (400 cells) cultured as a 
hanging drop in methocel-containing EGM medium for 24 h were found to form a 
spheroid of similar size, regardless whether cells were not infected or pre-infected for 
24 h with a multiplicity of infection (MOI) of 300 bacteria per cell. Noteworthy, 
compared to the typical regular spheroid morphology formed by HUVEC which were 
uninfected or pre-infected by the isogenic deletion mutants ΔvirB4 (deficient for a 
functional T4SS (Schmid et al., 2004)) or ΔbepA-G (lacking the entire set of 
translocated effector proteins (Schulein et al., 2005)), HUVECs pre-infected with wild-
type bacteria (a spontaneous streptomycin-resistant variant of the well-characterized 
clinical isolate and typing strain ATCC49882T (Schmid et al., 2004)) resulted in a 
slightly less regular and compact morphology. This is illustrated in Fig. 1A by bright 
field imaging or maximum intensity z-projections of confocal microscopy stacks of 
spheroids stained with the EC marker CD31. 
To study the ability of Bh to manipulate sprouting, these spheroids were 
embedded in collagen gels and the outgrowth of sprouts representing capillary-like 
structures was evaluated after 24 h. Quantification of in vitro angiogenesis was 
assessed by measuring the cumulative sprout length (CSL) of individual spheroids 
(Fig 1B, determined as the mean +/- SD of 10 spheroids per experimental group). 
Spheroids of uninfected HUVECs embedded in collagen-gel showed a very low level 
of spontaneous sprouting (Fig. 1B, C), but were readily responsive to exogenous 
addition of VEGF (25 ng/ml) resulting in an approximately five-fold increased CSL 
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(Fig. 1B, G). Compared to uninfected control spheroids, we observed a higher 
sprouting activity of spheroids formed from HUVECs pre-infected with Bh wild-type 
(Fig. 1B, D), displaying an increase in CSL comparable to the stimulation by VEGF. 
Compared to wild-type, the sprouting activity was reduced about two-fold in 
spheroids of HUVECs pre-infected with the isogenic deletion mutants ΔvirB4 (Fig. 1B, 
E) or ΔbepA-G (Fig. 1B, F). Hence, Bh wild-type showed a clear VirB/VirD4- and 
Bep-dependent angiogenic activity on top of a basal level of VirB/VirD4/Bep-
independent sprout formation. Similar results were obtained when bacteria were 
added at the stage of spheroid-formation (data not shown). In contrast, the addition 
of bacteria onto the collagen gel immediately after embedding of spheroids had no 
stimulatory effect on sprouting, probably as the non-motile Bh can not sufficiently 
interact with the spheroids embedded in the collagen matrix (data not shown). 
Strikingly, spheroids of wild-type infected HUVECs displayed similar, but distinct 
sprout morphology in comparison to those induced by VEGF (Fig. 2). Bh wild-type 
bacteria clearly stimulated invasion of ECs into the gel, but the thickness of the 
capillary sprouts seemed reduced and appeared less regular. Moreover, less cell 
nuclei migrated into the collagen gel and some of the outgrowths rather had the 
appearance of cell protrusions than migratory cells. 
 
Pro- and anti-angiogenic activities of Bartonella effector proteins (Beps) 
To investigate the role of translocated Bep effectors in VirB/VirD4-mediated 
angiogenesis, we performed assays using isogenic strains of the effector-less mutant 
∆bepA-G expressing individual bep genes (bepA to bepG) on a plasmid in trans. 
Spheroids were generated and embedded into collagen gels. 24 h later sprouting 
was quantified by measuring the CSL (Fig. 3A). Expression of BepA, which is 
involved in protection of HUVECs from apoptosis (Schmid et al., 2006), showed a 
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strong sprout-promoting activity (Fig. 3A, F), with a three-fold increase in CSL 
compared to the ∆bepA-G mutant and a two-fold increase compared to wild-type. We 
also observed a moderate increase of sprouting for the ∆bepA-G mutant expressing 
bepD in trans, with a 1.5-fold increased CSL in comparison to the ∆bepA-G mutant 
(Fig. 3A, I). BepD is known to become tyrosine-phosphorylated upon translocation 
into host cells (Schulein et al., 2005) and possibly interferes with host cell signalling 
processes (Backert and Selbach, 2005). The ∆bepA-G mutant expressing bepG in 
trans displayed a marked reduction in CSL of about six-fold in comparison to the 
∆bepA-G mutant and almost nine-fold compared to wild-type (Fig. 3A, L). BepG is 
involved in actin rearrangements leading to invasome-formation (Rhomberg et al., 
2008). No statistically significant differences in CSL were observed for the ∆bepA-G 
mutant strains expressing in trans either bepB, bepC, bepE, or bepF (Fig.3A, G, H, 
J, K). 
Confirmative evidence for the data obtained with ∆bepA-G mutant strains 
expressing individual Bep effectors in trans was obtained by analysing a set of 
isogenic mutants carrying in-frame deletions of genes encoding individual Bep 
effectors (Fig. 4; ∆bepA, ΔbepC, ΔbepD, ΔbepE, ΔbepF, and ΔbepG). Compared to 
wild-type, the ΔbepA mutant showed a three-fold reduced CSL (Fig. 4A, F). We 
measured a slight decrease of 1.3-fold in CSL for the ∆bepD mutant (Fig.4A, H), 
whereas the ΔbepG stimulated a statistically significant 1.3-fold increase of the CSL 
in comparison to wild-type (Fig. 4A, J). Loss of bepG though did not completely 
unlock CSL to levels triggered by BepA, possibly indicating that additional factors 
might be involved in inhibition of sprouting. Deletion of bepC (Fig. 4A, G), bepE (data 
not shown), or bepF (Fig. 4A, I) had no significant effect on CSL compared to 
wild-type. In conclusion, BepA and BepD showed distinct pro- and BepG a marked 
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anti-angiogenic activity in the established three-dimensional in vitro angiogenesis 
assay. 
 Most of the single gene deletion mutants (i.e. ΔbepA, ΔbepD, ΔbepE, and 
ΔbepF, bright field images Fig, 4F, H and I) also stimulated the altered sprout 
morphology as illustrated for wild-type (Fig. 2). In contrast, the sprouts stimulated by 
ΔbepC and ΔbepG deletion mutants had the typical sprout appearance as previously 
described for VEGF stimulation of uninfected spheroids (bright field images Fig. 4G 
and J). Sprouts induced by the expression of individual Bep effectors in the ∆bepA-G 
mutant background showed as well a morphology comparable to those promoted by 
VEGF (Fig.2, illustrated for BepA, bright field images Fig. 3F-L). The slightly altered 
sprout morphology triggered by wild-type bacteria thus appears to depend on the 
translocation of multiple Bep effectors, including at least BepC and BepG. 
 
The C-terminal part of BepA is sufficient to promote sprouting 
BepA is sufficient to mediate protection of ECs against apoptosis. Moreover, 
deletion of its N-terminal Fic domain (a domain of unknown molecular function) 
demonstrated that the BID domain and the proximal positively charged C-terminal 
tail, which together constitute a functional signal for effector translocation (Schulein et 
al., 2005), are enough for the full anti-apoptotic activity. In accordance with this 
finding also the Bq ortholog BepA2, which due to an internal stop codon lacks a FIC 
domain, is inhibiting EC apoptosis (Schmid et al., 2006). To elucidate whether the 
prominent sprout-promoting activity of BepA is also independent of the Fic domain 
we compared the ability of full-length BepA, a truncated version harbouring only the 
BID domain plus positively charged C-terminal tail (tBepA encoded by plasmid 
ptbepA), and the Bq ortholog BepA2 (encoded by plasmid Bq pbepA2) to promote 
sprouting of spheroids. BepC and a truncated version (tBepC encoded by plasmid 
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ptbepC) were used as negative controls. Spheroids formed form HUVECs infected 
with the ∆bepA-G mutant complemented in trans with the indicated plasmids were 
embedded in collagen and sprout formation was quantified after 24 h (Fig. 5A). 
Similar to full-length BepA, the truncated version of BepA, as well as the Bq ortholog 
BepA2 resulted in an increased CSL, whereas infection with ∆bepA-G mutant strains 
expressing either full-length BepC or truncated BepC in trans had no effect on 
sprouting. 
Ectopic expression of full-length BepA fused to GFP was previously shown to 
be sufficient to protect ECs from apoptosis (Schmid et al., 2006). To test whether 
BepA alone is also enough to promote sprouting in the established three-dimensional 
angiogenesis assay in the absence of any additional bacterial factor, we transfected 
HUVECs prior to spheroid formation for 24 h with plasmids encoding GFP (gfp) or a 
GFP-BepA fusion (gfp-bepA), or left cells untransfected for this period. Spheroids 
formed by those cell populations were embedded in collagen gels and in vitro 
angiogenesis was quantified 24 h later by measuring the CSL (Fig. 5B). Ectopic 
expression of the GFP-BepA fusion (Fig. 5B, F) lead to a statistically significant 
increase of CSL of about two-fold compared to spheroids formed from either GFP-
expressing or untransfected HUVECs (Fig. 5B, C, E). Conclusively, paralleling what 
was previously described for the anti-apoptotic activity (Schmid et al., 2006) the BID-
domain plus C-terminal tail of BepA was sufficient to promote sprouting. 
 
BepG interferes with sprout-formation from spheroids 
Invasome-mediated entry of Bh into ECs (Dehio et al., 1997) depends on the 
VirB/VirD4 T4SS (Schmid et al., 2004) and thereby translocated effector(s) (Schulein 
et al., 2005). A ∆bepA-G mutant expressing BepG was recently found to promote the 
actin cytoskeletal rearrangements characteristic for the invasome structure, whereas 
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no other single Bep elicits a similar actin remodelling (Rhomberg et al., 2008). To test 
the impact of this F-actin modulating effector on spheroid sprouting, we infected 
HUVECs with BepG-expressing strains of either the ∆bepA-G mutant background 
(not expressing BepA) or the ∆bepB-G mutant background (expressing BepA). As 
negative control we used the ∆bepA-G and ∆bepB-G mutant backgrounds 
expressing BepC, which alone does not interfere with spheroid sprouting. Spheroids 
formed from such infected ECs were embedded in collagen and in vitro angiogenesis 
was quantified after 24 h (Fig. 6A). Overexpression of BepG in the ∆bepA-G mutant 
lead to a marked reduction of CSL in comparison to the ∆bepA-G mutant (Fig. 6A, 
G), while BepC did not alter the basal VirB/VirD4-independent sprouting activity (Fig. 
6A, F). Similarly, when BepG was over-expressed in the ∆bepB-G background, this 
effector reduced the BepA-induced increase in CSL more than three-fold (Fig. 6A, J), 
whereas BepC had no influence (Fig. 6A, I). Thus, BepG antagonizes the BepA-
triggered sprouting activity, but also generally interfered with VirB/VirD4-independent 
sprouting in the in-gel based three-dimensional in vitro angiogenesis model. 
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Discussion 
BA, BP, and VP lesions illustrate the remarkable capacity of the three 
Bartonella species Bh, Bq, and Bb, to trigger vasoproliferative processes resembling 
tumour angiogenesis. The molecular and cellular bases of these pathogen-triggered 
vascular proliferations, as well as their significance for establishing chronic infection 
of the vasculature are poorly understood. The underlying process of sprouting 
angiogenesis – the growth of new capillary vessels out of pre-existing ones – 
involves a sequence of highly orchestrated morphogenic events. In the healthy adult 
homeostatic mechanisms typically keep numerous positive and negative regulators of 
angiogenesis in balance in order to maintain a quiescence state of the vasculature. 
However, changes in the physiological state (e.g. in the microenvironment of 
tumours), that either result in an up-regulation of pro-angiogenic factors (such as 
VEGF) or a down-regulation of anti-angiogenic factors (such as angiostatin) may 
trigger angiogenesis (Carmeliet, 2003). 
In this study we have addressed the angiogenic potential of Bh by employing a 
three-dimensional in vitro sprouting angiogenesis assay of collagen-embedded 
HUVEC spheroids, which allows the quantitative assessment of both pro- as well as 
anti-angiogenic factors (Korff and Augustin, 1999). We could show that Bh triggers an 
angiogenic response, which is manifested by a cumulative sprout length in a similar 
range as induced by the potent angiogenic factor VEGF. Formation of these sprouts 
was in part dependent on a functional VirB/VirD4 T4SS. Importantly, we observed 
that three out of the seven known VirB/VirD4-translocated Bep effectors had distinct 
and in part opposing activities in this assay. BepA showed a marked and BepD a 
rather moderate pro-angiogenic effect, while BepG displayed a prominent anti-
angiogenic activity. 
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BepA is known to inhibit apoptosis in HUVECs via a rise in the cytosolic 
concentration of the second messenger cyclic AMP (cAMP) (Schmid et al., 2006). As 
reported for the cAMP-dependent anti-apoptotic activity, an N-terminally truncated 
version of BepA harbouring only the BID-domain and the C-terminal tail sequence 
was sufficient to promote sprouting. Likewise, the ectopic expression of a GFP-BepA 
fusion protein alone was sufficient to trigger sprout formation, indicating that the 
same protein domains and effector mechanisms could be involved in anti-apoptosis 
and sprout-induction. The potent angiogenic response triggered by VEGF is known to 
depend on its distinct activities on ECs – not only as a mitogen but also as a survival 
factor that inhibits apoptosis (Ferrara et al., 2003). The strong angiogenic activity of 
BepA demonstrated in the employed three-dimension in vitro angiogenesis assay 
could therefore depend to a large extent on its cAMP-mediated anti-apoptotic activity, 
boosting the VirB/VirD4-independent mitogenic activation of ECs. Remarkably, 
overexpression of Bh BepA or the BepA2 homologue of Bq in an otherwise Bep-
deficient genetic background of Bh was found to display a pro-angiogenic activity 
even superior to that of VEGF. Likewise, Bartonella exceeded the effect of VEGF in 
the in vitro cord formation and 3-D collagen assay (Kirby, 2004). 
BepD displayed a significant, although much weaker pro-angiogenic activity 
than BepA. Upon translocation in ECs, this effector becomes phosphorylated on 
specific tyrosine residues (Schulein et al., 2005) that may serve as specific docking 
sites for host cell signalling proteins bearing phosphotyrosine binding (PTB) or Src-
homology 2 (SH2) domains (Backert and Selbach, 2005). This signalling complex 
could then modulate angiogenesis. Interestingly, the effectors BepE and BepF that 
bear similar tyrosine-phosphorylation motifs than BepD did not significantly affect 
sprout formation, which indicates the specificity of the pro-angiogenic signaling 
events triggered by BepD. 
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BepG was the only effector that demonstrated a marked anti-angiogenic 
activity. BepG was previously shown to be able to promote actin rearrangements 
required for invasome-mediated invasion, a specific mode of Bh entry into ECs 
(Dehio et al., 1997). This F-actin dependent BepG-triggered sequence of events 
appears to inhibit the uptake of individual bacteria via conventional endocytosis 
(Rhomberg et al., 2008). Notably, invasome formation is associated with a reduction 
in EC motility (Dehio et al., 1997), which may represent a link of the BepG-dependent 
processes of invasome-medicated invasion and the inhibition of in vitro angiogenesis 
as reported here. It is unknown how BepG interferes with endocytosis and migration 
in ECs, however, these activities may relate to the co-localization of BepG with F-
actin (Rhomberg et al., 2008). BepG might thus block sprouting angiogenesis by 
altering the actin cytoskeleton and therefore the protrusive force needed for 
outgrowth and EC migration. 
Further to the pro- and anti-angiogenic activities of individual Bep effectors, we 
observed that the interaction of several effectors can result in modified sprout 
morphology. The altered sprouting phenotype seemed to require multiple Bep 
proteins, including BepG, which by itself inhibits sprout formation, and BepC, which 
by itself does not affect sprout formation, and probably in addition at least one sprout-
inducing effector, such as BepA. The atypical representation of capillaries observed 
in BA lesions (Chian et al., 2002) may represent the clinical correlate of the altered 
sprouts induced by Bh wild-type in the employed in vitro angiogenesis assay. 
It is unclear whether Bartonella-induced vasoproliferation represents a cause 
or rather a consequence. Bacterial factors may directly target the angiogenic switch 
in order to trigger proliferation as part of a dedicated infection strategy that expands 
the specific host cell habitat (Kempf et al., 2002). However, vasoproliferation may as 
well represent a “biological accident” induced by the complex physiological changes 
Chapter 2
D-17
resulting from chronic vascular colonization. It is likely that a yet unidentified 
immunological parameter on the host side influences the different clinical 
manifestations of Bartonella-infection, as BA and BP lesions triggered by Bh or Bq 
infections are almost exclusively observed in patients with a severe immuno-
suppression, although chronic infections by these pathogens also occur in immuno-
competent individuals. Bb on the contrary regularly causes VP lesions in immuno-
competent humans (Chian et al., 2002). Based on these clinical observations it is 
tempting to speculate that all three vasoproliferative Bartonella species encode 
vascular colonization factors that, either directly or indirectly, contribute to a potent 
pro-angiogenic response, while Bh and Bq may in addition encode anti-angiogenic 
factors to compensate this pro-angiogenic activity, at least in individuals with an intact 
immune response. The Bep effector proteins translocated by the VirB/VirD4 T4SS of 
Bh and Bq represent strong candidates for such modulators of the angiogenic 
response. First, the VirB/VirD4/Bep system was horizontally acquired and evolved as 
host adaptation system in the “modern” Bartonella lineage comprising Bh and Bq, 
while it is absent from the ancestral lineage solely represented by Bb (Saenz et al., 
2007). Second, the VirB/VirD4 system and its translocated effector can suppress a 
VirB/VirD4-independent strong proliferative response of ECs (Schmid et al., 2006, 
Schulein et al., 2005). Third, the here observed prominent but adverse effects of 
BepA and BepG on spheroid-sprouting point towards a modulatory role of these 
effectors on angiogenesis. 
Taken together, we provide in this study a novel model and an initial 
characterization of the distinct activities of VirB/VirD4-translocated Bep effectors of 
Bh in modulating sprouting angiogenesis. The adapted collagen gel-embedded 
HUVEC spheroid model represents a validated quantitative in vitro assay of sprouting 
angiogenesis that in further studies will allow elucidating the molecular basis of the 
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described pro- and anti-angiogenic activities of BepA, BepD and BepG. Noteworthy, 
a recent report demonstrated that HUVEC spheroids as used here for in vitro 
sprouting angiogenesis can also be used in vivo (Alajati et al., 2008). To this end, 
HUVEC spheroids embedded in a mixture of matrigel and fibrin are subcutaneously 
injected into severe combined immunodeficiency (SCID) mice. In the presence of 
pro-angiogenic factors (i.e. a mixture of VEGF and FGF-2) the grafted HUVEC 
spheroids were shown to build a complex three-dimensional capillary network that 
even connected to the mouse vasculature and displayed blood flow. Using this novel 
murine xenotransplantation model with HUVEC spheroids pre-infected with Bh as 
described here may allow in future studies to establish the badly needed animal 
model to study Bartonella-triggered angiogenesis in vivo. 
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Experimental procedure 
Reagents 
Recombinant human vascular endothelial growth factor-A165 (VEGF) was produced 
in Sf9 insect cells (Tumor Biology Centre, University of Freiburg). Antibiotics and 
Carboxymethylcellulose (methocel, 4000 centipoises) were from Sigma 
(http://www.sigmaaldrich.com). Collagen type I was isolated from rat tail tendons 
(Augustin, 2004). The monoclonal mouse anti-human CD31 antibody (clone JC70A) 
was purchased from DAKO (http://www.dako.com). Monoclonal mouse anti-human 
VE-cadherin (clone 55-7H1) was obtained from BD Pharmingen 
(http://www.bdbiosciences.com). Secondary AlexaFluor 488-conjugated goat anti-
mouse antibody was from Molecular Probes (http://www.invitrogen.com). TRITC-
phalloidin from Sigma (http://www.sigmaaldrich.com) was used to stain F-actin and 
DAPI from Roche (https://www.roche-applied-science.com) to stain double-stranded 
DNA. 
 
Bacterial strains and Growth Conditions 
The bacterial strains used are listed in Table 1. Bartonella spp. were grown on 
Columbia agar (CBA) plates containing 5% defibrinated sheep blood in a humified 
atmosphere at 35°C and 5% CO2 for 2-3 days. Strain RSE247, a spontaneous 
streptomycin-resistant strain of ATCC 49882T (Schmid et al., 2004) served as wild-
type in this study. Media were supplemented with 30 µg/ml kanamycin, 100 µg/ml 
streptomycin, 12.5 µg/ml gentamicin, and/or 500 µM isopropyl β-D-thiogalactosidase 
(IPTG, http://www.applichem.de) when indicated. 
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Construction of In-frame Deletions 
In-frame deletion mutants of B. henselae RSE247 were generated by a two-step 
gene replacement procedure as described (Schulein & Dehio, 2002, Schmid et al., 
2004). The basic mutagenesis vector pTR1000 was described before (Schmid et al., 
2004). All mutagenesis plasmids harbour a cassette with the flanking regions of the 
in-frame deletion in the gene(s) of interest. This cassette was generated from two 
PCR fragments amplified from chromosomal DNA of RSE247 as template, either by 
megaprime PCR or by conventional cloning. 
Construction of the in-frame mutant ∆bepA has been described previously 
(Schmid et al., 2004).  
pTR1069 used for generating a ∆bepC in-frame mutant was constructed as 
follows. Oligonucleotide primers prTR082 and prTR083 amplified fragment 1 (846 bp) 
and prTR084 and prTR085 amplified fragment 2 (753 bp, containing 256 bp of 3` end 
of bepD). Both fragments were combined by megaprime PCR with oligonucleotide 
primers prTR082 and prTR085, resulting in a fragment of 1.59 kb carrying an in-
frame deletion of 1.58 kb in bepC. By using flanking BamHI sites, the fragment was 
inserted into the corresponding site of pTR1000, yielding pTR1069. The use of 
pTR1069 for gene replacement in RSE247 resulted in the ∆bepC mutant TRB288.  
pPG161 used for generating a ∆bepD in-frame mutant was constructed as 
follows. Oligonucleotide primers prTR041 and prTR051 amplified fragment 1 (853 bp, 
containing 321 bp of 5` end of bepC) and prTR042 and prTR044 amplified fragment 
2 (860 bp, containing 473 bp of 3` end of bepE). Both fragments were combined by 
megaprime PCR with oligonucleotide primers prTR041 and prTR044, resulting in a 
fragment of 1.67 kb carrying an in-frame deletion of 1.54 kb in bepD. By using 
flanking BamHI sites, the fragment was inserted into the corresponding site of 
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pTR1000, yielding pPG161. The use of pPG161 for gene replacement in RSE247 
resulted in the ∆bepD mutant PGC08.  
pPG162 used for generating a ∆bepE in-frame mutant was constructed as 
follows. Oligonucleotide primers prPG134 and prPG135 amplified fragment 1 (898 
bp, containing 497 bp of 5` end of bepD) and prPG136 and pr137 amplified fragment 
2 (906 bp, containing 522 bp of 3` end of bepF). Both fragments were combined by 
megaprime PCR with oligonucleotide primers prPG134 and prPG137, resulting in a 
fragment of 1.75 kb carrying an in-frame deletion of 1.33 kb in bepE. By using 
flanking BamHI sites, the fragment was inserted into the corresponding site of 
pTR1000, yielding pPG162. The use of pPG162 for gene replacement in RSE247 
resulted in the ∆bepE mutant PGD20.  
pTR1075 used for generating a ∆bepF in-frame mutant was constructed as 
follows. Oligonucleotide primers prTR053 and prTR054 amplified fragment 1 (736 bp, 
containing 356 bp of 5` end of bepE) and prTR055 and prTR056 amplified fragment 2 
(665 bp, containing 345 bp of 3` end of bepG). Both fragments were combined by 
megaprime PCR with oligonucleotide primers prTR053 and prTR056, resulting in a 
fragment of 1.38 kb carrying an in-frame deletion of 2.45 kb in bepF. By using 
flanking XbaI sites, the fragment was inserted into the corresponding site of 
pTR1000, yielding pTR1075. The use of pTR1075 for gene replacement in RSE247 
resulted in the ∆bepF mutant TRB222.  
pTR1078 used for generating a ∆bepG in-frame mutant was constructed as 
follows. Oligonucleotide primers prTR057 and prTR058 amplified fragment 1 (713 kb, 
containing 339 bp of 5` end of bepF) and prTR059 and prTR060 amplified fragment 2 
(625 kb). Both fragments were combined by megaprime PCR with oligonucleotide 
primers prTR057 and prTR060, resulting in a fragment of 1.26 kb carrying an in-
frame deletion of 2.93 kb in bepG. By using flanking XbaI sites, the fragment was 
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inserted into the corresponding site of pTR1000, yielding pTR1078. The use of 
pTR1078 for gene replacement in RSE247 resulted in the ∆bepG mutant TRB223. 
 
Cell Culture 
Human umbilical vein endothelial cells (HUVEC) were isolated as described before 
(Dehio et al., 1997) and cultured in EGM medium (http://www.promocell.com) in a 
humified atmosphere at 37°C and 5% CO2. 
 
Infection Assay 
HUVEC (passage 4-7) were plated in gelatine-coated well plates at 6*104/ml using 
EGM. The next day cells were washed twice with M199 with Earls salts (M199, 
Gibco, http://www.invitrogen.com) supplemented with 10% fetal calf serum (FCS, 
http://www.invitrogen.com) and unless stated differently infected with a multiplicity of 
infection (MOI) of 300 bacteria per cell in M199/10% FCS/500 μM IPTG and 
incubated for 24 hours. 
 
HUVEC Transfection 
HUVECs were transfected using Amaxa nucleofection technology (Amaxa, 
http://www.amaxa.com) following the manufacturer’s guidelines for HUVEC 
transfection. After transfection, cells were seeded into gelatine-coated six-well plates. 
 
Generation of endothelial cell (EC) spheroids 
EC spheroids of defined cell number were generated as described previously (Korff 
and Augustin, 1998) with some modifications. In brief, uninfected respectively 
infected EC monolayers were trypsinized and suspended in EGM containing 20% 
methocel (Weber et al., 2008). Spheroids were generated by pipetting 400 EC (in 25 
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μl) on quadratic Greiner Petri dishes (http://www.huberlaborworld.ch) and grown 
overnight as hanging drops in a humified atmosphere at 35°C and 5% CO2. Under 
these conditions, all suspended cells contribute to the formation of a single spheroid 
of defined cell number per drop. 
 
Spheroid whole-mount staining 
Staining of spheroids was performed in 2 ml Eppendorf tubes as done previously 
(Scharpfenecker et al., 2005). Spheroids were harvested and fixed for 1 hour in PFA-
fixans (0.02mM CaCl2, 1.36 % w/v saccharose, 4% PFA in PBS). The fixative was 
removed and spheroids were washed three times with 1 ml PBS. Permeabilization 
was done with 150 μl 0.1% Triton X-100 in PBS for 10 minutes. Spheroids were 
washed three times with 1 ml PBS and blocked with 300 μl 3% FCS in PBS. 
Spheroids were then incubated for 1 hour with a mouse anti-human-CD31 antibody 
(1:100) diluted in 150 μl blocking solution. After three washing steps with 1 ml PBS, 
spheroids were then exposed to AlexaFluor 488-conjugated goat anti-mouse 
antibody (1:200) and DAPI (1:1000, 1mg/ml stock) in 150 μl blocking solution. After 1 
hour, spheroids were washed tree times with 1 ml PBS and supernatants were 
removed. Then, one drop of mowiol (http://www.sigmaaldrich.com) was added and 
spheroids were transferred to glass slides and sealed with coverslips. Short pieces of 
human hair or parafilm were used as spacers in order to not destroy the 3D structure 
of the spheroids. Z-stacks were acquired using a spinning disc confocal microscope 
(Olympus IX81, Andor Revolution XD) and analyzed using the ImageJ software 
(http://rsb.info.nih.gov/ij/). 
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Spheroid-based in vitro angiogenesis assay 
The in vitro angiogenesis assay was performed as described (Weber et al., 2008). 
The generated spheroids were harvested and suspended in the methocel solution 
containing 20% FCS. Subsequently, the ice-cold collagen solution (rat tail type I 
collagen in 0.1% acidic acid) was neutralized by adding 10% 10-fold Medium 199 
and approx. 10% 0.2 N NaOH to adjust the pH to 7.4. EC spheroid/ methocel solution 
was mixed 1:1 with the neutralised collagen solution and 1 ml of the mixed solution 
containing approximately 50 EC spheroids were pipetted into individual wells of a 
pre-warmed 24 well plate to allow polymerisation in the incubator in a humified 
atmosphere at 35 °C, 5% CO2. After 30 min VEGF was added to an end-
concentration of 25 ng/ml by pipetting 100 μl of a 10-fold concentrated working 
dilution on top of the polymerised gel. Plates were incubated in a humified 
atmosphere at 35 °C, 5% CO2 for 24 h and fixed by adding 3.7% paraformaldehyde. 
Pictures were taken with a Leica DM IRBE inverted microscope using a MicroMAX 
camera (Princeton Instruments with MetaMorph software) using the 20x objective. In 
vitro angiogenesis was digitally quantitated by measuring the cumulative length of the 
sprouts (CSL) that had grown out of each spheroid using the MetaMorph software 
analyzing 10 spheroids per experimental group and experiment. 
 
In-gel staining of sprouting spheroids 
HUVEC monolayers were infected with indicated Bh strains (MOI 300) or left 
uninfected in M199/10% FCS/500 μM IPTG for 24 h. As for the spheroid 
angiogenesis assay EC spheroids were generated, harvested, suspended in 
methocel 20% FCS and mixed 1:1 with neutralized collagen. 2 ml of the mix was 
distributed over the wells of an 8 well μ-slide (http://www.ibidi.de) and was allowed to 
polymerize. 50 μl of a 10-fold concentrated working dilution of VEGF was pipetted on 
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top of the polymerised gel. The μ-slides were incubated in a humified atmosphere at 
35 °C, 5% CO2 for 24 h and fixed by adding 3.7% paraformaldehyde. Gels were 
washed tree times with 150 μl PBS and blocked with 200 μl PBS 5% bovine serum 
albumin (BSA) for 2 hours before being incubated with DAPI and TRITC-phalloidin in 
100 μl PBS-BSA overnight at 4°C. Gels were washed tree times with PBS and 
analyzed by confocal spinning disc microscopy (Olympus IX81, Andor Revolution 
XD). 3D reconstruction of in-gel sprouting spheroids was done using image stacks 
and the ImageJ software. 
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Table 1 Bacterial strains and plasmids used in this study. 
Strain  Genotype or relevant characteristics Reference or source 
or plasmid 
B. henselae strains  
ATCC 49882 T ‘Houston-1’, isolated from a bacteremic HIV-patient (Regnery et al., 1992) 
RSE247 Spontaneous Smr strain of ATCC 49882 T, (Schmid et al., 2004) 
  serving as wild-type 
RSE242 ΔvirB4 mutant of RSE247 (Schmid et al., 2004) 
MSE150 ΔbepA-G mutant of RSE247 (Schulein et al., 2005) 
TRB106 ΔbepB-G mutant of RSE247 (Schulein et al., 2005) 
MSE156 MSE150 containing pPG101 (∆bepA-G/pbepA) (Schmid et al., 2006) 
MSE167 MSE150 containing pMS006 (∆bepA-G/pbepB) (Rhomberg et al., 2008) 
MSE159 MSE150 containing pMS007 (∆bepA-G/pbepC) (Rhomberg et al., 2008) 
PGD03  MSE150 containing pPG104 (∆bepA-G/pbepD) (Rhomberg et al., 2008) 
PGD10  MSE150 containing pPG105 (∆bepA-G/pbepE) (Rhomberg et al., 2008) 
TRB171 MSE150 containing pPG106 (∆bepA-G/pbepF) (Rhomberg et al., 2008) 
TRB169 MSE150 containing pPG107 (∆bepA-G/pbepG) (Rhomberg et al., 2008) 
MSE269 MSE150 containing pMS106 (∆bepA-G/pbepA2) (Schmid et al., 2006) 
MSE218 MSE150 containing pMS100-A (∆bepA-G/ptbepA) (Schmid et al., 2006) 
MSE228 MSE150 containing pMS100-C (∆bepA-G/ptbepC) (Schmid et al., 2006) 
MSE154 ΔbepA mutant of RSE247 (Schmid et al., 2006) 
TRB288 ΔbepC mutant of RSE247 This work 
PGC80  ΔbepD mutant of RSE247 This work 
PGD20  ΔbepE mutant of RSE247 This work 
TRB222 ΔbepF mutant of RSE247 This work 
TRB223 ΔbepG mutant of RSE247 This work 
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Plasmids   
pPG100 E.coli – Bartonella spp. Shuttle vector, encoding a (Schulein et al., 2005) 
 short FLAG epitope 
pPG101 Derivative of pPG100, encoding FLAG::Bh_BepA  (Schmid et al., 2006) 
pMS006 Derivative of pPG100, encoding FLAG::Bh_BepB  (Schmid et al., 2006) 
pMS007 Derivative of pPG100, encoding FLAG::Bh_BepC  (Schmid et al., 2006) 
pPG104 Derivative of pPG100, encoding FLAG::Bh_BepD (Schulein et al., 2005) 
pPG105 Derivative of pPG100, encoding FLAG::Bh_BepE (Rhomberg et al., 2008) 
pPG106 Derivative of pPG100, encoding FLAG::Bh_BepF (Rhomberg et al., 2008) 
pPG107 Derivative of pPG100, encoding FLAG::Bh_BepG (Rhomberg et al., 2008) 
pMS100 Inserton of a multiple cloning site into pPG100 (Schmid et al., 2006) 
pMS106 Derivate of pMS100, encoding FLAG::Bq_BepA2  (Schmid et al., 2006) 
pMS100-A Derivate of pMS100, encoding FLAG::Bh_BepA305-542 (Schmid et al., 2006) 
pMS100-C Derivate of pMS100, encoding FLAG::Bh_BepC292-542 (Schmid et al., 2006) 
pWAY21 Plasmid for ectopic expression of N-terminal Molecular Motion, 
 eGFP fusion proteins Montana Lab 
pMS21 Derivate of pWAY21, encoding GFP::Bh_BepA (Schmid et al., 2006) 
pTR1000 Basic mutagenesis vector to generate in-frame (Schulein et al., 2005) 
 mutants of RSE247 
pTR1069 Derivate of pTR1000 to generate a ∆bepC in-frame This work 
 mutant in Bh 
pPG161 Derivate of pTR1000 to generate a ∆bepD in-frame This work 
 mutant in Bh 
pPG162 Derivate of pTR1000 to generate a ∆bepE in-frame This work 
 mutant in Bh 
pTR1075 Derivate of pTR1000 to generate a ∆bepF in-frame This work 
 mutant in Bh 
pTR1078 Derivate of pTR1000 to generate a ∆bepG in-frame This work 
 mutant in Bh 
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Table 2 Oligonucleotide primers used in this study. 
Name Sequence a Restriction site 
prPG134: CGGGATCCCGAAAGATGAAGTTACTTCAAAGC  BamHI 
prPG135: GTTTAGATGGCGAAAGCTATTGTTTCTGTGGAA 
 TGAGTTGTCG 
prPG136: CGACAACTCATTCCACAGAAACAATAGCTTTCG 
 CCATCTAAAC 
prPG137: CGGGATCCGTGTAGCTCCTTGTCTTTTGC   BamHI 
prTR041: GCGGATCCGCACACTCTGTGGAAAAACC   BamHI 
prTR042: CATTCCTTTTTGATTTGTGGGAGTCGGAGGGGATGGTCG 
prTR044: CGGGATCCGCTTGGACCAATGGATTGT   BamHI 
prTR051: CGACCATCCCCTCCGACTCCCACAAATCAAAAAGGAATG 
prTR053 GCTCTAGAGGGGCATAATGTATGTGGC  XbaI 
prTR054 GCCAGCACCATTTTTTGTGGAGATGTGGAAGAGGATGG 
prTR055 CACAAAAAATGGTGCTGGC 
prTR056 GCTCTAGAGGCGTTACACAGGGAAGAG  XbaI 
prTR057 GCTCTAGAGCTCCGCTTGCTGGCAAG  XbaI 
prTR058 GGTCGAACTATCTGTTCTACAGGTGTTGAAGGGGCTGG 
pTR059 GTAGAACAGATAGTTCGACC 
prTR060 GCTCTAGAGTTACGAGTCTGTCCAGCC  XbaI 
prTR082 CGCGGATCCGGGCGCTCATTTTACCTCC  BamHI 
prTR083 CGTGTTTAGTTGGTAAGAGCCTCTAACATATATTTTCTCCTTG 
prTR084 GCTCTTACCAACTAAACACG 
prTR085 CGCGGATCCCGGCACGTCGCCCATTC  BamHI 
 
a Restriction endonuclease cleavage sites are underlined  
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Figure 1: Bartonella henselae VirB/VirD4/Bep system modulates sprouting 
angiogenesis of collagen gel-embedded EC spheroids 
(A) Human umbilical vein endothelial cells (HUVEC) where infected with a MOI of 
300 with the indicated strains 24 h before a defined number of cells was suspended 
in culture medium containing methylcellulose and grown overnight as hanging drops. 
Spheroids were whole-mount stained with a mouse anti-human CD31-specific 
monoclonal antibody and detected with an anti-mouse secondary antibody 
conjugated to AlexaFluor488. Bright field image and maximum intensity z-projections 
of stacks acquired by confocal spinning disc microscopy are shown. (B-G) Spheroids 
out of uninfected HUVECs or HUVECs infected with the indicated strains were 
embedded in collagen and control uninfected spheroids were stimulated with VEGF 
(25 ng/ml). (B) Quantification of in vitro angiogenesis of collagen embedded 
spheroids after 24 h by calculating the cumulative length of sprouts from individual 
spheroids. Shown are means / SD of ten spheroids per experimental group. 
Differences between experimental groups were analyzed by Student’s t-test. * p < 
0.05, ** p < 0.01 were considered statistically significant. (C-G) Bright field images of 
one-day-old collagen embedded HUVEC spheroids. Shown are representative 
images demonstrating strong capillary-like sprouting of spheroids upon stimulation 
with VEGF (G), as well as VirB/D4 T4SS-dependent sprouting of spheroids out of Bh 
wild-type-infected HUVECs (D). The bar represents 100 μm. 
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Figure 2: Bh wild-type induces sprout outgrowth with a distinct morphology 
Spheroids from uninfected HUVECs or HUVECs infected with the indicated strains 
were embedded in collagen and control was stimulated with VEGF (25 ng/ml). 
Collagen gels were incubated with the DNA stain DAPI as well as TRITC-phalloidin 
binding to actin. Stacks were acquired by confocal microscopy. Shown are maximum 
intensity z-projections. DAPI staining demonstrated that nuclei migrate into the 
collagen gel, TRITC and DIC showed that especially outgrowths induced by Bh wild-
type display some loss of sprout integrity. 
 
Figure 3: Modulation of spheroid sprout formation by Bartonella henselae 
mutant strains translocating individual Bep effectors 
Spheroids out of uninfected HUVECs or HUVECs infected with Bh wt or the effector-
less mutant ∆bepA-G trans-complemented with single bep genes were embedded in 
collagen and control was stimulated with VEGF (25 ng/ml). (A) Quantification of in 
vitro angiogenesis of collagen embedded spheroids after 24 h. The cumulative length 
of sprouts of individual spheroids was calculated. Shown are means / SD of ten 
spheroids per experimental group. Differences between experimental groups were 
analyzed by Student’s t-test. * p < 0.05, ** p < 0.01 were considered statistically 
significant. (B-L) Corresponding representative bright field images of one-day-old gel-
embedded spheroids. BepA involved in anti-apoptosis promoted strongly sprout 
formation (F). BepG, involved in cytoskeletal rearrangement, showed a potent 
interference with sprout formation (L). BepD, which is tyrosine phosphorylated by 
eukaryotic kinases, exhibited a positive modulatory effect on sprout formation (I). 
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Figure 4: Modulation of spheroid sprout formation by Bartonella henselae 
mutant strains deficient for the translocation of individual Bep effectors 
Spheroids out of uninfected HUVECs or HUVECs infected with Bh wt, the effector-
less mutant ∆bepA-G, or the indicated in-frame deletion mutants of individual bep 
genes were embedded in collagen and control was stimulated with VEGF (25 ng/ml). 
(A) Quantification of in vitro angiogenesis of collagen embedded spheroids after 24 h. 
The cumulative length of sprouts of individual spheroids was calculated. Shown are 
means / SD of ten spheroids per experimental group. Differences between 
experimental groups were analyzed by Student’s t-test. * p < 0.05, ** p < 0.01 were 
considered statistically significant. (B-J) Corresponding representative bright field 
images of one-day-old gel-embedded spheroids. Loss of BepA (F) reduced sprouting 
activity of Bh wt to ΔbepA-G mutant basal sprouting level (E). A small reduction in 
sprouting was observed if BepD is missing (H). Knock-out of bepG enhanced 
induction of spheroid sprouting upon infection (J). 
 
Figure 5: Ectopic expression of BepA promotes sprouting and BepA BID-
domain plus C-tail is sufficient to promote sprouting of infected HUVEC 
Spheroids out of uninfected respectively untransfected HUVECs, HUVECs infected 
with the indicated strains, or transfected with the indicated constructs were 
embedded in collagen and control was stimulated with VEGF (25 ng/ml). (A, B) 
Quantification of in vitro angiogenesis of collagen embedded spheroids after 24 h. 
The cumulative length of sprouts of individual spheroids was calculated. Shown are 
means / SD of ten spheroids per experimental group. Differences between 
experimental groups were analyzed by Student’s t-test. * p < 0.05, ** p < 0.01 were 
considered statistically significant. (A) N-terminally truncated BepA (tBepA) 
harbouring BID-domain plus C-tail (sufficient for anti-apoptosis) is enough to promote 
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sprouting of spheroids. Moreover the B. quintana homolog BepA2, encoded by the 
down-stream ORF of the split bepA locus containing only the BID-domain and C-tail, 
also strongly promoted sprouting. (C-F) Representative bright field images of one-
day-old gel-embedded spheroids for the ectopic expression of GFP-BepA fusion. 
HUVEC transfected with gfp-BepA (plMS21, F) show increased capillary-like 
sprouting compared to untransfected cells or cells transfected with control gfp 
(pWay21, E). 
 
Figure 6: BepG is interfering with sprouting of spheroids 
Spheroids out of uninfected HUVECs or HUVECs infected with the indicated strains 
were embedded in collagen and control was stimulated with VEGF (25 ng/ml). (A) 
Quantification of in vitro angiogenesis of collagen embedded spheroids after 24 h. 
The cumulative length of sprouts of individual spheroids was calculated. Shown are 
means / SD of ten spheroids per experimental group. Differences between 
experimental groups were analyzed by Student’s t-test. * p < 0.05, ** p < 0.01 were 
considered statistically significant. (B-J) Corresponding representative bright field 
images of one-day-old gel-embedded spheroids. The overexpression of BepG in the 
ΔbepA-G mutant background which promotes invasome formation reduces baseline 
sprouting (G); moreover BepG overexpression in the ΔbepB-G mutant background 
reduces BepA-induced sprouting (J). 
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The Bartonella henselae VirB/VirD4/Bep System Interferes with 
VEGF-induced ERK1/2-mediated Endothelial cell proliferation 
 
F. Scheidegger and C. Dehio 
 
In preparation 
 
The close association of Bartonella henselae (Bh) with proliferating endothelial 
cells (ECs) in bacillary angiomatosis / peliosis (BA/BP) and the fact that antibiotic 
treatment leads to regression of those lesions indicate an active role of Bh triggering 
these vascular proliferations. In addition to a direct stimulation of proliferation and 
inhibition of apoptosis in ECs the activation of a paracrine loop of vascular 
endothelial growth factor (VEGF), an essential regulator of physiological as well as 
pathological angiogenic processes, is thought to be involved in Bh-induced vascular 
tumour formation. We addressed in this study the effect of exogenous VEGF on Bh-
infected ECs. 
Assessing the biological activity of VEGF in assays such as proliferation, 
wounding assay and capillary-like sprout formation revealed an intriguing 
interference of the VirB/VirD4/Bep system with responsiveness of infected ECs to 
stimulation with this potent growth factor. Sprouting, proliferation, and migration could 
be readily induced by VEGF if human umbilical vein endothelial cells (HUVECs) were 
uninfected or infected with the ∆bepA-G mutant. Infection with Bh wild-type interfered 
with EC responsiveness to VEGF. 
Analysis of the VEGF receptor 2 (VEGFR2) pathways further showed that Bh 
wild-type inhibited phosphorylation of tyrosine 1175 (Tyr1175) in the C-terminus of 
VEGFR2. Tyr1175 is one of the critical docking sites for adaptor proteins mediating 
VEGFR2 downstream signalling. Phospholipase Cγ1 (PLCγ1) is amongst the 
proteins binding to Tyr1175. The membrane phospholipid phophatidylinositol (4,5)-
bisphosphate (PIP2) is hydrolysed by PLCγ1 giving rise to the second messengers 
diacylglycerol (DAG) and inositol 1,4,5-triphosphate (IP3). DAG is the activator of 
PKC, mediating the activation of the mitogen-activated protein kinase ERK1/2 which 
is the major mediator of VEGF-induced cell proliferation. IP3 generation results in 
increase of intracellular concentration of calcium [Ca2+]i. Consistent with a lack of 
Tyr1175 phosphorylation upon stimulation of Bh wild-type-infected ECs with VEGF, 
E-1 
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we observed no PLCγ1 recruitment and phosphorylation and no calcium flux and 
ERK1/2 phosphorylation. First experiments done with other stimuli than VEGF, such 
as ATP or thrombin triggering GPCR-coupled calcium flux, indicate that Bh 
interference is at least specific for receptor tyrosine kinases. 
The data presented in this work challenge the proposed VEGF-driven 
paracrine loop in case of an active VirB/VirD4/Bep system. Furthermore, together 
with the fact that the VirB/VirD/Bep system masks a potent VirB-independent 
mitogenic activity and that BepG potently interferes with sprouting (chapter 2), this 
interference of the VirB/VirD4/Bep system with the signalling of one of the most 
important regulator of angiogenesis speaks against the VirB T4SS as major pro-
angiogenic factor in Bh pathogenesis. Thus, the VirB/VirD4/Bep system more likely 
represents a host adaptation system, a modulator needed to balance the angiogenic 
activity of Bh during chronic infection of the human vasculature. 
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Abstract 
The zoonotic gram-negative pathogen B. henselae (Bh) causes amongst various 
clinical manifestations tumour-like vascular proliferations. A direct stimulation of 
endothelial cell (EC) proliferation, inhibition of apoptosis in ECs, and the activation of 
a paracrine loop of pro-angiogenic factors such as vascular endothelial growth factor 
(VEGF) are thought to be involved. VEGF is an essential regulator of angiogenesis 
under physiological as well as pathological conditions. Here we report that Bh 
actually interferes with responsiveness of ECs to VEGF. Proliferation or wound 
closure could not be stimulated by VEGF in cells infected with Bh, neither could 
VEGF induce capillary-like sprouting of spheroids from Bh-infected ECs. Tyrosine-
phosphorylation on position 1175 of the VEGF receptor 2 (VEGFR2) was inhibited; 
consequently we observed a lack of PLCγ1 activation and interference with VEGF-
triggered cytosolic calcium flux. Thus, Bh constrained the signalling cascade leading 
to the activation of the mitogen-activated protein kinase ERK1/2 upon stimulation of 
VEGFR2 with its ligand. This interference was dependent on a functional VirB/VirD4 
type IV secretion system and its effectors, the Bartonella-effector proteins (Beps). 
The presented data emphasize the role of the VirB/VirD4/Bep system as an 
important factor balancing the angiogenic potential of Bh during chronic infection of 
the vasculature. 
 
Chapter 3
E-4
Introduction 
Rarely showing any symptoms in the feline reservoir host Bartonella henselae 
(Bh) is responsible for a number of clinical outcomes during infection of the human 
incidental host. Clinical manifestations range from self-limiting but long-lasting 
swelling of lymph nodes (cat-scratch-disease, CSD) in immunocompetent patients to 
tumour-like vasoproliferative lesions on the skin or inner organs known as bacillary 
angiomatosis or peliosis (BA/BP) especially in patients with a compromised immune 
system (Florin et al., 2008). The close association of Bh with proliferating endothelial 
cells (ECs) in BA/BP (Chian et al., 2002) and the fact that antibiotic treatment leads 
to regression of those lesions (Koehler and Tappero, 1993) indicate an active role of 
Bh triggering these vascular proliferations. Bh-triggered vasculoproliferative lesions 
resemble tumour angiogenesis – the pathological process of the formation of new 
capillaries out of pre-existing blood vessels. Foremost among the several different 
growth factors and their associated receptor tyrosine kinases (RTKs), the vascular 
endothelial growth factor (VEGF) family and VEGF receptors (VEGFRs) are essential 
regulators of angiogenesis under physiological as well as pathological conditions 
(Takahashi and Shibuya, 2005). 
The secretion of VEGF from Bh-infected macrophages, recruited to the site of 
infection as a result of a pro-inflammatory response in ECs (Schmid et al., 2004; 
Fuhrmann et al., 2001), or from infected epithelial cells surrounding the blood vessel 
is proposed to contribute to BA/BP by promoting EC proliferation in a paracrine 
manner (Resto-Ruiz et al., 2002; Kempf et al., 2001). Bh also demonstrates a potent 
direct mitogenic stimulation of ECs (Conley et al., 1994). Furthermore, the inhibition 
of EC apoptosis upon Bh-infection might play indirectly a role in vasoproliferation by 
increasing cell survival (Kirby and Nekorchuk, 2002). Another characteristic of 
infection of human umbilical vein endothelial cells (HUVECs) with Bh are massive 
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cytoskeletal actin rearrangements leading to a unique structure termed invasome 
(Dehio et al., 1997). Almost all these activities depend on the VirB/VirD4 type IV 
secretion system (T4SS) of Bh and the thereby translocated Bartonella effector 
proteins (BepA-BepG) (Schulein et al., 2005; Schmid et al., 2004). The NFκ-B-
dependent pro-inflammatory is to some extend T4SS-independent (Fuhrmann et al., 
2001), whereas the direct mitogenic stimulus is completely lying outside of the 
VirB/VirD4 T4SS. Intriguingly, this potent direct stimulation of EC proliferation is even 
counterbalanced by the VirB/VirD4/Bep system (Schmid et al., 2004). The role of the 
VirB/VirD4 T4SS and the Beps in the VEGF-based paracrine loop is unknown. A 
recently established three-dimensional spheroid sprouting assay allowed the 
assessment of the complex angiogenic properties of Bh in an elaborate in vitro model 
and revealed distinct but also adverse activities of the Beps modulating capillary-like 
sprout formation (Scheidegger et al., 2008). 
Observations done during the establishment of the spheroid-based in vitro 
model prompted us to study the effect of exogenous VEGF on Bh-infected ECs. 
Spheroids formed from HUVECs pre-infected with Bh wild-type showed sprouting 
which could not be further stimulated by VEGF. VEGF-stimulated proliferation as well 
as migration was suppressed in Bh wild-type-infected ECs. Immunoblot analyses 
demonstrate that the Bh VirB/VirD4/Bep system altered VEGFR2 signalling, more 
precisely inhibited the signalling cascade leading to the activation of the mitogen-
activated protein kinase ERK1/2 by interfering with tyrosine-phosphorylation of a 
specific site of the VEGFR2. The presented data emphasize the role of the 
VirB/VirD4/Bep system, which displays both pro- as well as anti-angiogenic 
characteristics, as an important factor balancing the angiogenic potential of Bh in the 
course of human vascular infection. 
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Results 
The VirB/VirD4/Bep system of Bartonella henselae inhibits VEGF-induced 
spheroid sprouting 
The recently established three-dimensional spheroid-based in vitro model of 
Bartonella-triggered angiogenesis (Scheidegger et al., 2008) was used as an 
elaborate assay for VEGF activity. Therefore spheroids from uninfected HUVECs 
respectively HUVECs infected with a multiplicity of infection (MOI) of 300 with Bh 
wild-type or the isogenic effector-less mutant ∆bepA-G were embedded in collagen 
and subsequently either stimulated with VEGF (25 ng/ml) or left untreated. After 24 h 
in vitro angiogenesis was quantified by calculating the cumulative sprout length 
(CSL) of individual spheroids (Fig 1A, determined as the mean +/- SD of 10 
spheroids per experimental group). To quantify the effect of VEGF we calculated a 
VEGF sprout factor by dividing CSL of spheroids stimulated with VEGF by CSL of 
spheroids without VEGF (Fig 1B, shown are means +/- SD of the indicated number of 
experiments). As previously observed spheroids formed from HUVECs pre-infected 
with Bh wild-type displayed an increase in CSL in comparison to uninfected control 
spheroids. Compared to wild-type, the sprouting activity was reduced in spheroids of 
HUVECs pre-infected with the ΔbepA-G mutant. Surprisingly, spheroids made from 
HUVECs previously infected with Bh wild-type were not responsive to VEGF as the 
CSL with or without VEGF were comparable (Fig. 1A, C), leading to a VEGF sprout 
factor of 1 (Fig. 1B). In contrast, sprouting could be readily induced about six- 
respectively 2.5-fold by VEGF for uninfected spheroids or for spheroids from 
HUVECs pre-infected with the mutant lacking the VirB/VirD4-translocated effectors 
BepA-BepG (Fig. 1A, B, C). 
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The VirB/VirD4/Bep system of Bartonella henselae interferes with VEGF-
induced proliferation and wound closure 
Further to the spheroid-based three-dimensional in vitro angiogenesis assay 
quantifying sprout formation, two classical in vitro assays were used to asses the 
effect of exogenous VEGF on ECs infected with Bh. To determine the effect of Bh-
infection on VEGF-stimulated proliferation, cell numbers were compared after 4 days 
in presence or absence of VEGF (25 ng/ml) of uninfected cells and HUVECs either 
infected with wild-type or the effector-less ∆bepA-G mutant (Fig. 2A, determined as 
the mean +/- SD of 10 images per well). Cells were seeded in 96-well plates and 
infected with a MOI of 50. Cell numbers were determined by staining nuclei with 
DAPI, automated image acquisition and automated cell counting using the 
CellProfiler software (Carpenter et al., 2006). As reported previously the ∆bepA-G 
mutant as such strongly promoted cell proliferation and this T4SS-independent 
stimulus was only slightly affected in Bh wild-type infection at the low MOI used in 
this assay. Addition of VEGF stimulated cell proliferation about four-fold for 
uninfected HUVECs. Proliferation of HUVECs infected with the ∆bepA-G mutant 
could be further increased 1.5-fold by exogenous VEGF. In contrary, VEGF had no 
effect on wild-type-infected cells. 
To asses the effect of infection and exogenous VEGF on cell migration cells 
were seeded in 6-well plates and infected for 24 h with a MOI of 150 with the 
indicated strains. The confluent cell layers were wounded by scratching with a pipette 
tip, stimulated with VEGF (25 ng/ml) and followed by microscopy (Fig. 2B). 
Stimulation of uninfected HUVECs with VEGF led to complete closure of the wound 
after two days. Similarly if not faster, HUVECs pre-infected with the ∆bepA-G mutant 
and stimulated with VEGF readily moved to fill the damaged area. Pre-infection with 
Bh wild-type led to a prominent interference with migration, which could not be 
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rescued by exogenous VEGF. Interestingly, wild-type infected HUVECs did project 
towards the centre of the wound, thus they were activated to migrate, but the rear 
back of those cells seemed to stick to the surface, indicating that HUVECs infected 
with Bh wild-type might have difficulties to detach from the substrate. 
 
The VirB/VirD4/Bep system alters VEGF receptor 2 Tyr1175 signalling 
VEGFR2 signalling was assessed in a series of immunoblots using antibodies 
against a number of key components of the VEGR2 signalling cascade (Fig. 3). For 
this, HUVECs were infected for 24 h with a MOI of 300 with the indicated strains. 
Subsequently, cells were either stimulated with VEGF (25 ng/ml) for 5 minutes or left 
untreated and total cell lysates were harvested. In HUVECs infected with Bh wild-
type and stimulated with VEGF general tyrosine-phosphorylation of VEGFR2 was 
slightly reduced, albeit showing similar levels of total VEGFR2. This effect was 
VirB/Bep-dependent. Tyrosine 1175 (Tyr1175) in the C-terminus of VEGFR2 has 
been shown to be one of the important docking sites for downstream signalling 
proteins and to have a critical role in the regulation of angiogenesis (Holmes et al., 
2007; Sakurai et al., 2005). Bh interfered in a VirB/Bep-dependent manner with 
phosphorylation on this position. Phospholipase Cγ1 (PLCγ1) is amongst the proteins 
binding to phosphorylated Tyr1175. This interaction promotes phosphorylation and 
subsequent increase in the catalytic activity of PLCγ1, which further mediates the 
activation of the mitogen-activated protein kinase (MAPK)/extracellular-signal-
regulated kinase-1/2 (ERK1/2) (Takahashi et al., 2001). Consistent with the lack of 
Tyr1775-phosphorylation in HUVECs infected with wild-type and stimulated with 
VEGF, less PLCγ1 was recruited and the enzyme did not get phosphorylated. 
Moreover, we observed a VirB/Bep-dependent reduced phosphorylation of the 
ERK1/2 kinase with no difference in total ERK1/2. The phosphorylation of p38 MAPK 
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was generally increased upon infection. We saw no differences, also not upon 
stimulation with VEGF, for the phosphorylation of the serine/threonine kinase 
AKT/PKB, and the phosphorylation of the activating Tyr418 or inhibitory Tyr529 of 
Src. The adaptor protein Shb has also been reported to bind to phosphorylated 
Tyr1175 (Holmqvist et al., 2004). Shb is able to bind a number of proteins, amongst 
them the focal-adhesion kinase (FAK) (Holmqvist et al., 2003), an important factor for 
cellular attachment and cellular migration (Parsons, 2003). In Bh wild-type-infected 
ECs phosphorylation of FAK following stimulation with VEGF might be impaired. 
 
The VirB/VirD4/Bep system blocks calcium flux upon stimulation with VEGF 
ERK-phosphorylation involves a protein kinase C (PKC)-dependent pathway 
starting from the activation of PLCγ1. PLCγ1 hydrolyses the membrane phospholipid 
phophatidylinositol (4,5)-bisphosphate (PIP2) to generate the second messengers 
diacylglycerol (DAG) and inositol 1,4,5-triphosphate (IP3). IP3 generation further 
results in increase of intracellular concentration of calcium [Ca2+]i through opening of 
IP3-operated calcium-release channels (IP3R) of the endoplasmatic reticulum (ER), 
whereas DAG is the activator of a number of PKC isoforms (Holmes et al., 2007). 
HUVECs infected for 24 h with different MOI of Bh wild-type were loaded with the 
fluorescent Ca2+ indicator Fluo-4 NW to further asses the nature of Bh interference 
along the ERK1/2 signalling cascade. Baseline fluorescence was measured before 
cells were stimulated with VEGF (25 ng/ml). Application of VEGF to HUVECs 
induced a rapid increase in [Ca2+]i, followed by a sustained plateau phase clearly 
above baseline (Fig. 4A, control). With increasing MOI the initial calcium peak was 
diminished to baseline level (Fig. 4A). A MOI of 150 cut the calcium peak by half. 
Treatment with Ionomycin (Fig. 4 A, B) or Thapsigargin (data not shown) showed that 
calcium stores are not emptied upon infection. 
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ECs either infected with the ∆virB4 mutant deficient for translocation via the 
VirB/VirD4 T4SS or the ∆bepA-G mutant lacking BepA to BepG behaved as 
uninfected ECs (Fig. 4B). Furthermore, heat-killed Bartonella or bacteria lacking 
batR, the two-component-regulator of virB/virD4/bep expression, did not affect 
VEGF-induced increase in [Ca2+]i (data not shown). Thus, the MOI-correlating 
interference with calcium flux was dependent on viable bacteria with a functional 
VirB/VirD4 T4SS and at least one of the effectors. 
To test the specificity of Bh-interference with calcium flux we assessed [Ca2+]i 
in HUVECs after stimulation with Thrombin (1 U/ml) or ATP (100 μM). Both stimuli 
lead to accumulation of IP3 and subsequent increase of [Ca2+]i by the activation of 
PLCβ connected to G protein-coupled receptors (GPCRs) (Rozengurt, 2007; 
McLaughlin et al., 2005; Communi et al., 2000). Bh wild-type neither blocked 
Thrombin- nor ATP-induced calcium flux (Fig. 4C). Hence, the results obtained so far 
indicate that Bh can interfere with calcium flux, that follow the activation of PLCγ 
coupled to RTKs. 
Loss of bep genes had effects in both directions (Fig. 5). Infections with a 
mutant lacking bepD-F, harbouring tyrosine phosphorylation motifs, as well as a 
mutant having a single deletion in bepE led to a more potent suppression of the 
VEGF-triggered calcium flux. Surprisingly, infection with the ∆bepA mutant, BepA 
being the effector responsible for inhibition of apoptosis (Schmid et al., 2006), 
resulted in VEGF-induced calcium flux comparable to the one triggered in cells 
infected with the ∆bepA-G mutant. Cells infected with the a mutant lacking BepG, the 
effector able to promote actin rearrangements required for invasome-mediated 
invasion (Rhomberg et al., 2008) , showed already half of the interference with 
calcium flux. When infected with a double-knockout of bepC and bepG, a mutant not 
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able to make invasomes (Rhomberg, T. unpublished observation), the cells showed 
unhindered VEGF-stimulated calcium flux. 
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Discussion 
Major phenotypic changes have been described for Bh-infected ECs in vitro. 
Whereas some depend on the VirB/VirD4/Bep system others are VirB/VirD4/Bep-
independent (Scheidegger et al., 2008; Schulein et al., 2005; Schmid et al., 2004). 
They are thought to play a role in the remarkable capacity of Bh to trigger BA and BP 
which are vasoproliferative processes resembling tumour angiogenesis. In addition to 
a direct stimulation of proliferation and inhibition of apoptosis in ECs the activation of 
a paracrine loop of pro-angiogenic factors such as VEGF is thought to be involved in 
Bartonella-triggered vascular tumour formation (Dehio, 2005). VEGF is known as an 
essential regulator of physiological as well as pathological angiogenic processes 
(Takahashi and Shibuya, 2005). Based on observations done with a recently 
established spheroid-based in vitro model of Bh-triggered angiogenesis (Scheidegger 
et al., 2008) we addressed in this study the effect of exogenous VEGF on Bh-infected 
ECs. 
Surprisingly, the VirB/VirD4/Bep system interfered with EC responsiveness to 
stimulation with the potent EC specific growth factor VEGF. If HUVECs were pre-
infected with Bh wild-type neither sprouting, nor proliferation, nor migration could be 
induced by VEGF. Bh wild-type inhibited phosphorylation of Tyr1175, one of the 
critical docking site for different adaptor proteins mediating VEGFR2 downstream 
signalling (Holmes et al., 2007). PLCγ1 is one of those proteins. PLCγ1 feeds into the 
signalling cascade leading to the activation of the mitogen-activated protein kinase 
ERK1/2. ERK1/2 has a pivotal role in VEGF-stimulated EC proliferation (Takahashi et 
al., 2001). PLCγ1-recruitment and phosphorylation upon VEGF-stimulation was 
inhibited by Bh in a VirB/Bep-dependent manner. Consequently, we observed also a 
lack of downstream calcium release from the ER. The importance of PLCγ1 for 
VEGF function is highlighted by the fact that PLCγ1 deficient zebrafish embryos fail 
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to respond to exogenous VEGF and that overall the mutant phenotype of these 
embryos resembles the ones of mutants lacking VEGF function (Lawson et al., 
2003). 
Another adaptor protein binding to Tyr1175 is Shb, which can bind FAK 
(Holmqvist et al., 2004; Holmqvist et al., 2003). FAK is involved in focal-adhesion 
turnover during cellular migration (Parsons, 2003). In ECs infected with Bh wild-type 
FAK-phosphorylation upon stimulation with VEGF appeared to be reduced, which 
could explain the defects in migration observed during the scratch wound assay even 
in the presence of VEGF. Small interfering RNA (siRNA)-mediated gene silencing of 
Shb results in an inhibition of not only VEGF-induced cytoskeletal reorganisation and 
migration but also activation of phosphoinositide 3-kinase (PI3K) (Holmqvist et al., 
2003). Signalling pathways downstream of PI3K affect cell growth, cell survival, and 
cell movement. Amongst the downstream targets of PI3K the protein serine-threonine 
kinases AKT (also called protein kinase B, PKB) is of particular interest (Cantley, 
2002). AKT mediates VEGF-induced cell survival (Gerber et al., 1998) and regulates 
NO (Fulton et al., 1999). The fact that serum induces AKT-activation (Andjelkovic et 
al., 1996) might explain why in this setup we did not observe any changes in AKT-
phosphorylation, neither upon stimulation with VEGF nor influenced by infection. Bh 
requires serum for efficient translocation of the Bep effector proteins via the 
VirB/VirD4 T4SS (Quebatte, M. unpublished observation). 
Other signalling molecules have been implicated in VEGF-induced migration, 
such as the sequential activation of CDC42, p38 MAPK and phosphorylation of heat-
shock protein-27 (HSP27) following the phosphorylation of Tyr1214 of VEGFR2 
(Lamalice et al., 2004). The activation p38 MAPK seems to have various and 
somewhat adverse effects on processes associated with angiogenesis, such as 
being pro-migratory but restraining cell proliferation (McMullen et al., 2005). ECs 
 
Chapter 3
E-14
infected with Bh generally showed an increase in p38-phosphorylation. The p38 
MAPK is strongly activated by environmental stresses and inflammatory cytokines, 
and less by serum and growth factors (Cuenda and Rousseau, 2007). Hence, the 
effect we wanted to address upon stimulation with VEGF could have been masked 
as even in uninfected cells we could not see a difference between stimulated and 
unstimulated ECs. Nevertheless, Bh-triggered activation of p38 might play a role in 
pathogenesis as proposed for B. quintana (Bq) and B. bacilliformis (Bb) (Liberto et 
al., 2004; Verma and Ihler, 2002). 
Experiments done with other stimuli than VEGF, such as ATP or thrombin 
triggering GPCR-coupled calcium flux, indicate that Bh interference might be specific 
for RTKs. The observation that the Bh ∆bepA-G mutant lacking the seven known 
effectors behaved as uninfected cells, strongly suggests a role for the Beps in the 
observed interference of Bh with responsiveness towards VEGF. An initial analysis of 
individual in-frame mutants in calcium flux assays points to an interplay of the anti-
apoptotic BepA and BepC / BepG involved actin rearrangements. It remains to be 
investigated how the VirB/VirD4/Bep system interferes with VEGFR2 signalling, 
whether for example Beps directly interact with signalling components of the VEGF 
signalling cascades or whether they would indirectly interfere by sequestering key 
factors. Other open questions need to be addressed, such as if VEGFR2 kinase 
activity itself is changed upon Bh-infection, whether other tyrosine-phosphorylation 
sites known to bind adaptor proteins are influenced, and if signalling kinetics are 
altered, and last but not least the translation of these in vitro observations into in vivo 
relevance. Another important fact to consider is that the experiments addressing the 
role of Bh in the paracrine loop model and attributing a crucial role to the non-fimbrial 
adhesin BadA (Bartonella adhesin A) in the induction of a pro-angiogenic cell 
response (Riess et al., 2004; Kempf et al., 2001), were carried out with the Bh 
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Marseille strain (Drancourt et al., 1996). Whereas here, a spontaneous streptomycin-
resistant variant of the Houston-1 clinical isolate and typing strain ATCC49882T 
served as wild-type (Schmid et al., 2004; Regnery et al., 1992). Although the length 
of the gene varies significantly, badA seems to be present in all Bh strains tested so 
far. Single-base deletions or insertions and recombinations are proposed to affect 
BadA expression, resulting in the coexistence of BadA-positive and BadA-negative 
substrains within one Bh type strain (Riess et al., 2007). BadA and its relevance have 
not been tackled so far in the strain used in this study. 
In summary, we demonstrated an intriguing effect of the VirB/VirD4/Bep 
system, antagonizing a major signalling cascade of VEGFR2 following its activation 
by VEGF. Observations done on the level of phosphorylation to assess activation of 
proteins were reflected in assays such as proliferation, migration and sprout 
formation assessing the biological function of VEGF. Together with the fact that the 
VirB/VirD/Bep system masks a potent T4SS-independent mitogenic activity (Schmid 
et al., 2004) and that BepG potently interferes with sprouting (Scheidegger et al., 
2008), this strong interference of the VirB/VirD4/Bep system with the signalling of one 
of the most important regulator of angiogenesis speaks against the VirB/VirD4 T4SS 
as major pro-angiogenic factor in Bh pathogenesis, at least for cells infected with Bh. 
Along this line, the human-specific Bb strongly promotes vascular proliferation 
(Garcia et al., 1990) even though it has no VirB/VirD4 T4SS (Saenz et al., 2007). 
Thus, the VirB/VirD4/Bep system more likely is a true host adaptation system, a 
modulator needed for the regulation of the angiogenic activity of Bh during infection – 
antagonizing potent mitogenic stimuli but inducing minor perturbation in cell 
proliferation and cell death tolerated by the host but necessary in the long run for 
chronic vascular infection. 
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Experimental procedures 
Reagents 
Vascular endothelial growth factor-A165 (VEGF) was a generous gift from Dr. H. 
Weber, Tumor Biology Centre, University of Freiburg. Antibiotics, ATP and 
Carboxymethylcellulose (methocel, 4000 centipoises) were from Sigma 
(http://www.sigmaaldrich.com). Collagen type I was isolated from rat tail tendons 
(Augustin, 2004). Thrombin and Ionomycin were purchased from Calbiochem 
(http://www.emdbiosciences.com). The mouse anti-phosphotyrosine antibody (clone 
4G10) and mouse anti-actin (clone C4) were purchased from Millipore 
(http://www.millipore.com). Rabbit anti-VEGFR2 (clone 55B11), rabbit anti-phospho 
VEGFR2 (Tyr1175, clone 19A10), mouse anti-p44/42 (ERK1/2) MAP Kinase, mouse 
anti-phospho p44/42 (Thr202/Tyr204, clone E10), rabbit anti-phospho p38 
(Thr180/Tyr182, clone12F8), rabbit anti-phospho AKT (Thr308, clone 244F9), rabbit 
anti-PLCγ1, and rabbit anti-phospho PLCγ1 (Tyr783) antibodies were purchased 
from Cell Signalling Technology (http://www.cellsignal.com). The mouse anti-FAK 
(clone 77) was obtained from BD Pharmingen (http://www.bdbiosciences.com), rabbit 
anti-phospho FAK (Tyr397) from abcam (http://www.abcam.com). Rabbit anti-
phospho Src (Tyr418 and Tyr529) antibodies were from Biosource 
(http://www.biosource.com). Secondary HRP-conjugated antibodies were obtained 
from Amersham (http://www.amersham.com). 
 
Bacterial strains and Growth Conditions 
The bacterial strains used are listed in Table 1. Bartonella spp. were grown on 
Columbia agar (CBA) plates containing 5% defibrinated sheep blood in a humified 
atmosphere at 35°C and 5% CO2 for 2-3 days. Strain RSE247, a spontaneous 
streptomycin-resistant strain of ATCC 49882T (Schmid et al., 2004) served as wild-
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type in this study. Media were supplemented with 30 µg/ml kanamycin, 100 µg/ml 
streptomycin, 12.5 µg/ml gentamicin, and/or 500 µM isopropyl β-D-thiogalactosidase 
(IPTG, http://www.applichem.de) if needed. 
 
Cell Culture 
Human umbilical vein endothelial cells (HUVECs) were isolated as described before 
(Dehio et al., 1997) and cultured in EGM medium (http://www.promocell.com) in a 
humified atmosphere at 37°C and 5% CO2. 
 
Infection Assay 
HUVECs (passage 4-7) were plated in gelatine-coated well plates using EGM. The 
next day cells were washed twice with M199 with Earls salts (M199, Gibco, 
http://www.invitrogen.com) supplemented with 10% fetal calf serum (FCS, 
http://www.invitrogen.com) and infected with the indicated multiplicity of infection 
(MOI) bacteria per cell in M199/10% FCS/500 μM IPTG and incubated for 24 hours. 
 
Generation of endothelial cell spheroids 
EC spheroids of defined cell number were generated as described previously (Korff 
and Augustin, 1998) with some modifications. In brief, uninfected respectively 
infected HUVEC monolayers were trypsinized and suspended in EGM containing 
20% methocel (Weber et al., 2008). Spheroids were generated by pipetting 400 ECs 
(in 25 μl) on quadratic Greiner Petri dishes (http://www.huberlaborworld.ch) and 
grown overnight as hanging drops in a humified atmosphere at 35°C and 5% CO2. 
Under these conditions, all suspended cells contribute to the formation of a single 
spheroid of defined cell number per drop. 
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Spheroid-based in vitro angiogenesis assay 
The in vitro angiogenesis assay was performed as described (Weber et al., 2008). 
The generated spheroids were harvested and suspended in the methocel solution 
containing 20% FCS. Subsequently, the ice-cold collagen solution (rat tail type I 
collagen in 0.1% acidic acid) was neutralized by adding 10% 10-fold Medium 199 
and approx. 10% 0.2 N NaOH to adjust the pH to 7.4. EC spheroid/ methocel solution 
was mixed 1:1 with the neutralised collagen solution and 1 ml of the mixed solution 
containing approximately 50 EC spheroids were pipetted into individual wells of a 
pre-warmed 24 well plate to allow polymerisation in the incubator in a humified 
atmosphere at 35°C, 5% CO2. After 30 min VEGF was added to an end-
concentration of 25 ng/ml by pipetting 100 μl of a 10-fold concentrated working 
dilution on top of the polymerised gel. Plates were incubated in a humified 
atmosphere at 35°C, 5% CO2 for 24 h and fixed by adding 3.7% paraformaldehyde. 
Pictures were taken with a Leica DM IRBE inverted microscope using a MicroMAX 
camera (Princeton Instruments with MetaMorph software) using the 20x objective. In 
vitro angiogenesis was digitally quantitated by measuring the cumulative length of the 
sprouts (CSL) that had grown out of each spheroid using the MetaMorph software 
analyzing 10 spheroids per experimental group and experiment. 
 
Proliferation assay 
1000 HUVECs were seeded in 96-well plates and infected with a MOI of 50 in the 
presence or absence of VEGF (25 ng/ml). After 4 days cells were fixed with 3.7% 
paraformaldehyde and exposed to DAPI (1:1000, 1mg/ml stock). Plates were imaged 
with an automated fluorescence microscope (IXM, MDC Molecular Devices) and 
assessed quantitatively by using CellProfiler (Carpenter et al., 2006). Results are 
given as average cell number per image, analysing ten images per well. 
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Scratch wound assay 
1.2*105 HUVECs were seeded in 6-well plates and infected with a MOI of 150. Small 
areas of the confluent monolayers were disrupted by scratching three straight lines 
with a p200 pipette tip. Debris were removed by washing the cells once, stimulated 
with VEGF (25 ng/ml) and followed by microscopy with a 10x objective. To obtain the 
same fields during the image acquisition we used a Leica DM-IRBE microscope with 
automated staging. 
 
Immunoprecipitation and Immunoblotting 
6*105 HUVECs were seeded in 10-cm dishes and infected with a MOI of 300 with the 
indicated strains for 24 hours and then stimulated with 25 ng/ml VEGF for 5 min. 
Proteins from total cell lysates were separated by SDS-PAGE, transferred onto 
nitrocellulose membranes (Hybond-C, http://www.amersham.com), and examined 
using the indicated antibodies (1:1000). The secondary horseradish peroxidase 
(HRP)-conjugated antibody (1:2000) was visualized by enhanced 
chemiluminescence (http://www.perkinelmer.com). If indicated membranes were 
treated with strip-buffer (0.2 M Tris-HCl ph 6.8, 2% w/v SDS, 0.7% v/v 
mercaptoethanol) and reprobed. 
 
Ca2+ mobilization measurements 
5000 HUVECs were seeded per well of a 96-well plate and unless stated differently 
infected with a MOI of 300 in M199/10% FCS for 24 hours. Media was removed and 
cells were loaded with the fluorescent Ca2+ indicator Fluo-4 NW 
(http://www.invitrogen.com) for 45 min in the incubator in the dark. Following the 
manufacturers protocol baseline fluorescence was measured for two minutes before 
cells were stimulated with VEGF (25 ng/ml) or Thrombin (1 U/ml) respectively ATP 
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(100 μM) and fluorescence was recorded for another seven minutes before 
Ionomycin (0.5 μM) was added if indicated. 
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Table 1 Bacterial strains and plasmids used in this study. 
Strain  Genotype or relevant characteristics Reference or source 
or plasmid 
B. henselae strains 
ATCC 49882 T ‘Houston-1’, isolated from a bacteremic HIV-patient (Regnery et al., 1992) 
RSE247 Spontaneous Smr strain of ATCC 49882 T, (Schmid et al., 2004) 
  serving as wild-type 
RSE242 ΔvirB4 mutant of RSE247 (Schmid et al., 2004) 
MSE150 ΔbepA-G mutant of RSE247 (Schulein et al., 2005) 
MSE154 ΔbepA mutant of RSE247 (Schmid et al., 2006) 
TRB288 ΔbepC mutant of RSE247 (Rhomberg et al., 2008) 
PGC80  ΔbepD mutant of RSE247 (Rhomberg et al., 2008) 
PGD20  ΔbepE mutant of RSE247 (Rhomberg et al., 2008) 
TRB222 ΔbepF mutant of RSE247 (Rhomberg et al., 2008) 
TRB223 ΔbepG mutant of RSE247 (Rhomberg et al., 2008) 
 
Plasmids 
pTR1000 Basic mutagenesis vector to generate in-frame (Schmid et al., 2004) 
 mutants of RSE247 
pTR1069 Derivate of pTR1000 to generate a ∆bepC in-frame (Scheidegger et al., 2008) 
 mutant in Bh 
pPG161 Derivate of pTR1000 to generate a ∆bepD in-frame (Scheidegger et al., 2008) 
 mutant in Bh 
pPG162 Derivate of pTR1000 to generate a ∆bepE in-frame (Scheidegger et al., 2008) 
 mutant in Bh 
pTR1075 Derivate of pTR1000 to generate a ∆bepF in-frame (Scheidegger et al., 2008) 
 mutant in Bh 
pTR1078 Derivate of pTR1000 to generate a ∆bepG in-frame (Scheidegger et al., 2008) 
 mutant in Bh 
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Figure 1: Bh VirB/VirD4/Bep system interferes with VEGF-induced spheroid 
sprouting 
Spheroids made from uninfected HUVECs respectively HUVECs infected with the 
indicated strains were embedded in collagen and either stimulated or not with VEGF 
(25 ng/ml). (A) Quantification of in vitro angiogenesis of collagen embedded 
spheroids after 24 h by calculating the cumulative length of sprouts originating from 
an individual spheroid (CSL). Shown are means +/- SD of ten spheroids per 
experimental group. Differences between experimental groups were analyzed by 
Student’s t-test. p < 0.05 was considered statistically significant. (B) VEGF sprout 
factor was calculated by dividing CSL stimulated by VEGF by unstimulated CSL. 
Shown are means +/- SD of the indicated number of experiments (C) Bright field 
images of one-day-old collagen embedded HUVEC spheroids. Shown are 
representative images demonstrating strong capillary-like sprouting of spheroids 
upon stimulation with VEGF for control spheroids as well as spheroids from ∆bepA-
G-infected HUVECs, but interference with responsiveness to VEGF by infection with 
Bh wild-type. 
 
Figure 2: Bh VirB/VirD4/Bep system interferes with VEGF-induced proliferation 
and wound closure 
(A) Cell numbers were determined after 4 days of infection in presence and absence 
of VEGF (25 ng/ml). Proliferation was stimulated by infection, especially with the 
∆bepA-G mutant. Whereas proliferation could be further increased in uninfected cells 
or HUVECs infected with the ∆bepA-G mutant, Bh wild-type completely blocked the 
effect of exogenous VEGF. Shown are average numbers and SD of ten acquired 
images (B) Confluent cell layers, uninfected or pre-infected with the indicated strains 
for 24 h, were wounded by scratching three straight lines with a pipette tip, stimulated 
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with VEGF (25 ng/ml) and followed by microscopy. Stimulation of uninfected 
HUVECs with VEGF led to complete closure of the wound after two days. Pre-
infection with Bh wild-type severely interfered with cell migration even in the 
presence of VEGF, whereas HUVECs pre-infected with the ∆bepA-G mutant readily 
moved to fill the damaged area. Shown are representative bright field images. 
 
Figure 3: Changes in VEGF receptor 2 Tyr1175 signalling upon infection 
HUVECs were infected with the indicated strains or left uninfected for 24 h before 
being subjected to VEGF (25 ng/ml) for 5 min. Total cell extracts were separated by 
SDS-PAGE and immunoblots were performed with the indicated antibodies. General 
tyrosine-phosphorylation of VEGFR2 upon stimulation with VEGF was reduced in 
HUVECs infected with Bh wild-type. Bh wild-type interfered with Tyr1175 
phosphorylation of VEGFR2, consequently PLCγ1 was less recruited and thus not 
activated as shown by decreased phosphorylation of PLCγ1 and weaker signal for 
total PLCγ1. VEGF-stimulated downstream Erk1/2- and less pronounced FAK-
phosphorylation were affected. These observations were dependent on a functional 
VirB/VirD4 T4SS and at least one of the Beps. Phosphorylation of p38 MAP Kinase 
was generally slightly increased upon infection. No differences were observed for 
phosphorylation of AKT/PKB and Src. For total PLCγ1, phospho-SRC (Tyr529), and 
total FAK imunnoblots for phospho-PLCγ1, phospho-SRC (Tyr418), and phospho-
FAK respectively were stripped and reprobed. 
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Figure 4: VirB/Bep-dependent interference with receptor tyrosine kinase 
specific calcium flux upon stimulation with VEGF 
Uninfected HUVECs respectively. HUVECs infected with the indicated strains were 
loaded with the calcium indicator Fluo4. Baseline fluorescence was measured for two 
minutes, then cells were stimulated with VEGF (25 ng/ml) or Thrombin (1 U/ml) 
respectively ATP (100 μM) and fluorescence was recorded for another seven 
minutes before Ionomycin (0.5 μM) was added if indicated. (A) Bh wild-type interferes 
with calcium flux initiated by VEGF in a MOI-dependent manner. (B) Interference is 
VirB/Bep-dependent. (C) GPCR (Thrombin or ATP)-triggered calcium flux is not 
influenced by Bh. 
 
Figure 5: Role of Beps in interference with calcium flux upon stimulation with 
VEGF 
Uninfected HUVECs respectively HUVECs infected with Bh wild-type or the indicated 
inframe-deletion mutants were loaded with the calcium indicator Fluo4. Baseline 
fluorescence was measured for two minutes, then cells were stimulated with VEGF 
(25 ng/ml) and fluorescence was recorded for another seven minutes. Double-
deletion of bepC and bepG lead to loss of interference, surprisingly also the knockout 
of bepA. 
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The Role of the VirB/VirD4/Bep System in the Paracrine 
Loop Model of Bartonella henselae-triggered VEGF 
Production (unpublished) 
 
The vascular endothelial growth factor (VEGF) is an essential regulator of 
angiogenesis under physiological as well as pathological conditions (Takahashi and 
Shibuya, 2005). Evidence for a role of VEGF in Bartonella henselae (Bh)-induced 
vasoproliferation came from co-culture experiments done with Ea.hy926 cells (a 
fusion of human umbilical vein endothelial cells, HUVECs, with the lung carcinoma 
cell line A549), HeLa cells (an epithelial cervical cancer cell line), or THP-1 cells (a 
human acute monocytic leukemia cell line) where it was shown that upon infection 
with Bh those cells secrete biologically active VEGF. Either taken as a model for 
monocytes recruited to the site of infection or cells of epidermal origin surrounding 
blood vessels, those cells would provide a paracrine source of VEGF stimulating 
endothelial cell (EC) proliferation and thus contributing to bacillary angiomatosis and 
peliosis (BA/BP) (Resto-Ruiz et al., 2002; Kempf et al., 2001). 
 
Results 
VirB/Bep-induced increase in VEGF secretion upon infection of HeLa cells with 
Bartonella henselae 
To address whether the VirB/VirD4/Bep system affects VEGF production, I 
measured VEGF levels by ELISA in culture supernatants of HeLa and Ea.hy926 cells 
infected with a MOI of 300 with different Bh mutant strains. Stimulation with 25 ng/ml 
PMA (phorbol-12-myristate-13-acetate) served as control. As previously observed 
HeLa cells produced large amounts of VEGF upon exposure to Bh (Fig. 1A). 
Infection with Bh wild-type even exceeded the effect of PMA. The deletion of virB4, 
leading to a non-functional T4SS, reduced VEGF secretion, which could be restored 
by in trans-complentation of virB4 on a plasmid. Comparable to the ∆virB4 mutant a 
∆bepA-G mutant, lacking the known effector proteins, triggered less VEGF, indicating 
that at least one of the Beps is responsible for the induction of increased VEGF 
production. Similarly also Ea.hy926 were stimulated to secrete VEGF in a VirB/Bep-
dependent manner, although showing in general low levels (Fig. 1B). Dead bacteria 
were not able to induce VEGF production (data not shown). 
Chapter 4 
Initial experiments with THP-1 cells showed an increased VEGF production upon 
infection in general for monocytes (Fig. 1C) and indicated a slight T4SS-dependent 
effect on top of a VirB-independent action in PMA-differentiated THP-1 macrophages 
(Fig. 1D). Noteworthy are the already high levels of VEGF in uninfected cells. 
 
 
Figure 1 VEGF production of (A) HeLa cells, (B) Ea.hy926 cells, (C) THP-1 monocytes, and (D) THP-
1 macrophages (differentiated with 100ng/ml PMA, phorbol-12-myristate-13-acetate) infected with a 
MOI of 300 with different Bh mutant strains. Control cells were uninfected or stimulated with PMA (25 
ng/ml). Determination of VEGF by ELISA in cell culture supernatants after 24, 48, 72, and 120 hours 
respectively. Shown are mean / SD of triplicates. 
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The VirB/VirD4 T4SS effector BepD promotes VEGF production in HeLa cells 
I performed ELISA measurements of supernatants from infections with the 
∆bepB-G mutant trans-complemented with single bep genes and compared resulting 
levels to those triggered by wild-type or the effector-less ∆bepA-G mutant to further 
elucidate which of the Beps are involved in triggering VEGF. I observed in this 
experiment an already strong VirB/Bep-independent level of VEGF production 
although still increased about 1.8-fold for wild-type infection. Infection with the 
∆bepB-G mutant still expressing bepA showed a 1.3-fold increased stimulation of 
VEGF secretion in comparison to the ∆bepA-G mutant. On top of this, BepD further 
augmented VEGF production about 1.7-fold (2.2-fold if compared to the ∆bepA-G 
mutant) exceeding the amount of VEGF triggered by the wild-type as such (Fig. 2). 
 
 
Figure 2 VEGF production of HeLa cells infected with a MOI of 300 with Bh wild-type, the effector-less 
∆bepA-G and the ∆bepB-G mutant trans-complemented with single bep genes. Control cells were 
uninfected or stimulated with PMA (25 ng/ml). Determination of VEGF by ELISA in cell culture 
supernatants after 120 hours. Shown are mean / SD of triplicates. 
 
BepD carries the classical bipartite translocation signal in its C-terminus, 
composed of the BID (Bep intracellular delivery) domain and an unconserved 
positively charged tail. The N-terminus harbours several minor repeats condensed in 
two major repeats with tyrosine-phosphorylation motifs, such as EPLYA and ETIYA. 
Indeed, BepD becomes tyrosine-phosphorylated by host cell-derived tyrosine kinases 
upon translocation into ECs (Schulein et al., 2005) and thereby possibly provides 
docking sites for cell signalling proteins (Backert and Selbach, 2005). To trigger 
VEGF production in HeLa cells both major repeats seemed to be needed (data not 
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shown). The importance of tyrosine-phosphorylation in eukaryotic signalling 
pathways as reversible switches (Hunter, 1995) makes it an attractive target for 
pathogens. By changing signalling cascades with tyrosine-phosphorylated proteins or 
adapters, virtually any function of the host cell can be accessed and subverted. 
Further studies could provide insights into how BepD is able to interfere with 
signalling pathways to alter host cell functions such as secretion of VEGF. 
 
Acidification of cell culture supernatant upon VirB/VirD4 T4SS activity 
During the ELISA experiments I noticed dramatic changes in the colour of the 
HeLa cell culture supernatant. Cell media often contain phenol red (PR, 
phenolsulfonephtalein) as a pH indicator to assure near-neutral pH needed for cell 
growth. Under normal conditions these growth media will have a pink-red colour. In 
cases were cells are overgrown by bacteria or waste products accumulate, the pH 
will gradually decrease turning the solution to orange and then yellow. Bacteria can 
stimulate the metabolism of the cultured cells but also can be themselves 
metabolically very active. The supernatant of HeLa cells stimulated with PMA or 
infected with the ∆virB4 or the ∆bepA-G mutant was slightly shifted to a pale pink 
colour. For cells infected with Bh actually translocating effectors the colour of the cell 
culture supernatant turned to orange, even more yellowish for the ∆bepB-G mutant 
overexpressing BepD in trans on a plasmid (Fig. 3). 
 
 
Figure 3 Colour changes of HeLa cell culture media after 120 h. Uninfected cells compared to PMA-
stimulated cells or cells infected with a MOI of 300 with the indicated Bh strains. 
 
The conversion of the pink form of PR to the orange form can be followed by 
measuring absorbance at 440 nm (acidic form of PR, yellow) and 560 nm (basic form 
of PR, red) respectively (Wang et al., 2003). Indeed, measurements of absorbance 
indicating decrease of the basic and increase of the acidic form of PR paralleled the 
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visual observations, though did not show a significant difference for ∆bepB-G mutant 
overexpressing BepD (Fig. 4A). 
 
 
Figure 4 (A) Measurement of absorbance to follow the acidic form (440 nm, yellow) and basic form 
(560 nm, red) of phenol red respectively of HeLa cell culture supernatants. Shown are mean / SD of 
duplicates. (B) Corresponding measurement of pH. 
 
A shift in colour depending on PR has also been reported for horseradish 
peroxide-mediated oxidation of PR by hydrogen peroxide (Pick and Keisari, 1980). 
Therefore I measured the pH of the HeLa cell culture supernatants (Fig. 4B). 
VirB/VirD4 T4SS translocation activity correlated with a decrease of pH, indicating 
that the colour changes observed are probably based on changes in pH. 
Interestingly, acidic extracellular pH has been shown to be able to induce VEGF 
mRNA expression and protein production (Shi et al., 2001). Thus, the increase in 
VEGF secretion observed upon infection with the ∆bepB-G mutant background could 
be explained by decrease in pH associated with infection with Bh harbouring an 
active VirB T4SS translocating effector proteins. 
Dulbecco’s modified essential medium (DMEM), used in the aforementioned 
experiments, is a nutrient-rich growth media commonly used in mammalian tissue 
culture experiments usually buffered by addition of sodium bicarbonate. HEPES is a 
zwitterionic organic chemical buffering agent. Compared to bicarbonate buffers it is 
better at maintaining physiological pH despite changes in carbon dioxide. However, 
addition of HEPES to DMEM generally lowered absorbance measured at 560 nm but 
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did not prevent the shift in colour of the cell culture media upon infection (Fig. 5A) nor 
influenced the pattern of VEGF production (Fig. 5B). 
 
 
Figure 5 (A) Measurement of absorbance to follow the basic form (560 nm, red) of phenol red of HeLa 
cell culture supernatants. Shown are mean / SD of duplicates. (B) Corresponding measurement of 
VEGF production. Shown are mean / SD of triplicates. 
 
Observations done by M. Quebatte in the lab revealed a narrow window of 
optimal pH for the expression of the virB- and bep-operons which is best reached 
performing the infections using the cell culture media M199 buffered with HEPES. I 
did not observe a shift in colour when using M199 supplemented with non-essential 
amino acids (Fig. 5A) and rather a Bh-dependent reduction than induction of VEGF 
production (Fig. 5B). HeLa cells severely suffered during prolonged infections 
performed in M199 regardless of the Bh strain used (data not shown), indicating that 
M199 might not cover the metabolic demands of HeLa cells during infection. This 
possibly explains the observed general reduction in VEGF secretion in Bh-infected 
cells. As for the source responsible for acidification of cell culture supernatant, a 
plausible explanation would be an increase in cell metabolism, especially glycolysis. 
A glycolytic phenotype has been proposed to arise as an adaptation to local hypoxia, 
resulting from limited oxygen, and altered glucose metabolism is considered a 
common property of tumours. Glycolysis under low oxygen settings requires first the 
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conversion of glucose to pyruvate and then to the waste product lactic acid. Thus, 
constitutive and persistence glylcolysis results in acidification of the local 
environment (Gatenby and Gillies, 2004). Proposed by Kempf et al. (Kempf et al., 
2005) inhibition of apoptosis and replication of intracellular bacteria resulting in high 
oxygen consumption and reduced ATP levels in the host cell would lead to the 
stabilization of the transcription factor hypoxia-inducible factor-1α (HIF1α). VEGF 
itself, glucose transporters, and glycolytic enzymes are amongst the various 
downstream targets of HIF1α (Kaelin, 2008). 
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Conclusions 
In summary it remains unclear how Bh triggers VEGF production in HeLa cells 
and whether VEGF production and the pH shift in cell culture media I observed are 
connected “cause and effect” or parallel events. Infection with Bh could provide an 
acidic extracellular milieu inducing VEGF by for example increasing the metabolic 
need of their host cell or directly affecting the cell culture media by bacterial growth 
and VirB T4SS translocation activity. Alternatively, as already proposed, Bh might 
induce a hypoxia-like cell response stabilising HIF1α leading to a cell metabolism 
shifted toward glycolysis and stimulation of growth factors such as VEGF involved in 
angiogenesis. Especially the prominent action of BepD cannot be explained only by 
changes in pH or oxygen. Albeit I noticed a shift in cell culture supernatant going 
even more towards yellow for the overexpression of BepD in the ∆bepB-G 
background – BepD-triggered VEGF production neither correlated with additional 
shift in PR absorbance nor pH in comparison to the ∆bepB-G mutant, speaking for an 
additional mechanism probably involving tyrosine-phosphorylation and interference 
with host cell signalling. 
An important fact to consider are the different Bh genotypes such as Bh 
Marseille (Drancourt et al., 1996) and Bh Houston-1 (Regnery et al., 1992) used to 
address the role of Bh in the paracrine loop model. Studies attributing a crucial role to 
the non-fimbrial adhesin BadA in the induction of a pro-angiogenic cell response 
were done with the Bh Marseille strain (Riess et al., 2004), whereas I used as wild-
type a spontaneous streptomycin-resistant variant of the Houston-1 clinical isolate 
and typing strain ATCC49882T (Schmid et al., 2004), previously used in our lab to 
characterize the VirB/VirD4/Bep system. For this strain, BadA expression is unknown 
so far. Whereas the original ATCC49882T strain expresses BadA, a lab variant 
thereof lacks BadA. Loss of BadA expression, by single-base deletions or insertions 
and recombinations, upon extensive passaging on agar plates in vitro without any 
ecological pressure are proposed to affect BadA expression – resulting in the 
coexistence of BadA-positive and BadA-negative substrains within one Bh type strain 
(Riess et al., 2007). However, I observed a prominent VirB/Bep-dependent induction 
of VEGF production upon infection with our Bh Houston-1 variant. Initial CRAFT 
experiments done to test effector translocation (Schulein et al., 2005) indicate that 
the Bh Marseille does not show an efficient VirB T4SS translocation activity, 
especially not in the presence of BadA (Pulliainen, A., Teoh, J., unpublished 
Chapter 4 
F-9 
 
observation). Hence, possibly two independent mechanisms are able to elicit the 
observed induction of VEGF production in cells used as a model for a paracrine 
source upon infection with Bh. It is thus important to address both the presence of 
BadA and the activity of the VirB/VirD4/Bep system to understand Bh-host cell 
interaction. 
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Experimental procedures 
Bacterial strains and Growth Conditions 
The bacterial strains used are listed in Table 1 of chapter 2 (p. D-31). Bartonella spp. 
were grown on Columbia agar (CBA) plates containing 5% defibrinated sheep blood 
in a humified atmosphere at 35°C and 5% CO2 for 2-3 days. Strain RSE247, a 
spontaneous streptomycin-resistant strain of ATCC 49882T (Schmid et al., 2004) 
served as wild-type in this study. Media were supplemented with 30 µg/ml 
kanamycin, 100 µg/ml streptomycin, 12.5 µg/ml gentamicin, and/or 500 µM isopropyl 
β-D-thiogalactosidase (IPTG, http://www.applichem.de) if needed. 
 
Cell Culture 
HeLa and Ea.hy926 cells were grown in Dulbecco's Modified Eagle Media (DMEM, 
Gibco, http://www.invitrogen.com) with 10% fetal calf serum (FCS, 
http://www.invitrogen.com). The human acute monocytic leukemia THP-1 cell line 
was cultured in RPMI 1640 medium (http://www.sigmaaldrich.com) with 10% FCS. 
Cells were grown in a humified atmosphere at 37°C and 5% CO2. 
 
Infection Assay 
HeLa and Ea.hy926 cells were plated in 24-well plates at 105/ml using DMEM with 
10% FCS. The next day cells were washed and unless stated differently infected with 
a multiplicity of infection (MOI) of 300 bacteria per cell in DMEM/10% FCS/500 μM 
IPTG and sedimented onto cultured cells by centrifugation for 5 minutes at 1800 rpm. 
Cells were incubated for the indicated time. For some assay M199 with Earls salts 
(M199, Gibco, http://www.invitrogen.com) and 10% FCS was used. The medium was 
supplemented with non-essential amino acids or 25 mM HEPES where indicated. 
THP-1 monocytes were directly seeded in 24-well plates at 7*105/ml and infected 
with a MOI of 300 in RPMI/10% FCS/500 μM IPTG. Bacteria-cell contact was 
facilitated by centrifugation for 5 minutes at 1800 rpm. Alternatively, THP-1 cells were 
differentiated into macrophages by overnight treatment with 100 ng/ml phorbol-12-
myristate-13-acetate (PMA, http://www.sigmaaldrich.com). Media was changed the 
next day and cells left for two days before there were infected as described for THP-1 
monocytes. 
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Detection of VEGF in cell culture supernatants 
Stimulation of VEGF secretion by PMA (25 ng/ml) served as a positive control. At the 
indicated timepoints cell culture supernatants were collected, centrifuged for 3 
minutes at 12k rpm at 4°C and stored at -20°C. VEGF concentration in culture 
medium was measured using a human VEGF165-ELISA kit 
(http://www.rndsystems.com) following the manufacturer’s instructions. 
 
Measurement of absorbance of cell culture supernatants 
To measure the absorbance at 560 nm and 440 nm respectively, 100 μl of cell 
culture supernatants were transferred to a 96-well plate and assed with a 
SpectraMax M2 microplate reader (http://www.moleculardevices.com). 
 
Determination of pH of cell culture supernatants 
300 μl of cell culture supernatants were transferred to 1.4 ml U-tubes 
(http://www.micronic.com) and pH was measured with a high-precision pH meter 
(827 pH lab, http://www.metrohm.com). 
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Summary 
 
Bartonella henselae (Bh) rarely shows any symptoms in its feline reservoir 
host but is responsible for a number of clinical outcomes during infection of the 
human incidental host. Bh shares with B. quintana (Bq) and B. bacilliformis (Bb) the 
remarkable capacity to induce tumour-like vascular proliferations. The study of 
Bartonella-host cell interactions might not only provide insides into the pathogenesis 
of Bh but might also serve as a model to investigate general mechanisms involved 
pathological angiogenesis, which is a hallmark of tumour growth. The Bh VirB/VirD4 
type IV secretion system (T4SS) and the thereby translocated Bartonella-effector 
proteins (Beps) have been shown to be responsible for the subversion of a number of 
endothelial cell (EC) functions upon infection. This thesis aimed to elucidate the role 
of the VirB/VirD4/Bep system in Bh-triggered angioproliferation. 
 
The first chapter characterizes the Bh VirB T4SS translocated protein BepA as 
an effector mediating the inhibition of apoptosis in human umbilical vein endothelial 
cells (HUVECs). Either overexpressed in the effector-less ∆bepA-G mutant or 
ectopically expressed, BepA was sufficient to promote the anti-apoptotic activity. 
Delineation of BepA revealed that this activity is confined to the BID (Bep intracellular 
delivery) domain of BepA. Interestingly, only the homologue BepA2 (corresponding to 
the BID domain plus C-terminus of BepA) from Bq inhibited apoptosis as well. In 
contrast to Bh and Bq, B. tribocorum is not associated to vascular proliferation and its 
BepA-homologue did not show any anti-apoptotic activity. Upon translocation into the 
host cell BepA was targeted to the membrane. BepA-mediated anti-apoptosis 
correlated with an increase in cAMP and increased expression of cAMP-responsive 
genes, pointing to a mechanism involving the regulation of this second messenger. 
BepA not only inhibited chemically ActD-induced but also CTL-triggered apoptosis. 
Thus, BepA has the potential to play a role in vasoproliferation in an indirect way by 
enhancing cell survival. 
 
Chapter 2 presents a spheroid-based three-dimensional in vitro sprouting 
assay established to address the angiogenic potential of Bh. Compared to spheroids 
from uninfected HUVECs, spheroids from HUVECs pre-infected with Bh wild-type 
showed an increased sprouting activity, albeit sprout morphology was distinct from 
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the sprouts induced by vascular endothelial growth factor (VEGF). Formation of 
those sprouts was in part VirB/Bep-dependent. Overexpressed BepA in the ∆bepA-G 
mutant strongly promoted sprout formation. Delineation of the domain required for 
this stimulation indicates parallels to the anti-apoptotic activity. BepD showed a 
moderate sprout-promoting effect. In contrary, BepG, involved in cytoskeletal 
rearrangement, displayed a potent interference with sprout formation. This novel in 
vitro model of Bh-triggered sprouting angiogenesis revealed distinct activities of the 
Beps in modulating sprout formation and contributing to the regulation of the Bh 
angiogenic activity in the course of the chronic vascular infection. 
 
In chapter 3 the effect of exogenous VEGF on Bh-infected ECs is addressed. 
VEGF is thought to be involved in Bh-induced vascular tumour formation by 
promoting EC proliferation in a paracrine manner. Assessing the biological activity of 
VEGF in assays such as proliferation, wound assay and capillary-like sprout 
formation revealed an intriguing interference of the VirB/VirD4/Bep system with 
responsiveness of infected ECs to stimulation with VEGF. Analysis of the VEGF 
receptor 2 pathways showed that Bh inhibited phosphorylation of tyrosine 1175. In 
Bh-infected ECs stimulated with VEGF, PLCγ1 was less recruited and 
phosphorylated and consequently downstream calcium flux and ERK1/2 activation 
were blocked. These data rather challenge the idea of a VEGF-driven paracrine loop 
in the presence of an active VirB/VirD4/Bep system and emphasize the modulatory 
role of the VirB T4SS balancing the angiogenic activity of Bh. 
 
The last chapter reports the role of the VirB/VirD4/Bep system in the 
paracrine-loop model of VEGF production. HeLa cells produced VEGF upon 
exposure to Bh in a VirB/Bep-dependent manner. BepD elicited a strong stimulation 
of VEGF secretion in HeLa cells when overexpressed in the ∆bepB-G mutant. A shift 
in colour of the cell culture supernatant, depending on the cell culture media used, 
was associated to VirB T4SS translocation activity but not particularly to VEGF 
production. The shift probably is due to acidification of the supernatant. Hence, in 
addition to the previously reported BadA also the VirB/VirD4/Bep system, especially 
BepD, independently is able to trigger the production of an essential regulator of 
angiogenesis. 
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The anti-apoptotic effector BepA 
The protection of ECs against apoptosis by Bh can be mediated by a single 
effector, BepA (chapter 1) (Schmid et al., 2006). 
Knowledge of the cellular binding partners and interactions of BepA is a 
requirement for understanding the association of BepA, cAMP, and anti-apoptosis. 
Ongoing work approaches this issue by mass spectrometry-based proteomics 
(Aebersold and Mann, 2003). Classical co-immunoprecipitation and co-localization 
studies as well as functional approaches such as small interfering RNA (siRNA) 
knockdown experiments and ectopic expression of variants can be used to validate 
potential hits. An image-based siRNA screen combined with assays involving 
inhibitors, antibodies, drugs, or molecular probes might further give insights into the 
host cell signalling pathways targeted by BepA to mediated anti-apoptosis. 
Manipulation of EC apoptosis has been proposed to accompany as well the 
mitogenic stimulation observed for Bq (Liberto et al., 2004; Kirby and Nekorchuk, 
2002). The human specific Bq is thought to have evolved from Bh by reductive 
evolution (Alsmark et al., 2004) and indeed showed an inhibition of apoptosis 
depending on the VirB/VirD4 T4SS and the Bq BepA homologue (chapter 1) (Schmid 
et al., 2006). Interestingly, Bartonella species not associated to angioproliferative 
lesions such as B. vinsonii or B. elizabethae did not inhibit cell death (Kirby and 
Nekorchuk, 2002). Likewise, neither B. tribocorum nor its BepA did show any anti-
apoptotic activity (chapter 1) (Schmid et al., 2006). In contrast to Bh and Bq, Bb lacks 
a corresponding VirB/VirD4/Bep system (Saenz et al., 2007). GroEL has been 
proposed to affect EC apoptosis during co-culture of cells with Bb (Smitherman and 
Minnick, 2005), but so far there are no data showing if Bb would influence ECs 
challenged with for example chemically ActD-induced apoptosis. 
Another fact that needs to be taken into account is the prominent activation of 
an NF-κB-dependent pro-inflammatory phenotype in ECs upon infection with Bh, 
which is even though in part depending on the VirB/VirD4 T4SS not associated to 
BepA (Schmid et al., 2006; Schmid et al., 2004). NF-κB has been shown to have a 
role in the regulation of the apoptotic program (Karin and Lin, 2002) indicating a 
possible additional mechanism how Bh could manipulate EC cell death. 
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BepA was able to promote capillary-like sprout formation in a spheroid-based 
three-dimensional in vitro model of sprouting angiogenesis. Deletion of bepA 
significantly reduced sprouting induced by Bh, which indicates a prominent role for 
BepA in Bh-triggered sprouting angiogenesis. An initial delineation indicates parallels 
to the anti-apoptotic activity of BepA (chapter 2) (Scheidegger et al., 2008). Further 
research is needed to elucidate whether indeed the ability of BepA to induce 
sprouting is directly connected to inhibition of cell death and whether cAMP for 
example is involved. Knowing the cellular interaction partners of BepA might here as 
well give insights into the pathways manipulated by BepA. Comparing sprouting 
induced by ectopic expression of BepA to sprout formation of spheroids from 
HUVECs pre-infected with the ∆bepA-G mutant overexpressing BepA, might point to 
synergistic effects of inhibition of apoptosis and VirB/VirD4 T4SS-independent 
mitogenic stimulation. Similarly, VEGF is known to act on ECs not only as a mitogen 
but also as a survival factor (Ferrara et al., 2003). 
Surprisingly, deletion of bepA was sufficient to unlock the antagonizing effect 
on VEGF-induced calcium flux otherwise observed for Bh wild-type (chapter 3). It 
remains to be shown whether in ECs infected with a ∆bepA mutant and stimulated 
with VEGF the phosphorylation of VEGFR2 Tyr11775, PLCγ1 recruitment and 
activation, and downstream ERK1/2-phosphorylation follow the control pattern 
observed for uninfected ECs. The double knockout of bepC and bepG behaved as 
the ∆bepA mutant in the calcium assay. Thus, the presence alone of BepA is not 
responsible for the interference with VEGF signalling. How BepA presumably 
together with BepC and BepG is able to manipulate EC responsiveness to VEGF and 
whether this is a direct action or the indirect result of manipulation of EC function by 
the Beps, remains to be discovered. 
The recurrent involvement of BepA puts a strong emphasis on this VirB/VirD4 
T4SS effector. The specificity of the observations connected to BepA, notably to the 
BID domain of BepA, is astonishing. BepB and BepC are paralogues of BepA neither 
showing any anti-apoptotic effect nor affecting sprouting (chapter 1 and 2) 
(Scheidegger et al., 2008; Schmid et al., 2006). Moreover, the BID domain is part of 
the bipartite translocation signal found in all Beps and as well in the conjugative 
relaxases of plasmid-borne bacterial conjugation systems (Schulein et al., 2005). 
Structural information might help to solve the uniqueness lying in the BID domain of 
BepA. In the end yet, the relevance and actual contribution of the anti-apoptotic and 
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possible other activities of BepA to the process of vascular tumor formation remains 
a central question and calls for an appropriate animal model to study Bartonella-
triggered vasoproliferation in vivo. However, BepA clearly belongs to those bacterial 
effectors displaying a tumourigenic potential. 
 
A three-dimensional in vitro model for sprouting angiogenesis 
The established spheroid-based in vitro model of sprouting angiogenesis 
revealed pronounced yet opposing effects of individual Beps on sprout formation 
(chapter 2) (Scheidegger et al., 2008). 
Each in vitro assay has its benefits and limitations. Moving from cell 
monolayers to three-dimensional cultures is motivated by the need to work with 
cellular models that mimic the functions of living tissues, but where complexity is 
reduced to a defined setup and standardized experimental conditions can be applied 
(Pampaloni et al., 2007). Issues to consider using such a three-dimensional assay 
are the need of advanced imaging techniques to visualize moderately thick 
specimens and complicated biochemical analysis due to the lower cell density and 
the additional steps required to separate the cells from the matrix. Spinning-disk 
confocal laser microscopy (CLSM), used in this work to image spheroids, offers a fast 
image acquisition and represents the commercially available state-of-the-art imaging 
method, but like other CLSM suffers from a limited penetration depth, marked 
difference in lateral and axial resolution, and sample bleaching. Selective plane 
illumination microscopy (SPIM), where the sample is not illuminated by a light volume 
but a light sheet, has the potential to overcome the limitations of CLSM (Huisken et 
al., 2004). Considering the matrix itself, most of the currently available ECM gels are 
extracted from animals or cultured cells and hence quality control is difficult. 
Components between batches may vary and affect the reliability and reproducibility 
of the assay (Pampaloni et al., 2007). 
The collagen gel-embedded HUVEC spheroid model adapted during this work 
represents a validated quantitative and robust in vitro assay of sprouting 
angiogenesis (Korff and Augustin, 1999). Amongst the advantages over other three-
dimensional assays such as cord formation or formation of capillary networks 
originating from single gel-embedded cells, the spheroid-based assay better reflects 
the angiogenic process originating from the confluent endothelium of the pre-existing 
vessel still allowing the assessment of both pro- as well as anti-angiogenic factors. 
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Furthermore, the assay is assessable by treatment of gel-embedded spheroids with 
soluble compounds such as inhibitors, activators or antibodies and ECs can be 
manipulated before the formation of spheroids by for example siRNA knockdown or 
ectopic expression of genes of interest. This provides the possibility to elucidate the 
molecular basis of the observed angiogenic activities of Bh. The fact that spheroids 
as used for in vitro sprouting angiogenesis can also be used in vivo (Alajati et al., 
2008) offers an attractive opportunity to refine the spheroid-based model of Bh-
triggered sprouting towards the establishment of the badly needed animal model. 
 
Interference with VEGF signalling 
The presence of an active VirB/VirD4/Bep system intriguingly inhibited EC 
responsiveness to VEGF (chapter 3). Yet, VEGF production was increased in a 
VirB/Bep-dependent manner in epithelial HeLa cells (chapter 4). 
Time-course experiments are needed to evaluate the effects of Bh-infection on 
the phosphorylation kinetics of VEGFR2 and downstream signalling components in 
ECs to validate the so far observed phosphorylation pattern. Additional readouts 
such as the measurements of PIP2, the precursor for the second messengers DAG 
and IP3 (Berridge and Irvine, 1984), nitric oxide (NO) required for VEGF-induced 
vascular permeability (Fukumura et al., 2001; Busse and Mulsch, 1990) or 
prostacyclin (PGI2) acting together with NO on vascular smooth muscle cells 
(VSMCs) to promote vasodilation and increased blood flow production (Li et al., 
2002) might further give insights into the VEGFR2 Tyr1175 downstream cascade 
manipulated by Bh. Careful analysis of VEGFR2 expression would strengthen the 
fact that the observed interference is due to direct influence on signalling and not to 
reduced presence of the receptor. Deciphering how the Beps interfere with VEGF-
signalling is a challenge, which likely requires the understanding of the interplay of 
BepA, BepC and BepG. 
The cellular and molecular mechanisms underlying VirB/Bep-induced 
production of VEGF remain unclear. Albeit a wealth of information on fundamental 
process that occurs in human cells, both normal and abnormal, was gained using the 
cancer-derived HeLa cells as a model system, there is no common stock of HeLa 
cells but these cells show genetic and phenotypic differences as a result of genetic 
drift and being subjected to different conditions in various laboratories (Masters, 
2002). Thus, a major concern regarding the approach taken to propose the paracrine 
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loop is the use of those cells as model for an epithelial cell surrounding a blood 
vessel or even a monocytic cell. Experiments using THP-1 or MonoMac6 cells as 
model for the macrophages present in bacillary angiomatosis (BA) (Arrese Estrada 
and Pierard, 1992) are more convincing. Macrophages are indeed capable to 
produce potent angiogenic factors upon activation (Sunderkotter et al., 1994). SMCs 
involved in the stabilization of the blood vessels would represent cells in close 
contact to ECs (Armulik et al., 2005) and could possibly be a target for paracrine 
activity on ECs. Reports about an interaction of Bartonella with SMCs are restricted 
to the observation that SMCs do not proliferate upon co-culture with Bartonella 
(Maeno et al., 1999; Garcia et al., 1990). 
In summary, whereas experiments done with HeLa cells indicate an 
involvement of the VirB/VirD4 T4SS in the paracrine-loop model, the relevance of this 
VEGF-based model of paracrine support of EC proliferation itself, in presence of an 
active VirB/VirD4 T4SS, is questioned. Thus, the careful choice of a model cell line 
for in vitro experiments is part of the crucial parameters influencing the interpretation 
of the role of the VirB/VirD4/Bep system in Bh-triggered angioproliferation. Hence it 
would be crucial to know with which cell type Bh actually interacts in vivo. 
 
Bartonella henselae, the VirB/VirD4/Bep system and tumour-like 
vasoproliferative lesions 
The knowledge about the involvement of the VirB/VirD4 T4SS in Bh-host cell 
interaction gathered using different model systems revealed both pro- as well as 
angiogenic traits lying in the VirB/VirD4/Bep system. Many of those effects have 
been addressed individually to reduce complexity. Often, although observing a clear 
phenotype for the ∆bepA-G mutant lacking the known effectors, it remains unclear 
which Beps actually are involved. Hence, the timing of effector translocation, the 
quantities of translocated Beps and the composition of the effector set injected into a 
given cell type is an open question possibly determining whether pro- or anti-
angiogenic activities of the VirB/VirD4 T4SS would prevail. 
Nevertheless, interference of the VirB/VirD4/Bep system with both potent 
intrinsic (direct mitogenic stimulus) and extrinsic (paracrine-loop) pro-angiogenic Bh 
factors strongly argues against its function as a major element driving BA. 
Consistently, the human-specific Bb strongly promotes very similar vascular 
proliferative lesions (Garcia et al., 1990) although it lacks the VirB/VirD4 T4SS 
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(Saenz et al., 2007). The VirB/VirD4 T4SS has recently emerged as a potent host 
adaptation factor and is proposed to be a highly conserved molecular platform 
equipped with a set of different effectors to modulate the cellular habitats of the 
corresponding reservoir hosts (Dehio, 2008). In this respect, vasoproliferation 
associated to Bh in the human incidental host may as well represent a “biological 
accident” induced by the complex physiological changes resulting from chronic 
vascular colonization and a maladjusted action of the bacteria on cell signalling. 
Speculatively, the VirB/VirD4/Bep system therefore could have an important role as a 
balancing factor actually preventing drastic effect on its host such as BA but 
promoting subtle changes needed for a chronic infection. Again an appropriate 
animal model would be required to asses this hypothesis experimentally. 
The causative role of Bh in vascular proliferation is clear. The involvement of 
the VirB/VirD4 T4SS though is ambiguous. It appears that the VirB/VirD4/Bep system 
represents a modulator controlling the angiogenic potential of Bh by affecting several 
EC functions connected to angiogenesis. Bh could indeed contribute to an anti-
apoptotic, proliferative state prone to tumour initiation, promotion, and progression by 
perturbing cell signalling processes (Lax and Thomas, 2002). But the VirB/VirD4 
T4SS also interferes with strong pro-angiogenic traits of Bh. Thus, the 
VirB/VirD4/Bep system clearly influences Bh-induced vasoproliferation, yet its 
causative role remains open for future research. A better understanding of the 
VirB/VirD4/Bep system during infection of the reservoir host might clarify as well the 
role of the VirB/VirD4 T4SS in pathogenesis during interaction with the incidental 
host. Furthermore, this could also give some indication whether induction of vascular 
proliferations indeed represent a dedicated infection strategy to expand the specific 
host cell habitat or whether it is a result of unbalanced interaction of Bh with its host. 
Research aiming at the understanding of mechanisms, such as the VirB/VirD4/Bep 
system, involved in the control of the balance between host and pathogen will help to 
answer the questions of how and to what extend bacteria are involved in 
tumourigenesis. Yet one needs to keep in mind that the molecular mechanisms 
underlying bacteria-induced tumour formation remain a challenge governed by the 
right mixture of multiple factors including bacterial properties, host factors, and 
environmental triggers. 
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